

The University of Alabama at Birmingham

**Report on Federal Awards in Accordance with the
OMB Uniform Guidance**

For the Year Ended September 30, 2022

EIN: 63-6005396

The University of Alabama at Birmingham

Index

For the Year Ended September 30, 2022

	Page(s)
Part I Federal Award Programs	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	1–2
Report of Independent Auditors on Compliance for Each Major Program; on Internal Control Over Compliance; and on Schedule of Expenditures of Federal Awards Required by Uniform Guidance	3–6
Schedule of Expenditures of Federal Awards	7–37
Notes to Schedule of Expenditures of Federal Awards.....	38–39
Part II Schedule of Findings and Questioned Costs	
Schedule of Findings and Questioned Costs.....	40-41
Management's Views and Corrective Action Plan.....	42
Part III Summary Schedule of Prior Audit Findings and Status	
Summary Schedule of Prior Audit Findings and Status	43
Part IV 2022 Financial Report	

Part I
Federal Award Programs



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Trustees of The University of Alabama

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham (“UAB”), a campus of The University of Alabama System, a component unit of the State of Alabama, as of and for the year ended September 30, 2022, and the related notes to the financial statements, which collectively comprise UAB’s basic financial statements, and have issued our report thereon dated January 24, 2023, which includes an emphasis of matter paragraph related to UAB changing the manner in which it accounts for leases and an emphasis of matter paragraph related to the presentation of UAB’s basic financial statements, both as discussed in Note 1 to the basic financial statements. Our report includes a reference to other auditors who audited the financial statements of Southern Research Institute (“SRI”), as described in our report on UAB’s basic financial statements. The financial statements of SRI were not audited in accordance with *Government Auditing Standards* and accordingly, this report does not include reporting on internal control over financial reporting or compliance and other matters associated with SRI or that are reported on separately by those auditors who audited the financial statements of SRI. The financial statements of Triton Health Systems, L.L.C., UAB Athletics Foundation, and UAB Research Foundation, certain of UAB’s blended component units, were not audited in accordance with *Government Auditing Standards* and accordingly, this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with these component units.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the basic financial statements, we considered UAB’s internal control over financial reporting (internal control) as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the basic financial statements, but not for the purpose of expressing an opinion on the effectiveness of UAB’s internal control. Accordingly, we do not express an opinion on the effectiveness of UAB’s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.



Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether UAB's basic financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the basic financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of UAB's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering UAB's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Birmingham, Alabama
January 24, 2023



Report of Independent Auditors on Compliance for Each Major Program; on Internal Control Over Compliance; and on Schedule of Expenditures of Federal Awards Required by Uniform Guidance

To the Board of Trustees of The University of Alabama

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited The University of Alabama at Birmingham's ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of UAB's major federal programs for the year ended September 30, 2022. UAB's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, UAB complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of UAB and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of UAB's compliance with the compliance requirements referred to above.

Other Matters – Federal Expenditures Not Included in the Compliance Audit

UAB's basic financial statements include the operations of Southern Research Institute ("SRI"), UAB's discretely presented component unit, which expended federal awards which are not included in UAB's schedule of expenditures of federal awards during the year ended September 30, 2022. Our compliance audit, described in the Opinion on Each Major Federal Program section of our report, does not include the operations of SRI because SRI engaged other auditors to perform an audit in accordance with the Uniform Guidance.



Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to UAB's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on UAB's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about UAB's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding UAB's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of UAB's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2022-001. Our opinion on each major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on UAB's response to the noncompliance finding identified in our audit described in the accompanying



management's views and corrective action plan. UAB's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the business-type activities and the discretely presented component unit of UAB as of and for the year ended September 30, 2022, including the related notes (collectively referred to as the "basic financial statements"). We issued our report thereon dated January 24, 2023, which contained unmodified opinions on those financial statements. Our audit was conducted for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in accordance with auditing standards



generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the basic financial statements as a whole.

PricewaterhouseCoopers LLP

Birmingham, Alabama

June 29, 2023, except with respect to the opinion on the supplemental schedule of expenditures of federal awards, as to which the date is January 24, 2023

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
RESEARCH AND DEVELOPMENT CLUSTER							
Department of Agriculture							
Agriculture and Food Research Initiative (AFRI)	10.310	\$ 99,108	\$ -			\$ 99,108	\$ 10,299
10.310 Total		99,108	-			99,108	10,299
Solid Waste Management Grants	10.762	-	4,750	ROWAN UNIVERSITY	CPAP000000598654	4,750	-
10.762 Total		-	4,750			4,750	-
Total Department of Agriculture		99,108	4,750			103,858	10,299
Department of Commerce							
Cluster Grants	11.020	51,940	-			51,940	-
11.020 Total		51,940	-			51,940	-
Unallied Management Projects	11.454	-	27,348	UNIVERSITY OF FLORIDA	NA20NMF4540293/ACQ-210-039-2021-UFL	27,348	-
11.454 Total		-	27,348			27,348	-
Coral Reef Conservation Program	11.482	-	21,985	COLLEGE OF CHARLESTON	NA18NOS4820181	21,985	-
11.482 Total		-	21,985			21,985	-
Measurement and Engineering Research and Standards	11.609	-	98,938	TROY STATE UNIVERSITY	70NANB19H139	98,938	-
Measurement and Engineering Research and Standards	11.609	-	4,933	TROY STATE UNIVERSITY	70NANB20H147	4,933	-
Measurement and Engineering Research and Standards	11.609	-	(283)	TROY STATE UNIVERSITY	70NANB18H289	(283)	-
11.609 Total		-	103,588			103,588	-
Total Department of Commerce		51,940	152,921			204,861	-
Department of Defense							
Basic and Applied Scientific Research	12.300	-	55,902	WRIGHT STATE UNIVERSITY	N00014-16-1-3159	55,902	-
12.300 Total		-	55,902			55,902	-
Military Medical Research and Development	12.420	9,927,679	-			9,927,679	2,111,681
Military Medical Research and Development	12.420	-	2,736,720	MISSISSIPPI STATE UNIVERSITY	W56HZV-17-C-0095	2,736,720	551,095
Military Medical Research and Development	12.420	-	455,442	ADVANCED TECHNOLOGY INTERNATIONAL	W81XWH-18-9-0001-11	455,442	22,600
Military Medical Research and Development	12.420	-	272,897	OCEAN STATE RESEARCH INSTITUTE	W81XWH-17-0619	272,897	-
Military Medical Research and Development	12.420	-	75,042	VIRGINIA COMMONWEALTH UNIVERSITY	W81XWH-20-10775	75,042	-
Military Medical Research and Development	12.420	-	51,770	COALITION FOR NATIONAL TRAUMA RESEARCH	W81XWH-20-2-0032	51,770	-
Military Medical Research and Development	12.420	-	34,321	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	W81XWH201340	34,321	-
Military Medical Research and Development	12.420	-	33,792	SUNFIRE BIOTECHNOLOGIES, LLC	W81XWH21P0022	33,792	-
Military Medical Research and Development	12.420	-	30,877	MEMORIAL SLOAN KETTERING CANCER CENTER	W81XWH-21-10188	30,877	-
Military Medical Research and Development	12.420	-	29,456	JOHNS HOPKINS UNIVERSITY	MCS BAA 17-01	29,456	-
Military Medical Research and Development	12.420	-	26,099	UNIVERSITY OF MINNESOTA	W81XWH1810577	26,099	-
Military Medical Research and Development	12.420	-	12,233	REGENTS OF THE UNIVERSITY OF COLORADO	W81XWH-17-0597	12,233	-
Military Medical Research and Development	12.420	-	11,804	CHILDREN'S HOSPITAL BOSTON	W81XWH-17-1-0532	11,804	-
Military Medical Research and Development	12.420	-	10,817	DUKE UNIVERSITY	W81XWH1810577	10,817	-
Military Medical Research and Development	12.420	-	3,934	SIMX, INC.	FA864921P1425	3,934	-
Military Medical Research and Development	12.420	-	342	UNIVERSITY OF SOUTHERN CALIFORNIA	W81XWH-13-MRPRA-MRFA	342	-
Military Medical Research and Development	12.420	-	(2,822)	DUKE UNIVERSITY	W81XWH-14-1-0473	(2,822)	-
Military Medical Research and Development	12.420	-	(45,495)	NOVAN INC	W81XWI-1910850	(45,495)	-
12.420 Total		9,927,679	3,737,229			13,664,908	2,685,376

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Uniformed Services University Medical Research Projects	12.750	-	242,948	TRISERVICE NURSING RESEARCH PROGRAM	11052-N21-05	242,948	21,436
Uniformed Services University Medical Research Projects	12.750	-	175,288	THE GENEVA FOUNDATION	11052-N21-17	175,288	
Uniformed Services University Medical Research Projects	12.750	-	32,720	THE GENEVA FOUNDATION	11052-N2101GR	32,720	
Uniformed Services University Medical Research Projects	12.750	7,297	-			7,297	
Uniformed Services University Medical Research Projects	12.750	-	3,909	HENRY M JACKSON FOUNDATION	HU0001-17-2-0023	3,909	
Uniformed Services University Medical Research Projects	12.750	-	(1,169)	THE GENEVA FOUNDATION	HU00011920043 N19-A09	(1,169)	
12.750 Total		<u>7,297</u>	<u>453,696</u>			<u>460,993</u>	<u>21,436</u>
Air Force Defense Research Sciences Program	12.800	93,892	-			93,892	48,851
Air Force Defense Research Sciences Program	12.800	-	69,704	UNIVERSITY OF CALIFORNIA - BERKELEY	FA9550-21-1-0230	69,704	
12.800 Total		<u>93,892</u>	<u>69,704</u>			<u>163,596</u>	<u>48,851</u>
Research and Technology Development	12.910	-	177,282	UNIVERSITY OF MICHIGAN	W56HZN-19-2-0001	177,282	
Research and Technology Development	12.910	-	142,433	GALOIS, INC.	N66001-21-C-4023	142,433	
Research and Technology Development	12.910	-	128,141	UNIVERSITY OF MICHIGAN	W56HZV-19-2-0001	128,141	
Research and Technology Development	12.910	-	(6,578)	UNIVERSITY OF MICHIGAN	W56HZV1920001	(6,578)	
12.910 Total		<u>-</u>	<u>441,278</u>			<u>441,278</u>	<u>-</u>
Contract	12.RD	-	392,179	STEEL FOUNDER'S SOCIETY OF AMERICA	SP4701-17-D-1161	392,179	
Contract #FA910118D0004/FA910121F0009	12.RD	267,217	-			267,217	
Contract #FA441721P0040	12.RD	92,873	-			92,873	
Contract	12.RD	-	61,319	FLORIDA INSTITUTE FOR HUMAN & MACHINE COGNITION, I	HR001119S0021	61,319	
Contract	12.RD	-	32,675	REGENTS OF THE UNIVERSITY OF COLORADO	W81XWH2020001	32,675	
Contract #FA910118D0004/FA910121F0039	12.RD	26,056	-			26,056	
Contract	12.RD	-	16,146	JOHNS HOPKINS UNIVERSITY	W81XWH1810810	16,146	
Contract	12.RD	-	5,621	ADVANCED TECHNOLOGY INTERNATIONAL	SP4701-15-C7003	5,621	
Contract	12.RD	-	2,831	REGENTS OF THE UNIVERSITY OF COLORADO	ID07200010-301-14	2,831	
Contract	12.RD	-	(3,374)	ALION SCIENCE AND TECHNOLOGY CORPORATION	FA8075-14-D-0014	(3,374)	
12.RD Total		<u>386,146</u>	<u>507,397</u>			<u>893,543</u>	<u>-</u>
Total Department of Defense		<u>10,415,014</u>	<u>5,265,206</u>			<u>15,680,220</u>	<u>2,755,663</u>
Department of Interior							
Marine Turtle Conservation Fund	15.645	18,662	-			18,662	
15.645 Total		<u>18,662</u>	<u>-</u>			<u>18,662</u>	<u>-</u>
Total Department of Interior		<u>18,662</u>	<u>-</u>			<u>18,662</u>	<u>-</u>
Department of Justice							
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	-	172,592	NATIONAL ORGANIZATION OF BLACK LAW ENFORCEMENT EXE	2019-BJ-BX-0011	172,592	
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	134,503	-			134,503	
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	-	27,016	UNIVERSITY OF ALABAMA IN TUSCALOOSA	15PNIJ-21-GK-02982-MUMU	27,016	
16.560 Total		<u>134,503</u>	<u>199,608</u>			<u>334,111</u>	<u>-</u>
Total Department of Justice		<u>134,503</u>	<u>199,608</u>			<u>334,111</u>	<u>-</u>
Department of Transportation							
University Transportation Centers Program	20.701	-	241,593	UNIVERSITY OF FLORIDA	69A3551747104	241,593	
University Transportation Centers Program	20.701	-	1,291	ROWAN UNIVERSITY	69A3551847102	1,291	
20.701 Total		<u>-</u>	<u>242,884</u>			<u>242,884</u>	<u>-</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Contract #DTNH2217D00066	20.RD	337,901	-			337,901	
Contract #DTNH2217D00066 OPT 3	20.RD	1,198	-			1,198	
Contract	20.RD	-	(196)	UNIVERSITY OF FLORIDA	69A3551747104	(196)	
20.RD Total		<u>339,099</u>	<u>(196)</u>			<u>338,903</u>	<u>-</u>
Total Department of Transportation		<u>339,099</u>	<u>242,688</u>			<u>581,787</u>	<u>-</u>
<u>National Aeronautics and Space Administration</u>							
Education	43.008	-	65,872	UNIVERSITY OF ALABAMA IN HUNTSVILLE	80NSSC20M0044	65,872	
Education	43.008	-	16,752	UNIVERSITY OF ALABAMA IN HUNTSVILLE	80NSSC19M0051	16,752	
43.008 Total		<u>-</u>	<u>82,624</u>			<u>82,624</u>	<u>-</u>
Contract #80JSC021D0001	43.RD	4,686,752	-			4,686,752	
Contract	43.RD	-	18,388	GEOCENT, LLC	80NSSC18C0169	18,388	
Contract #80NSSC22K1171	43.RD	5,652	-			5,652	
Contract #NNJ15HA80B	43.RD	(1,420)	-			(1,420)	
43.RD Total		<u>4,690,984</u>	<u>18,388</u>			<u>4,709,372</u>	<u>-</u>
Total National Aeronautics and Space Administration		<u>4,690,984</u>	<u>101,012</u>			<u>4,791,996</u>	<u>-</u>
<u>National Foundation on the Arts and the Humanities</u>							
Promotion of the Arts, Grants to Organizations and Individuals	45.024	30,624	-			30,624	
45.024 Total		<u>30,624</u>	<u>-</u>			<u>30,624</u>	<u>-</u>
Total National Foundation on the Arts and the Humanities		<u>30,624</u>	<u>-</u>			<u>30,624</u>	<u>-</u>
<u>National Science Foundation</u>							
Engineering Grants	47.041	104,274	-			104,274	
Engineering Grants	47.041	-	41,459	TRUSPIN NANOMATERIAL INNOVATION, INC.	IIP-2127012	41,459	
Engineering Grants	47.041	-	19,295	BOSTON UNIVERSITY MEDICAL CAMPUS	4500003100	19,295	
Engineering Grants	47.041	-	15,340	ROWAN UNIVERSITY	ECCS-1903466	15,340	
Engineering Grants	47.041	-	(92,506)	CETOTECH INC	1534697	(92,506)	
47.041 Total		<u>104,274</u>	<u>(16,412)</u>			<u>87,862</u>	<u>-</u>
Mathematical and Physical Sciences	47.049	1,326,282	-			1,326,282	
47.049 Total		<u>1,326,282</u>	<u>-</u>			<u>1,326,282</u>	<u>-</u>
Geosciences	47.050	559,660	-			559,660	
47.050 Total		<u>559,660</u>	<u>-</u>			<u>559,660</u>	<u>-</u>
Computer and Information Science and Engineering	47.070	340,937	-			340,937	
Computer and Information Science and Engineering	47.070	-	7,575	ROWAN UNIVERSITY	NSF 19-589	7,575	
47.070 Total		<u>340,937</u>	<u>7,575</u>			<u>348,512</u>	<u>-</u>
Biological Sciences	47.074	1,512,031	-			1,512,031	56,628
Biological Sciences	47.074	-	69,989	BROWN UNIVERSITY	IOS-1923445	69,989	
Biological Sciences	47.074	-	11,189	MINNESOTA STATE UNIVERSITY MOORHEAD	2120806	11,189	
47.074 Total		<u>1,512,031</u>	<u>81,178</u>			<u>1,593,209</u>	<u>56,628</u>
Social, Behavioral, and Economic Sciences	47.075	22,519	-			22,519	
47.075 Total		<u>22,519</u>	<u>-</u>			<u>22,519</u>	<u>-</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Education and Human Resources	47.076	1,389,317	-			1,389,317	159,400
Education and Human Resources	47.076	-	88,248	UNIVERSITY OF ALABAMA IN TUSCALOOSA	HRD1619659	88,248	
Education and Human Resources	47.076	-	(22)	SKAGIT VALLEY COLLEGE	1617-184	(22)	
47.076 Total		<u>1,389,317</u>	<u>88,226</u>			<u>1,477,543</u>	<u>159,400</u>
International Science and Engineering (OISE)	47.079	78,426	-			78,426	
47.079 Total		<u>78,426</u>	<u>-</u>			<u>78,426</u>	<u>-</u>
Office of Integrative Activities	47.083	-	456,812	UNIVERSITY OF ALABAMA IN HUNTSVILLE	OIA-1655280	456,812	
Office of Integrative Activities	47.083	316,352	-			316,352	
Office of Integrative Activities	47.083	-	107,874	RAND CORPORATION	49100421C0029	107,874	
Office of Integrative Activities	47.083	-	33,434	UNIVERSITY OF THE VIRGIN ISLANDS	OIA-1946412	33,434	
Office of Integrative Activities	47.083	-	29,642	CLEMSON UNIVERSITY	OIA-1632881	29,642	
Office of Integrative Activities	47.083	-	(637)	LOUISIANA STATE UNIVERSITY	OIA-1632891	(637)	
Office of Integrative Activities	47.083	-	(3,960)	UNIVERSITY OF SOUTHERN MISSISSIPPI	OIA-1632825	(3,960)	
47.083 Total		<u>316,352</u>	<u>623,165</u>			<u>939,517</u>	<u>-</u>
NSF Technology, Innovation, and Partnerships	47.084	7,931	-			7,931	
47.084 Total		<u>7,931</u>	<u>-</u>			<u>7,931</u>	<u>-</u>
Total National Science Foundation		<u>5,657,729</u>	<u>783,732</u>			<u>6,441,461</u>	<u>216,028</u>
Department of Veterans Affairs							
Contract - Intergovernmental Personnel Agreements	64.RD	2,850,640	-			2,850,640	
Contract #36C24E21D0038	64.RD	332,792	-			332,792	
Contract #36C24E2190175	64.RD	89,100	-			89,100	
Contract #VA247-17-C-0209	64.RD	37,428	-			37,428	
Contract #36C24221D0018/526D3004/526D103	64.RD	16,244	-			16,244	
Contract #36C24E21P0176	64.RD	5,792	-			5,792	
Contract #36C24720P1354/521D27105	64.RD	1,635	-			1,635	
Contract #36C24720P1328 BASE 521D27105	64.RD	1,052	-			1,052	
Contract #36C24720P1379	64.RD	(265)	-			(265)	
64.RD Total		<u>3,334,418</u>	<u>-</u>			<u>3,334,418</u>	<u>-</u>
Total Department of Veterans Affairs		<u>3,334,418</u>	<u>-</u>			<u>3,334,418</u>	<u>-</u>
Nuclear Regulatory Commission							
U.S. Nuclear Regulatory Commission Scholarship and	77.008	30,000	-			30,000	
77.008 Total		<u>30,000</u>	<u>-</u>			<u>30,000</u>	<u>-</u>
Total Nuclear Regulatory Commission		<u>30,000</u>	<u>-</u>			<u>30,000</u>	<u>-</u>
Department of Energy							
Office of Science Financial Assistance Program	81.049	1,120,111	-			1,120,111	166,084
Office of Science Financial Assistance Program	81.049	-	123,593	ARIZONA STATE UNIVERSITY	DE-SC0021230	123,593	
Office of Science Financial Assistance Program	81.049	-	13,496	TEXAS A&M UNIVERSITY	DE-SC0022550	13,496	
Office of Science Financial Assistance Program	81.049	-	18	APPLIED DIAMOND INC.	DE-SC0020499	18	
81.049 Total		<u>1,120,111</u>	<u>137,107</u>			<u>1,257,218</u>	<u>166,084</u>
Conservation Research and Development	81.086	-	47,417	OAK RIDGE NATIONAL LABORATORY	DE-AC05-00OR22725	47,417	
81.086 Total		<u>-</u>	<u>47,417</u>			<u>47,417</u>	<u>-</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Fossil Energy Research and Development	81.089	-	65,161	SOUTHERN STATES ENERGY BOARD	DE-FE0031888	65,161	-
Fossil Energy Research and Development	81.089	-	19,739	COLLABORATIVE COMPOSITE SOLUTIONS CORP	DE-FE0032045	19,739	-
81.089 Total		-	84,900			84,900	-
Stewardship Science Grant Program	81.112	220,614	-			220,614	-
81.112 Total		220,614	-			220,614	-
Total Department of Energy		1,340,725	269,424			1,610,149	166,084
Department of Education							
Education Research, Development and Dissemination	84.305	478,731	-			478,731	-
84.305 Total		478,731	-			478,731	-
Total Department of Education		478,731	-			478,731	-
Department of Health and Human Services							
Chronic Diseases: Research, Control, and Prevention	93.068	589,834	-			589,834	120,126
93.068 Total		589,834	-			589,834	120,126
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	-	28,408	UNIVERSITY OF MICHIGAN	5U54CA229974-04	28,408	-
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	309	-			309	-
93.077 Total		309	28,408			28,717	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	201,878	-			201,878	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	-	30,033	HEMOPHILIA OF GEORGIA INC	NU27DD000020-02-00	30,033	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	-	905	HEMOPHILIA OF GEORGIA INC	NU27DD000020-01-00	905	-
93.080 Total		201,878	30,938			232,816	-
Food and Drug Administration_Research	93.103	118,999	-			118,999	26,452
Food and Drug Administration_Research	93.103	-	45,660	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	1R01FD007275-01	45,660	-
Food and Drug Administration_Research	93.103	-	17,902	SEATTLE CHILDREN'S HOSPITAL	1R01FD006848-01	17,902	-
Food and Drug Administration_Research	93.103	-	8,319	NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDIC	5U01FD005478-04	8,319	-
Food and Drug Administration_Research	93.103	-	1,813	YALE UNIVERSITY	5U01FD005938-05	1,813	-
93.103 Total		118,999	73,694			192,693	26,452
Environmental Health	93.113	7,584,801	-			7,584,801	963,604
Environmental Health	93.113	-	111,851	WAYNE STATE UNIVERSITY	2R01ES022606-06	111,851	-
Environmental Health	93.113	-	45,765	REGENTS OF THE UNIVERSITY OF COLORADO	5R01ES032612-02	45,765	-
93.113 Total		7,584,801	157,616			7,742,417	963,604
Oral Diseases and Disorders Research	93.121	6,394,470	-			6,394,470	2,677,939
Oral Diseases and Disorders Research	93.121	-	67,953	UNIVERSITY OF PUERTO RICO	R01DE028195	67,953	-
Oral Diseases and Disorders Research	93.121	-	56,773	OREGON HEALTH & SCIENCES UNIVERSITY	5R01DE028329-04	56,773	-
Oral Diseases and Disorders Research	93.121	-	41,842	OREGON HEALTH & SCIENCES UNIVERSITY	7R01DE022350-08	41,842	-
Oral Diseases and Disorders Research	93.121	-	30,168	KAISER FOUNDATION RESEARCH INSTITUTE	5U01DE028727-03	30,168	-
Oral Diseases and Disorders Research	93.121	-	22,125	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	5UG3DE029973-02	22,125	19,115
Oral Diseases and Disorders Research	93.121	-	17,096	PHOENIX CHILDREN'S HOSPITAL	5U01DE029750-02	17,096	-
Oral Diseases and Disorders Research	93.121	-	17,002	KAISER FOUNDATION RESEARCH INSTITUTE	5U01DE028727-04	17,002	-
Oral Diseases and Disorders Research	93.121	-	14,821	UNIVERSITY OF TEXAS HEALTH SCIENCE CTR AT HOUSTON	4UH3DE029158-03	14,821	-
Oral Diseases and Disorders Research	93.121	-	6,407	UNIVERSITY OF UTAH	5R01DE027493-04	6,407	-
Oral Diseases and Disorders Research	93.121	-	4,307	INDIANA UNIVERSITY	1UG3DE030087-01	4,307	-
Oral Diseases and Disorders Research	93.121	-	2,027	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	UG3DE029973	2,027	2,027
Oral Diseases and Disorders Research	93.121	-	1,832	CREATV MICROTECH, INC.	1R41DE028475-01A1	1,832	-
93.121 Total		6,394,470	282,353			6,676,823	2,699,081

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Injury Prevention and Control Research and State and Community Based Programs	93.136	327,350	-			327,350	-
93.136 Total		<u>327,350</u>	<u>-</u>			<u>327,350</u>	<u>-</u>
Community Programs to Improve Minority Health Grant Program	93.137	238,067	-			238,067	-
93.137 Total		<u>238,067</u>	<u>-</u>			<u>238,067</u>	<u>-</u>
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	1,354,296	-			1,354,296	58,170
93.143 Total		<u>1,354,296</u>	<u>-</u>			<u>1,354,296</u>	<u>58,170</u>
AIDS Education and Training Centers	93.145	-	56,083	VANDERBILT UNIVERSITY MEDICAL CENTER	5U10HA30535-06-00	56,083	-
93.145 Total		<u>-</u>	<u>56,083</u>			<u>56,083</u>	<u>-</u>
Human Genome Research	93.172	2,289,149	-			2,289,149	270,487
Human Genome Research	93.172	-	348,472	HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	5U01HG007301-08	348,472	-
Human Genome Research	93.172	-	166,005	HARVARD MEDICAL - SCHEPHENS EYE RESEARCH	5U01HG007530-08	166,005	-
Human Genome Research	93.172	-	98,701	UNIVERSITY OF FLORIDA	3U01HG007269-08S1	98,701	-
Human Genome Research	93.172	-	23,941	UNIVERSITY OF UTAH	1R01HG11921-01	23,941	-
Human Genome Research	93.172	-	(8,080)	HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	5U01HG007301-07	(8,080)	-
93.172 Total		<u>2,289,149</u>	<u>629,039</u>			<u>2,918,188</u>	<u>270,487</u>
Research Related to Deafness and Communication Disorders	93.173	586,722	-			586,722	156,559
Research Related to Deafness and Communication Disorders	93.173	-	68,375	UNIVERSITY OF ALABAMA IN TUSCALOOSA	5R01DC016303-06	68,375	-
Research Related to Deafness and Communication Disorders	93.173	-	38,493	UNIVERSITY OF MINNESOTA	1R01DC017613-01A1	38,493	-
93.173 Total		<u>586,722</u>	<u>106,868</u>			<u>693,590</u>	<u>156,559</u>
Research and Training in Complementary and Alternative Medicine	93.213	1,575,962	-			1,575,962	359,456
Research and Training in Complementary and Alternative Medicine	93.213	-	176,919	UNIVERSITY OF MINNESOTA	5R01HL150053-03	176,919	-
Research and Training in Complementary and Alternative Medicine	93.213	-	73,217	BROWN UNIVERSITY	1R01AT011184-01	73,217	-
Research and Training in Complementary and Alternative Medicine	93.213	-	12,717	HARVARD COLLEGE	5R01ES022981-06	12,717	-
Research and Training in Complementary and Alternative Medicine	93.213	-	11,364	NORTHWESTERN UNIVERSITY	5R01HL146844-02	11,364	-
93.213 Total		<u>1,575,962</u>	<u>274,217</u>			<u>1,850,179</u>	<u>359,456</u>
Research on Healthcare Costs, Quality and Outcomes	93.226	1,662,994	-			1,662,994	527,905
Research on Healthcare Costs, Quality and Outcomes	93.226	-	25,467	UNIVERSITY OF ARKANSAS FOR MEDICAL STUDIES	1R01HS025703-01A1	25,467	-
Research on Healthcare Costs, Quality and Outcomes	93.226	-	(31)	UNIVERSITY OF ALABAMA IN TUSCALOOSA	1R21HS026571-01	(31)	-
93.226 Total		<u>1,662,994</u>	<u>25,436</u>			<u>1,688,430</u>	<u>527,905</u>
National Center on Sleep Disorders Research	93.233	666,203	-			666,203	237,800
National Center on Sleep Disorders Research	93.233	-	84,823	NORTHWESTERN UNIVERSITY	1R01HL152442	84,823	-
National Center on Sleep Disorders Research	93.233	-	(15)	NORTHWESTERN UNIVERSITY	1R01HL152442-01	(15)	-
93.233 Total		<u>666,203</u>	<u>84,808</u>			<u>751,011</u>	<u>237,800</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Mental Health Research Grants	93.242	12,281,644	-			12,281,644	1,206,143
Mental Health Research Grants	93.242	-	170,699	UNIVERSITY OF PITTSBURGH	1R01MH115754-01A1	170,699	
Mental Health Research Grants	93.242	-	94,529	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R34MH119962-03	94,529	
Mental Health Research Grants	93.242	-	91,607	SISTEMA UNIVERSITARIO ANA G. MENDEZ	1R21MH129037-01	91,607	
Mental Health Research Grants	93.242	-	78,633	UNIVERSITY OF CHICAGO	1R01MH125744-01	78,633	
Mental Health Research Grants	93.242	-	39,858	UNIVERSITY OF MARYLAND	1R34MH122265-01A1	39,858	
Mental Health Research Grants	93.242	-	39,140	YALE UNIVERSITY	5U19MH108206-06	39,140	
Mental Health Research Grants	93.242	-	27,237	UNIVERSITY OF MARYLAND	5R24MH122265-02	27,237	
Mental Health Research Grants	93.242	-	25,949	BROWN UNIVERSITY	2R01MH112386-04	25,949	
Mental Health Research Grants	93.242	-	23,070	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	5U01MH115495-04	23,070	
Mental Health Research Grants	93.242	-	18,422	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01MH113438-03	18,422	
Mental Health Research Grants	93.242	-	16,937	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R34MH118058-03	16,937	
Mental Health Research Grants	93.242	-	11,038	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R25MH067127-18	11,038	
Mental Health Research Grants	93.242	-	10,197	MASSACHUSETTS GENERAL HOSPITAL	5R01MH112385-01	10,197	
Mental Health Research Grants	93.242	-	1,604	WITS HEALTH CONSORTIUM (PTY) LTD	1R34MH126743-01	1,604	
Mental Health Research Grants	93.242	-	1,076	THE RESEARCH FOUNDATION OF SUNY	1R01MH128955-01	1,076	
Mental Health Research Grants	93.242	-	282	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH110925-04	282	
Mental Health Research Grants	93.242	-	20	JOHNS HOPKINS UNIVERSITY	5R25MH080661-13	20	
Mental Health Research Grants	93.242	-	(448)	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH110925-05	(448)	
93.242 Total		<u>12,281,644</u>	<u>649,850</u>			<u>12,931,494</u>	<u>1,206,143</u>
Occupational Safety and Health Program	93.262	1,287,386	-			1,287,386	465,396
Occupational Safety and Health Program	93.262	-	10,000	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5T42OH008673-16-00	10,000	
93.262 Total		<u>1,287,386</u>	<u>10,000</u>			<u>1,297,386</u>	<u>465,396</u>
Alcohol Research Programs	93.273	1,030,781	-			1,030,781	148,103
Alcohol Research Programs	93.273	-	86,951	UNIVERSITY OF WASHINGTON	5U01AA020793-08	86,951	
Alcohol Research Programs	93.273	-	16,036	JOHNS HOPKINS UNIVERSITY	1P01AA029544-01	16,036	
Alcohol Research Programs	93.273	-	6,955	UNIVERSITY OF MARYLAND	5K08AA024895-05	6,955	
93.273 Total		<u>1,030,781</u>	<u>109,942</u>			<u>1,140,723</u>	<u>148,103</u>
Drug Abuse and Addiction Research Programs	93.279	5,208,822	-			5,208,822	740,882
Drug Abuse and Addiction Research Programs	93.279	-	45,282	NORTHWESTERN UNIVERSITY	1R01HL152442-01	45,282	
Drug Abuse and Addiction Research Programs	93.279	-	42,689	YALE UNIVERSITY	1UG3DA047003	42,689	
Drug Abuse and Addiction Research Programs	93.279	-	16,108	THE ROYAL INSTITUTION OF THE ADVANCEMENT OF LEARNI	5R01DA037911	16,108	
Drug Abuse and Addiction Research Programs	93.279	-	12,211	MASSACHUSETTS GENERAL HOSPITAL	5R01DA050482-03	12,211	
Drug Abuse and Addiction Research Programs	93.279	-	11,138	YALE UNIVERSITY	5P30DA018343-17	11,138	
Drug Abuse and Addiction Research Programs	93.279	-	10,085	UNIVERSITY OF PITTSBURGH	1R01DA054832-01	10,085	
Drug Abuse and Addiction Research Programs	93.279	-	6,047	MEDICAL UNIVERSITY OF SOUTH CAROLINA	5UG1DA013727-23	6,047	
Drug Abuse and Addiction Research Programs	93.279	-	4,893	MEDICAL UNIVERSITY OF SOUTH CAROLINA	5UG1DA013727-22	4,893	
93.279 Total		<u>5,208,822</u>	<u>148,453</u>			<u>5,357,275</u>	<u>740,882</u>
The Affordable Care Act: Centers for Disease Control and Prevention, Investigations and Technical Assistance	93.283	906,953	-			906,953	-
93.283 Total		<u>906,953</u>	<u>-</u>			<u>906,953</u>	<u>-</u>
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	620,374	-			620,374	39,278
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	594	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	7R01EB020125-06	594	
93.286 Total		<u>620,374</u>	<u>594</u>			<u>620,968</u>	<u>39,278</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Minority Health and Health Disparities Research	93.307	5,200,723	-			5,200,723	803,718
Minority Health and Health Disparities Research	93.307	-	56,982	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01MD016834-01	56,982	11,229
Minority Health and Health Disparities Research	93.307	-	20,901	UNIVERSITY OF PENNSYLVANIA	5R01MD013558	20,901	
Minority Health and Health Disparities Research	93.307	-	18,099	UNIVERSITY OF PENNSYLVANIA	5R01MD013558-06	18,099	
Minority Health and Health Disparities Research	93.307	-	11,732	OREGON HEALTH & SCIENCES UNIVERSITY	1R01MD014618-01A1	11,732	
Minority Health and Health Disparities Research	93.307	-	9,875	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5U01MD011279-05	9,875	
Minority Health and Health Disparities Research	93.307	-	633	UNIVERSITY OF TEXAS HEALTH SCIENCE CTR AT HOUSTON	U24MD006941	633	
Minority Health and Health Disparities Research	93.307	-	258	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01MD011609-04	258	
Minority Health and Health Disparities Research	93.307	-	(569)	BAYOU LA BATRE CLINIC	1U54MD008602	(569)	
93.307 Total		<u>5,200,723</u>	<u>117,911</u>			<u>5,318,634</u>	<u>814,947</u>
COVID-19 Trans-NIH Research Support	93.310	970,520	-			970,520	
Trans-NIH Research Support	93.310	934,278	-			934,278	
Trans-NIH Research Support	93.310	-	672,342	BALL STATE UNIVERSITY	5U01AR071133-06	672,342	
Trans-NIH Research Support	93.310	-	148,161	HARVARD COLLEGE	5U01HG007530-08	148,161	
Trans-NIH Research Support	93.310	-	147,004	BALL STATE UNIVERSITY	7U01AR071133-05	147,004	
Trans-NIH Research Support	93.310	-	67,146	UNIVERSITY OF KANSAS MEDICAL CENTER	1U01MD017415-01	67,146	
Trans-NIH Research Support	93.310	-	63,338	YALE UNIVERSITY	5UG3NS115597-03	63,338	
Trans-NIH Research Support	93.310	-	40,089	UNIVERSITY OF UTAH	OT2HL161847-01	40,089	
Trans-NIH Research Support	93.310	-	18,083	BRIGHAM & WOMENS HOSPITAL	5U01CA242109-04	18,083	
Trans-NIH Research Support	93.310	-	2,642	BRIGHAM & WOMENS HOSPITAL	7U01CA242109-03	2,642	
Trans-NIH Research Support	93.310	-	(569)	YALE UNIVERSITY	5UG3NS115597-02	(569)	
93.310 Total		<u>1,904,798</u>	<u>1,158,236</u>			<u>3,063,034</u>	<u>-</u>
Rare Disorders: Research, Surveillance, Health Promotion, and Education	93.315	28,128	-			28,128	
93.315 Total		<u>28,128</u>	<u>-</u>			<u>28,128</u>	<u>-</u>
COVID-19 Protecting and Improving Health Globally	93.318	749,148	-			749,148	30,588
93.318 Total		<u>749,148</u>	<u>-</u>			<u>749,148</u>	<u>30,588</u>
National Center for Advancing Translational Sciences	93.350	23,214,718	-			23,214,718	6,868,050
National Center for Advancing Translational Sciences	93.350	-	223,427	NORTHWESTERN UNIVERSITY	1U01TR003528-01A1	223,427	
National Center for Advancing Translational Sciences	93.350	-	37,954	BRIGHAM & WOMENS HOSPITAL	1U01TR003201-01A1	37,954	
National Center for Advancing Translational Sciences	93.350	-	10,211	UNIVERSITY OF IOWA	5UL1TR002537-03	10,211	
National Center for Advancing Translational Sciences	93.350	-	9,976	UNIVERSITY OF MASSACHUSETTS WORCESTER	5U01TR001812-05	9,976	
COVID-19 National Center for Advancing Translational Sciences	93.350	1,775	-			1,775	
93.350 Total		<u>23,216,493</u>	<u>281,568</u>			<u>23,498,061</u>	<u>6,868,050</u>
Research Infrastructure Programs	93.351	6,005,626	-			6,005,626	
93.351 Total		<u>6,005,626</u>	<u>-</u>			<u>6,005,626</u>	<u>-</u>
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	1,036,830	-			1,036,830	620,038
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	-	4,455	CASE WESTERN UNIVERSITY	3P30CA043703-30S4	4,455	
93.353 Total		<u>1,036,830</u>	<u>4,455</u>			<u>1,041,285</u>	<u>620,038</u>
Nursing Research	93.361	1,832,368	-			1,832,368	147,486
Nursing Research	93.361	-	189,638	UNIVERSITY OF WASHINGTON	7R01NR018391-04	189,638	
Nursing Research	93.361	-	100,069	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01NR019758-01	100,069	
Nursing Research	93.361	-	38,909	UNIVERSITY OF MINNESOTA	5R21NR019676-02	38,909	
Nursing Research	93.361	-	23,052	CEDARS-SINAI MEDICAL CENTER	1R01NR019947-01	23,052	
Nursing Research	93.361	-	1,127	DANA-FARBER CANCER INSTITUTE	5R01NR016720-04	1,127	
Nursing Research	93.361	-	(133)	CASE WESTERN UNIVERSITY	7R01NR018391-04	(133)	
93.361 Total		<u>1,832,368</u>	<u>352,662</u>			<u>2,185,030</u>	<u>147,486</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
National and State Tobacco Control Program	93.387	1,229,332	-			1,229,332	556,432
93.387 Total		<u>1,229,332</u>	<u>-</u>			<u>1,229,332</u>	<u>556,432</u>
Cancer Cause and Prevention Research	93.393	8,776,202	-			8,776,202	969,775
Cancer Cause and Prevention Research	93.393	-	213,480	UNIVERSITY OF MASSACHUSETTS WORCESTER	5R01CA218008-02	213,480	
Cancer Cause and Prevention Research	93.393	-	170,178	CEDARS-SINAI MEDICAL CENTER	5R01CA258222-02	170,178	
Cancer Cause and Prevention Research	93.393	-	142,638	MASSACHUSETTS GENERAL HOSPITAL	7R01CA225792-04	142,638	
Cancer Cause and Prevention Research	93.393	-	135,147	UNIVERSITY OF KANSAS MEDICAL CENTER	1R01CA226838-05	135,147	
Cancer Cause and Prevention Research	93.393	-	105,910	UNIVERSITY OF TENNESSEE IN MEMPHIS	2R01CA242737-02	105,910	
Cancer Cause and Prevention Research	93.393	-	98,718	NEW YORK UNIVERSITY	1R01CA249981-01A1	98,718	
Cancer Cause and Prevention Research	93.393	-	53,501	VANDERBILT UNIVERSITY MEDICAL CENTER	5P01CA02882-33	53,501	
Cancer Cause and Prevention Research	93.393	-	49,725	CHILDREN'S HOSPITAL BOSTON	5U24CA248010-02	49,725	
Cancer Cause and Prevention Research	93.393	-	44,376	FRED HUTCHINSON CANCER RESEARCH CENTER	5R01CA213130-04	44,376	
Cancer Cause and Prevention Research	93.393	-	30,033	H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE	7R01CA53219-02	30,033	
Cancer Cause and Prevention Research	93.393	-	26,763	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE	5U01CA235507-04	26,763	
Cancer Cause and Prevention Research	93.393	-	23,682	JOHNS HOPKINS UNIVERSITY	1R01CA252101-01A1	23,682	
Cancer Cause and Prevention Research	93.393	-	21,052	DUKE UNIVERSITY	7R37CA233777-02	21,052	
Cancer Cause and Prevention Research	93.393	-	11,652	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	3R01CA213987-05S1	11,652	
Cancer Cause and Prevention Research	93.393	-	11,598	DARTMOUTH COLLEGE	1R01CA225792-01A1	11,598	
Cancer Cause and Prevention Research	93.393	-	5,508	GEORGIA STATE UNIVERSITY	5R01CA239120-03	5,508	
Cancer Cause and Prevention Research	93.393	-	(4,499)	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	5R01CA199167-03	(4,499)	
93.393 Total		<u>8,776,202</u>	<u>1,139,462</u>			<u>9,915,664</u>	<u>969,775</u>
Cancer Detection and Diagnosis Research	93.394	5,154,716	-			5,154,716	339,490
COVID-19 Cancer Detection and Diagnosis Research	93.394	669,935	-			669,935	
Cancer Detection and Diagnosis Research	93.394	-	472,676	PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDI	5P01CA221775-04	472,676	
Cancer Detection and Diagnosis Research	93.394	-	116,468	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R01CA237533-02	116,468	
Cancer Detection and Diagnosis Research	93.394	-	90,321	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R01CA237533-03	90,321	
Cancer Detection and Diagnosis Research	93.394	-	67,512	UNIVERSITY OF CALIFORNIA - BERKELEY	5R01CA246695-02	67,512	
Cancer Detection and Diagnosis Research	93.394	-	16,351	UNIVERSITY OF BRITISH COLUMBIA	1R01CA221918-01A1	16,351	
Cancer Detection and Diagnosis Research	93.394	-	5,231	UNIVERSITY OF MARYLAND	1R01CA228399-01A1	5,231	
Cancer Detection and Diagnosis Research	93.394	-	3,840	MEMORIAL SLOAN KETTERING CANCER CENTER	1R01CA235711-01A1	3,840	
Cancer Detection and Diagnosis Research	93.394	-	3,765	MEMORIAL SLOAN KETTERING CANCER CENTER	5R01CA235711-03	3,765	
Cancer Detection and Diagnosis Research	93.394	-	2,881	UNIVERSITY OF MICHIGAN	5U24CA086368-18	2,881	
Cancer Detection and Diagnosis Research	93.394	-	(1,661)	NRG ONCOLOGY INC	1U10CA180860-1	(1,661)	
93.394 Total		<u>5,824,651</u>	<u>777,384</u>			<u>6,602,035</u>	<u>339,490</u>
Cancer Treatment Research	93.395	4,625,486	-			4,625,486	548,407
Cancer Treatment Research	93.395	-	111,231	PUBLIC HEALTH INSTITUTE	3U10CA180886-08S3	111,231	
Cancer Treatment Research	93.395	-	104,117	TREOVIR, LLC	1R44CA250883-01	104,117	
Cancer Treatment Research	93.395	-	103,904	PUBLIC HEALTH INSTITUTE	7U10CA180886-08	103,904	
Cancer Treatment Research	93.395	-	88,607	CHILDREN'S HOSPITAL OF PHILADELPHIA	1U01CA228823-01	88,607	
Cancer Treatment Research	93.395	-	51,340	SEATTLE CHILDREN'S HOSPITAL	5R01CA225629-03	51,340	
Cancer Treatment Research	93.395	-	28,070	CHILDREN'S HOSPITAL OF PHILADELPHIA	2U10CA180886-06	28,070	
Cancer Treatment Research	93.395	-	22,571	CHILDREN'S HOSPITAL OF PHILADELPHIA	2U10CA180886	22,571	
Cancer Treatment Research	93.395	-	18,666	EASTERN COOPERATIVE ONCOLOGY GROUP	U10CA180820-06	18,666	
Cancer Treatment Research	93.395	-	11,280	SEATTLE CHILDREN'S HOSPITAL	5R01CA175216-05	11,280	
Cancer Treatment Research	93.395	-	10,186	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01CA269974-01	10,186	
Cancer Treatment Research	93.395	-	9,801	PUBLIC HEALTH INSTITUTE	U10CA180886	9,801	
Cancer Treatment Research	93.395	-	8,586	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	U24CA055727	8,586	
Cancer Treatment Research	93.395	-	7,108	PUBLIC HEALTH INSTITUTE	5U10CA180886-09 REVISED	7,108	
Cancer Treatment Research	93.395	-	6,865	UNIVERSITY OF CALIFORNIA IN SAN DIEGO	1R01CA255780-01	6,865	

The accompanying notes are an integral part of this schedule.

**The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022**

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cancer Treatment Research	93.395	-	5,694	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	2U24CA055727-28	5,694	
Cancer Treatment Research	93.395	-	5,390	SEATTLE CHILDREN'S HOSPITAL	5R01CA175216-04	5,390	
Cancer Treatment Research	93.395	-	4,403	PUBLIC HEALTH INSTITUTE	7U10CA180866-09	4,403	
Cancer Treatment Research	93.395	-	3,465	NRG ONCOLOGY INC	5U10CA180868-09	3,465	
Cancer Treatment Research	93.395	-	1,799	JOHNS HOPKINS UNIVERSITY	U01CA137443	1,799	
Cancer Treatment Research	93.395	-	1,488	NRG ONCOLOGY INC	2U10CA180868-06	1,488	
Cancer Treatment Research	93.395	-	663	CHILDREN'S HOSPITAL OF PHILADELPHIA	310CA180866-06S1	663	
Cancer Treatment Research	93.395	-	545	UNIVERSITY OF SOUTH FLORIDA	1R01CA244947-01	545	
Cancer Treatment Research	93.395	-	355	MAYO CLINIC ROCHESTER	5UG1CA189823-03	355	
Cancer Treatment Research	93.395	-	196	TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC	1R43CA246883-01	196	
Cancer Treatment Research	93.395	-	(2,045)	JOHNS HOPKINS UNIVERSITY	UM1CA137443	(2,045)	
Cancer Treatment Research	93.395	-	(4,284)	JOHNS HOPKINS UNIVERSITY	UM1 CA137443	(4,284)	
Cancer Treatment Research	93.395	-	(4,548)	JOHNS HOPKINS UNIVERSITY	5UM1CA137443	(4,548)	
Cancer Treatment Research	93.395	-	(5,526)	JOHNS HOPKINS UNIVERSITY	U01CA137443-01	(5,526)	
93.395 Total		<u>4,625,486</u>	<u>589,927</u>			<u>5,215,413</u>	<u>548,407</u>
Cancer Biology Research	93.396	6,359,278	-			6,359,278	346,094
Cancer Biology Research	93.396	-	163,363	UNIVERSITY OF PITTSBURGH	7R01CA230628-05	163,363	
Cancer Biology Research	93.396	-	113,399	UNIVERSITY OF MICHIGAN	2P01CA093000-16	113,399	
Cancer Biology Research	93.396	-	16,475	UNIVERSITY OF PITTSBURGH	7R01CA242021-03	16,475	
Cancer Biology Research	93.396	-	8,701	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	1R01CA238315-01A1	8,701	
Cancer Biology Research	93.396	-	138	PENNSYLVANIA STATE UNIVERSITY (THE)	1R01CA230628-01A1	138	
93.396 Total		<u>6,359,278</u>	<u>302,076</u>			<u>6,661,354</u>	<u>346,094</u>
Cancer Centers Support Grants	93.397	5,661,877	-			5,661,877	237,263
Cancer Centers Support Grants	93.397	-	597,817	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	5P50CA107399-14	597,817	90,926
Cancer Centers Support Grants	93.397	-	405,886	JOHNS HOPKINS UNIVERSITY	5P50CA098252-18	405,886	
Cancer Centers Support Grants	93.397	-	141,182	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	5P50CA107399-13	141,182	78,006
Cancer Centers Support Grants	93.397	-	17,262	JOHNS HOPKINS UNIVERSITY	2P50CA098252-16	17,262	
Cancer Centers Support Grants	93.397	-	9,846	MAYO CLINIC ROCHESTER	2P50CA136393-11A1	9,846	
93.397 Total		<u>5,661,877</u>	<u>1,171,993</u>			<u>6,833,870</u>	<u>406,195</u>
Cancer Research Manpower	93.398	2,392,280	-			2,392,280	9,039
93.398 Total		<u>2,392,280</u>	<u>-</u>			<u>2,392,280</u>	<u>9,039</u>
Cancer Control	93.399	54,399	-			54,399	17,022
Cancer Control	93.399	-	29,458	NRG ONCOLOGY INC	5UG1CA189867-08	29,458	
Cancer Control	93.399	-	27,325	OREGON HEALTH & SCIENCES UNIVERSITY	5UG1CA189974-08	27,325	
Cancer Control	93.399	-	8,060	PUBLIC HEALTH INSTITUTE	7UG1CA189955-08	8,060	
Cancer Control	93.399	-	5,402	CHILDREN'S HOSPITAL OF PHILADELPHIA	2UG1CA189955-06	5,402	
Cancer Control	93.399	-	(3,046)	OREGON HEALTH & SCIENCES UNIVERSITY	5UG1CA189974-07	(3,046)	
93.399 Total		<u>54,399</u>	<u>67,199</u>			<u>121,598</u>	<u>17,022</u>
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	-	60,118	UNIVERSITY OF VERMONT COLLEGE OF MEDICINE	6NU38OT000280-04-00	60,118	
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	-	18,399	WASHINGTON UNIVERSITY IN ST LOUIS	5-NU38OT000286-3	18,399	
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	-	1,034	UNIVERSITY OF VERMONT COLLEGE OF MEDICINE	6NU38OT000280-03-02	1,034	
93.421 Total		<u>-</u>	<u>79,551</u>			<u>79,551</u>	<u>-</u>
Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations	93.431	-	18,262	NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO	5NU58DP006488-04-00	18,262	
Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations	93.431	-	2,275	NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO	NU58DP006488	2,275	
93.431 Total		<u>-</u>	<u>20,537</u>			<u>20,537</u>	<u>-</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	3,194,668	-			3,194,668	502,620
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	117,491	UNIVERSITY OF CHICAGO	90REGE0005-01-00	117,491	33,785
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	19,450	CRAIG HOSPITAL	90DPTB0017-04-00	19,450	
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	14,730	KAMIN CONSULTING INC.	90BISA0042-01-00	14,730	
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	4,337	CRAIG HOSPITAL	90DPTB0017	4,337	
93.433 Total		<u>3,194,668</u>	<u>156,008</u>			<u>3,350,676</u>	<u>536,405</u>
Congressional Directives	93.493	<u>142,302</u>	-			<u>142,302</u>	
93.493 Total		<u>142,302</u>	-			<u>142,302</u>	-
Cardiovascular Diseases Research	93.837	<u>22,935,939</u>	-			<u>22,935,939</u>	<u>4,315,416</u>
Cardiovascular Diseases Research	93.837	-	1,626,437	BOSTON UNIVERSITY MEDICAL CAMPUS	3U01HL146382-03	1,626,437	
Cardiovascular Diseases Research	93.837	-	249,479	SEATTLE CHILDREN'S HOSPITAL	5R01HL146130-04	249,479	
Cardiovascular Diseases Research	93.837	-	228,178	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01HL148661-03	228,178	
Cardiovascular Diseases Research	93.837	-	182,899	INDIANA UNIVERSITY	5R01HL145528-03	182,899	
Cardiovascular Diseases Research	93.837	-	134,625	MASSACHUSETTS GENERAL HOSPITAL	5R01HL146751-03	134,625	
Cardiovascular Diseases Research	93.837	-	130,775	CORNELL UNIVERSITY	5R01HL080477-14	130,775	
Cardiovascular Diseases Research	93.837	-	124,359	UNIVERSITY OF MINNESOTA	5R01HL150053-03	124,359	
Cardiovascular Diseases Research	93.837	-	82,336	CHILDREN'S HOSPITAL BOSTON	5R01HL58097-02	82,336	
Cardiovascular Diseases Research	93.837	-	77,102	NORTHWESTERN UNIVERSITY	5R01HL149866-02	77,102	
Cardiovascular Diseases Research	93.837	-	72,230	MEDICAL COLLEGE OF WISCONSIN	5R01HL140493-03	72,230	
Cardiovascular Diseases Research	93.837	-	66,460	ARCUS-MED, LLC	1R41HL145838-01A1	66,460	
Cardiovascular Diseases Research	93.837	-	60,413	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	5R01HL146130-04	60,413	
Cardiovascular Diseases Research	93.837	-	57,010	UNIVERSITY OF VIRGINIA	1R01HL159945-01	57,010	
Cardiovascular Diseases Research	93.837	-	54,803	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1R01HL155226-01	54,803	
Cardiovascular Diseases Research	93.837	-	49,725	NORTHWESTERN UNIVERSITY	1R01HL149866-01A1	49,725	
Cardiovascular Diseases Research	93.837	-	45,951	BRIGHAM & WOMENS HOSPITAL	5U01HL123336-06	45,951	
Cardiovascular Diseases Research	93.837	-	42,823	NAVIDEA BIOPHARMACEUTICALS, INC.	1R41HL147640-01A1	42,823	
Cardiovascular Diseases Research	93.837	-	42,037	VANDERBILT UNIVERSITY MEDICAL CENTER	5P01HL128203-05	42,037	
Cardiovascular Diseases Research	93.837	-	41,442	UNIVERSITY OF MARYLAND	5U24HL134763	41,442	
Cardiovascular Diseases Research	93.837	-	41,253	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01HL142825-01A1	41,253	
Cardiovascular Diseases Research	93.837	-	40,799	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01HL155081-02	40,799	
Cardiovascular Diseases Research	93.837	-	40,613	INDIANA UNIVERSITY	2R25HL124208-06	40,613	
Cardiovascular Diseases Research	93.837	-	39,140	CORNELL UNIVERSITY	5R01HL135199-05	39,140	
Cardiovascular Diseases Research	93.837	-	33,235	OREGON HEALTH & SCIENCES UNIVERSITY	5R01HL136373-04	33,235	
Cardiovascular Diseases Research	93.837	-	31,698	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01HL143885-04	31,698	
Cardiovascular Diseases Research	93.837	-	31,067	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01HL146636-01A1	31,067	
Cardiovascular Diseases Research	93.837	-	21,968	DUKE UNIVERSITY	1R01HL15731-01A1	21,968	
Cardiovascular Diseases Research	93.837	-	21,786	UNIVERSITY OF PITTSBURGH	1R01HL160326-01	21,786	
Cardiovascular Diseases Research	93.837	-	20,027	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01HL157075-02	20,027	
Cardiovascular Diseases Research	93.837	-	18,213	OREGON HEALTH & SCIENCES UNIVERSITY	1UG3HL145269-01A1	18,213	
Cardiovascular Diseases Research	93.837	-	17,571	KAISER FOUNDATION RESEARCH INSTITUTE	1R01HL158790-01	17,571	
Cardiovascular Diseases Research	93.837	-	17,444	CHILDREN'S HOSPITAL BOSTON	5R01HL158097-02	17,444	
Cardiovascular Diseases Research	93.837	-	15,338	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01HL143885-02	15,338	
Cardiovascular Diseases Research	93.837	-	14,580	UNIVERSITY OF CALIFORNIA IN SAN DIEGO	5R25HL145817-03	14,580	
Cardiovascular Diseases Research	93.837	-	13,131	INDIANA UNIVERSITY	1R01HL158647-02	13,131	
Cardiovascular Diseases Research	93.837	-	12,775	NEW ENGLAND RESEARCH INSTITUTE	5U24HL135691-03	12,775	
Cardiovascular Diseases Research	93.837	-	11,394	UNIVERSITY OF PENNSYLVANIA	5R01HL151292-02	11,394	
Cardiovascular Diseases Research	93.837	-	11,090	DUKE UNIVERSITY	5U01HL134679-02	11,090	
Cardiovascular Diseases Research	93.837	-	10,926	BRIGHAM & WOMENS HOSPITAL	5U01HL101422	10,926	
Cardiovascular Diseases Research	93.837	-	10,357	UNIVERSITY OF UTAH	1R01HL142603-03	10,357	
Cardiovascular Diseases Research	93.837	-	10,158	MASSACHUSETTS GENERAL HOSPITAL	5U01HL123336-06	10,158	
Cardiovascular Diseases Research	93.837	-	8,949	UNIVERSITY OF WASHINGTON	5R01HL156991-02	8,949	
Cardiovascular Diseases Research	93.837	-	6,395	KENT COUNTY MEMORIAL HOSPITAL	1R01HL150170-01A1	6,395	
Cardiovascular Diseases Research	93.837	-	6,058	THE GEORGE WASHINGTON UNIVERSITY	U24HL140168	6,058	
Cardiovascular Diseases Research	93.837	-	5,955	BRIGHAM & WOMENS HOSPITAL	5R01HL132021-02	5,955	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cardiovascular Diseases Research	93.837	-	5,201	THE SOCIETY OF THORACIC SURGEONS	5R01AG047416-05	5,201	
Cardiovascular Diseases Research	93.837	-	4,992	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01HL160929-01	4,992	
Cardiovascular Diseases Research	93.837	-	4,851	UNIVERSITY OF PENNSYLVANIA	1R01HL152707-01	4,851	
Cardiovascular Diseases Research	93.837	-	4,730	KENT COUNTY MEMORIAL HOSPITAL	R01HL150170-01A1	4,730	
Cardiovascular Diseases Research	93.837	-	4,357	THE SOCIETY OF THORACIC SURGEONS	5R01HL130502-05	4,357	
Cardiovascular Diseases Research	93.837	-	4,218	BRIGHAM & WOMENS HOSPITAL	5U01HL130163-02	4,218	
Cardiovascular Diseases Research	93.837	-	3,280	EMORY UNIVERSITY	5R01HL150887-01	3,280	
Cardiovascular Diseases Research	93.837	-	3,224	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5R01HL148448-04	3,224	
Cardiovascular Diseases Research	93.837	-	3,206	UNIVERSITY OF WASHINGTON	1R01HL156991-01	3,206	
Cardiovascular Diseases Research	93.837	-	2,800	UNIVERSITY OF PENNSYLVANIA	5R01HL148272-02	2,800	
Cardiovascular Diseases Research	93.837	-	2,580	KENT COUNTY MEMORIAL HOSPITAL	5R01HL150170-02	2,580	
Cardiovascular Diseases Research	93.837	-	2,390	RAND CORPORATION	R01HL155187	2,390	
Cardiovascular Diseases Research	93.837	-	1,718	BOSTON UNIVERSITY MEDICAL CAMPUS	1U01HL146382-02	1,718	
Cardiovascular Diseases Research	93.837	-	1,259	UNIVERSITY OF WASHINGTON	1R01HL156792-01	1,259	
Cardiovascular Diseases Research	93.837	-	320	NEW ENGLAND RESEARCH INSTITUTES INC	U01HL107407	320	
Cardiovascular Diseases Research	93.837	-	51	DUKE UNIVERSITY	5R01HL126524-04	51	
Cardiovascular Diseases Research	93.837	-	(272)	EMORY UNIVERSITY	5R01HL129511-03	(272)	
Cardiovascular Diseases Research	93.837	-	(571)	HARVARD MEDICAL - SCHEPPENS EYE RESEARCH	1R01HL136685-001	(571)	
Cardiovascular Diseases Research	93.837	-	(4,436)	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01HL139837-01	(4,436)	
Cardiovascular Diseases Research	93.837	-	(20,814)	UNIVERSITY OF WASHINGTON	5U01HL077863-10	(20,814)	
93.837 Total		22,935,939	3,904,088			26,840,027	4,315,416
Lung Diseases Research	93.838	15,052,601	-			15,052,601	1,585,638
Lung Diseases Research	93.838	-	1,156,908	NEW YORK UNIVERSITY MEDICAL SCHOOL	OT2HL161847-01	1,156,908	
Lung Diseases Research	93.838	-	888,790	TULANE UNIVERSITY	5P01HL114470-10	888,790	
Lung Diseases Research	93.838	-	422,071	TULANE UNIVERSITY	5P01HL114470-09	422,071	
Lung Diseases Research	93.838	-	174,014	EMORY UNIVERSITY	2R01HL136414-05	174,014	
Lung Diseases Research	93.838	-	131,377	EMORY UNIVERSITY	5R01HL139876-04	131,377	
Lung Diseases Research	93.838	-	128,063	NORTHWESTERN UNIVERSITY	5R01HL122477-06A1	128,063	
Lung Diseases Research	93.838	-	103,873	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICA	1R01HL157256-01A1	103,873	
Lung Diseases Research	93.838	-	89,727	UNIVERSITY OF SOUTH ALABAMA	1R01HL140182-01A1	89,727	
Lung Diseases Research	93.838	-	87,725	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1UG3HL152323-01	87,725	
Lung Diseases Research	93.838	-	83,205	BRIGHAM & WOMENS HOSPITAL	1R01HL149861-01A1	83,205	
Lung Diseases Research	93.838	-	67,060	NATIONAL JEWISH MEDICAL AND RESEARCH CENTER	2R01HL089897	67,060	
Lung Diseases Research	93.838	-	65,443	BOSTON UNIVERSITY MEDICAL CAMPUS	2R01HL126066-05	65,443	
Lung Diseases Research	93.838	-	65,242	THE GEORGE WASHINGTON UNIVERSITY	OT2HL161847-01	65,242	
Lung Diseases Research	93.838	-	58,553	EMORY UNIVERSITY	5R01HL136414-04	58,553	
Lung Diseases Research	93.838	-	51,006	NORTHWESTERN UNIVERSITY	3R01HL122477-07S1	51,006	
Lung Diseases Research	93.838	-	48,487	TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC	1R41HL152921-01	48,487	
COVID-19 Lung Diseases Research	93.838	47,340	-			47,340	
Lung Diseases Research	93.838	-	38,312	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01HL093081-10	38,312	
Lung Diseases Research	93.838	-	34,762	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01HL137880-04	34,762	
Lung Diseases Research	93.838	-	30,421	UNIVERSITY OF SOUTH ALABAMA	1R01HL148069-01A1	30,421	
Lung Diseases Research	93.838	-	20,774	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U24HL141762-04	20,774	
Lung Diseases Research	93.838	-	18,717	THE GEORGE WASHINGTON UNIVERSITY	R01HL098354	18,717	
Lung Diseases Research	93.838	-	18,293	UNIVERSITY OF PENNSYLVANIA	5U01HL145435-03	18,293	
Lung Diseases Research	93.838	-	18,234	THE GEORGE WASHINGTON UNIVERSITY	5R01HL098354-08	18,234	
Lung Diseases Research	93.838	-	15,196	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01HL137880-05	15,196	
Lung Diseases Research	93.838	-	13,926	NORTHWESTERN UNIVERSITY	1R01HL159250-01	13,926	
Lung Diseases Research	93.838	-	10,857	JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL	5R01HL144718-02	10,857	
Lung Diseases Research	93.838	-	7,998	UNIVERSITY OF PENNSYLVANIA	5U01HL145435-04	7,998	
Lung Diseases Research	93.838	-	6,991	UNIVERSITY OF MICHIGAN	1R01HL153519-01	6,991	
Lung Diseases Research	93.838	-	6,950	JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL	5R01HL144718-03	6,950	
Lung Diseases Research	93.838	-	6,315	JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL	1UG3HL154944-01A1	6,315	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Lung Diseases Research	93.838	-	5,015	YALE UNIVERSITY	5U01HL145567-03	5,015	
Lung Diseases Research	93.838	-	4,641	NORTHWESTERN UNIVERSITY	5U01HL146408	4,641	
Lung Diseases Research	93.838	-	3,043	STANFORD UNIVERSITY	5UH3HL141722-03	3,043	
Lung Diseases Research	93.838	-	2,750	VANDERBILT UNIVERSITY MEDICAL CENTER	5U01HL123009-07	2,750	
Lung Diseases Research	93.838	-	2,061	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U24HL141762-05	2,061	
Lung Diseases Research	93.838	-	236	NORTHWESTERN UNIVERSITY	3U01HL146408-02S1	236	
Lung Diseases Research	93.838	-	76	UNIVERSITY OF MICHIGAN	1R01HL147261-01A1	76	
93.838 Total		<u>15,099,941</u>	<u>3,887,112</u>			<u>18,987,053</u>	<u>1,585,638</u>
Blood Diseases and Resources Research	93.839	<u>2,152,671</u>	-			<u>2,152,671</u>	<u>816,079</u>
Blood Diseases and Resources Research	93.839	-	32,670	MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION	5U01HL133990-05	32,670	
Blood Diseases and Resources Research	93.839	-	29,879	BETH ISRAEL DEACONESS MEDICAL CENTER	5P01HL131477-05	29,879	
Blood Diseases and Resources Research	93.839	-	24,321	UNIVERSITY OF PITTSBURGH	1UGHL143192-01A1	24,321	
Blood Diseases and Resources Research	93.839	-	23,614	UNIVERSITY OF PITTSBURGH	1UG3HL143192-01A1	23,614	
Blood Diseases and Resources Research	93.839	-	9,596	AUGUSTA UNIVERSITY	5R25HL106365-13	9,596	
Blood Diseases and Resources Research	93.839	-	4,579	ALL CHILDREN'S RESEARCH INSTITUTE, INC.	1U01HL130048-01A1	4,579	
93.839 Total		<u>2,152,671</u>	<u>124,659</u>			<u>2,277,330</u>	<u>816,079</u>
Translation and Implementation Science Rsrch for Heart, Lung, Blood Diseases, Sleep Disorders	93.840	-	69,384	YALE UNIVERSITY	5R01HL151603-02	69,384	
Translation and Implementation Science Rsrch for Heart, Lung, Blood Diseases, Sleep Disorders	93.840	-	30,132	YALE UNIVERSITY	5R01HL151603-03	30,132	
Translation and Implementation Science Rsrch for Heart, Lung, Blood Diseases, Sleep Disorders	93.840	-	21,149	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	1UG3HL156389-02	21,149	
93.840 Total		<u>-</u>	<u>120,665</u>			<u>120,665</u>	<u>-</u>
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	7,361,215	-			7,361,215	1,179,762
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	79,331	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	1R01AR078559-01A1	79,331	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	20,102	MEDICAL UNIVERSITY OF SOUTH CAROLINA	3P30AR072582-04 (REVISED)	20,102	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	10,106	PENNSYLVANIA STATE UNIVERSITY (THE)	7R01AR048266-17	10,106	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	2,018	CHILDREN'S HOSPITAL OF PHILADELPHIA	1R01AR074098-02	2,018	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	22	CHILDREN'S HOSPITAL OF PHILADELPHIA	5R01AR079822-02	22	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	(91)	THE HOSPITAL FOR SICK CHILDREN	5R21AR074006-02	(91)	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	(8,760)	NORTHWESTERN UNIVERSITY	UH2AR067681	(8,760)	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	(11,141)	BRIGHAM & WOMENS HOSPITAL	1U01AR068043-01A1	(11,141)	
93.846 Total		<u>7,361,215</u>	<u>91,587</u>			<u>7,452,802</u>	<u>1,179,762</u>
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	27,842,483	-			27,842,483	3,614,723
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	241,402	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01DK115575-03	241,402	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	170,073	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01DK082753-11	170,073	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	163,850	THE ROGOSIN INSTITUTE	1RC2DK125960-01A1	163,850	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	148,510	MOUNT SINAI SCHOOL OF MEDICINE	5U54DK083909-13	148,510	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	120,352	UNIVERSITY OF MINNESOTA	1R01DK125274-01A1	120,352	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	113,558	UNIVERSITY OF CHICAGO	5U01DK127786-02	113,558	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	105,692	UNIVERSITY OF MIAMI	1R01DK116875-01A1	105,692	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	95,779	JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL	5R01DK23205-02	95,779	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	90,575	THE GEORGE WASHINGTON UNIVERSITY	5U01DK098246-09	90,575	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	64,292	JOHNS HOPKINS UNIVERSITY	5R01DK111966-05	64,292	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	52,717	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01DK100867-09	52,717	

The accompanying notes are an integral part of this schedule.

**The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022**

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	44,534	OREGON HEALTH & SCIENCES UNIVERSITY	7R01DK104347-03	44,534	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	42,781	MOUNT SINAI SCHOOL OF MEDICINE	5R01DK127139-02	42,781	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	39,901	VANDERBILT UNIVERSITY MEDICAL CENTER	5P30DK114809-05	39,901	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	37,851	INDIANA UNIVERSITY	1R01DK128252-01	37,851	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	36,729	VANDERBILT UNIVERSITY MEDICAL CENTER	1U01DK129989-01	36,729	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	33,162	DUKE UNIVERSITY	1R01DK121007-02	33,162	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	30,666	THE GEORGE WASHINGTON UNIVERSITY	1R01DK104845-01	30,666	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	28,271	INDIANA UNIVERSITY	1R01DK121378-04	28,271	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	25,885	UNIVERSITY OF CHICAGO	5U01DK127786-03	25,885	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	23,985	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	2U01DK100866-09	23,985	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	21,437	PENNSYLVANIA STATE UNIVERSITY (THE)	1R01DK114888-01	21,437	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	18,435	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01DK126959-02	18,435	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	16,144	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01DK115575-04	16,144	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	15,799	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R01DK120886-04	15,799	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	15,037	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01DK100867-10	15,037	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	15,004	INDIANA UNIVERSITY	5R01DK121378-02	15,004	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	14,274	OREGON HEALTH & SCIENCES UNIVERSITY	7R01DK112358-02	14,274	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	13,730	UNIVERSITY OF CALIFORNIA IN SAN DIEGO	5R01DK128803-03	13,730	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	10,521	UNIVERSITY OF PITTSBURGH	1R01DK124426-01A1	10,521	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	10,496	UNIVERSITY OF KANSAS MEDICAL CENTER	5R01DK113111-05	10,496	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	10,127	TEXAS A&M UNIVERSITY	1R01DK119497-01A1	10,127	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	9,361	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	2R01DK095662-10A1	9,361	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	8,946	MOUNT SINAI SCHOOL OF MEDICINE	1R01DK127139-01	8,946	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	8,330	REGENTS OF THE UNIVERSITY OF MINNESOTA	1R01DK125274-01A1	8,330	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	8,206	UNIVERSITY OF MASSACHUSETTS DARTMOUTH	1R01DK129432-01	8,206	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	6,838	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5U01DK058369-20	6,838	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	3,789	THE GEORGE WASHINGTON UNIVERSITY	R01DK104845	3,789	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	3,500	TUFTS MEDICAL CENTER INC.	5U01DK102730-05	3,500	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,887	EMORY UNIVERSITY	5R01DK087694-09	1,887	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,685	UNIVERSITY OF FLORIDA	1U24DK133700-01	1,685	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,181	UNIVERSITY OF CALIFORNIA IN SAN DIEGO	7R01DK128803-02	1,181	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	862	REGENTS OF THE UNIVERSITY OF COLORADO	5UM1DK072493-16	862	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	184	UNIVERSITY OF VIRGINIA	7R01DK126444-02	184	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(12)	THE GEORGE WASHINGTON UNIVERSITY	5U01DK098246-08	(12)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(6,481)	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01DK100867-08	(6,481)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(9,053)	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	2U01DK100866-08	(9,053)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(42,772)	THE CHILDREN'S MERCY HOSPITAL	5U01DK066143-17	(42,772)	
93.847 Total		<u>27,842,483</u>	<u>1,868,020</u>			<u>29,710,503</u>	<u>3,614,723</u>
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	19,741,368	-			19,741,368	2,462,108
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	274,898	BROWN UNIVERSITY	5R01NS100016-03	274,898	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	193,939	STANFORD UNIVERSITY	5U01NS110728-03	193,939	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	101,561	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01NS097876-05	101,561	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	93,220	UNIVERSITY OF FLORIDA	1R01NS102624-01	93,220	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	89,470	UNIVERSITY OF TEXAS MD ANDERSON CENTER	1R01NS116704-01	89,470	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	88,432	CASE WESTERN UNIVERSITY	5U01NS112010-03	88,432	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	82,441	DUKE UNIVERSITY	7R01NS119520-02	82,441	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	60,588	UNIVERSITY OF CINCINNATI	1U01NS099043-01A1	60,588	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	57,404	NEUROPACE, INC.	5UH3NS109557-02	57,404	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	54,522	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01NS122449-02	54,522	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	53,757	UNIVERSITY OF CINCINNATI	1U01NS095869-01A1	53,757	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	53,351	UNIVERSITY OF UTAH	1U01NS107486-01A1	53,351	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	51,054	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01NS122449-01	51,054	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	46,210	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	1UG3NS117844-01A1	46,210	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	44,831	MAYO CLINIC JACKSONVILLE	5U01NS080168-09	44,831	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	44,717	DUKE UNIVERSITY	5R61NS120246-02	44,717	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	42,952	UNIVERSITY OF MICHIGAN	1RF1NS127606-01	42,952	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	33,090	UNIVERSITY OF CINCINNATI	7U01NS102353-02	33,090	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	27,929	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01NS095435-04	27,929	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	26,744	DUKE UNIVERSITY	5R21NS117973-02	26,744	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	26,369	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01NS099368-03	26,369	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	25,512	MASSACHUSETTS GENERAL HOSPITAL	1R01NS099209-01	25,512	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	23,023	UNIVERSITY OF CINCINNATI	1U01NS106513-01A1	23,023	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	22,545	UNIVERSITY OF FLORIDA	5U01NS119562-02	22,545	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	20,435	SOUTHERN RESEARCH INSTITUTE	1R01NS124037-01	20,435	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	18,344	VIRGINIA TECH	1R01NS120746-01	18,344	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	17,515	MAYO CLINIC ROCHESTER	5U54NS115198-03	17,515	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	15,984	UNIVERSITY OF CINCINNATI	1UF1NS102289-01	15,984	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	15,620	MASSACHUSETTS GENERAL HOSPITAL	1U24NS107155	15,620	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	15,490	SOUTHERN RESEARCH INSTITUTE	5R01NS101958-06	15,490	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	15,315	UNIVERSITY OF CINCINNATI	1U01NS106655-02	15,315	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	13,789	NORTHWESTERN UNIVERSITY	1R61NS120245-01	13,789	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,705	THE GEORGE WASHINGTON UNIVERSITY	5U54NS115054-04	9,705	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,404	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	1R01NS119897-01	9,404	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	8,519	STANFORD UNIVERSITY	1R01NS103037-01A1	8,519	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	8,016	CASE WESTERN UNIVERSITY	5U01NS112010-04	8,016	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	7,991	MASSACHUSETTS GENERAL HOSPITAL	1U10NS077420	7,991	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	5,044	MAYO CLINIC ROCHESTER	5U54NS115198-02	5,044	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	4,846	UNIVERSITY OF CINCINNATI	1U01NS100699-01A1	4,846	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,691	MAYO CLINIC JACKSONVILLE	5R01NS097876-02	3,691	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,310	THE METHODIST HOSPITAL RESEARCH INST	5U01NS104326-05	3,310	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	2,381	STANFORD UNIVERSITY	1U01NS110728-01	2,381	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	2,263	STANFORD UNIVERSITY	5U01NS038455-20	2,263	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	2,261	MAYO CLINIC ROCHESTER	5U54NS115198-04	2,261	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,783	NORTHWESTERN UNIVERSITY	1U01NS113851-01	1,783	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,041	THE METHODIST HOSPITAL RESEARCH INST	1U01NS104326-03	1,041	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	277	UNIVERSITY OF CINCINNATI	1U01NS120910-01	277	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(320)	CHILDREN'S HOSPITAL BOSTON	5U42NS092090-07	(320)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(725)	MAYO CLINIC JACKSONVILLE	5U01NS080168-07	(725)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(2,223)	STANFORD UNIVERSITY	5U01NS038455-18	(2,223)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(2,570)	ALBERT EINSTEIN COLLEGE OF MEDICINE	1R01NS109023-01A1	(2,570)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(4,664)	MAYO CLINIC JACKSONVILLE	5U01NS080168-04	(4,664)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(21,473)	CASE WESTERN UNIVERSITY	1R01NS119520-01	(21,473)	
93.853 Total		<u>19,741,368</u>	<u>1,789,608</u>			<u>21,530,976</u>	<u>2,462,108</u>
Allergy, Immunology and Transplantation Research COVID-19 Allergy, Immunology and Transplantation Research	93.855	50,290,164	-			50,290,164	16,273,560
Allergy, Immunology and Transplantation Research	93.855	1,304,699	-			1,304,699	95,990
Allergy, Immunology and Transplantation Research	93.855	-	597,366	EMORY UNIVERSITY	3UM1AI48684-02S2	597,366	
Allergy, Immunology and Transplantation Research	93.855	-	397,342	FAMILY HEALTH INTERNATIONAL	UM1AI068619	397,342	
Allergy, Immunology and Transplantation Research	93.855	-	360,949	SCRIPPS RESEARCH INSTITUTE	1R01AI164772-01A1	360,949	
Allergy, Immunology and Transplantation Research	93.855	-	245,117	UNIVERSITY OF CALIFORNIA LOS ANGELES	2UM1AI068636-15	245,117	
Allergy, Immunology and Transplantation Research	93.855	-	200,198	UNIVERSITY OF WISCONSIN IN MADISON	1R01AI148379-01	200,198	
Allergy, Immunology and Transplantation Research	93.855	-	167,386	SCRIPPS RESEARCH INSTITUTE	1U01AI163063-01	167,386	
Allergy, Immunology and Transplantation Research	93.855	-	157,213	EMORY UNIVERSITY	3UM1AI148684-02S1	157,213	
Allergy, Immunology and Transplantation Research	93.855	-	136,316	UNIVERSITY OF CALIFORNIA LOS ANGELES	7UM1AI068636-13	136,316	
Allergy, Immunology and Transplantation Research	93.855	-	130,207	CHILDREN'S HOSPITAL BOSTON	1U01AI163072-01	130,207	
Allergy, Immunology and Transplantation Research	93.855	-	127,832	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI068636-17	127,832	
Allergy, Immunology and Transplantation Research	93.855	-	119,247	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI106716-10	119,247	
Allergy, Immunology and Transplantation Research	93.855	-	117,382	OREGON HEALTH & SCIENCES UNIVERSITY	R01AI133712-02	117,382	
Allergy, Immunology and Transplantation Research	93.855	-	115,854	HARVARD COLLEGE	5R01AI145547-03	115,854	
Allergy, Immunology and Transplantation Research	93.855	-	112,817	DUKE UNIVERSITY	5UM1AI104681-09	112,817	
Allergy, Immunology and Transplantation Research	93.855	-	103,014	FRED HUTCHINSON CANCER RESEARCH CENTER	3UM1AI068614-14S1	103,014	
Allergy, Immunology and Transplantation Research	93.855	-	96,075	UNIVERSITY OF KANSAS	1R01AI138970-01	96,075	
Allergy, Immunology and Transplantation Research	93.855	-	85,646	SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY (SMU)	1R01AI152110-01	85,646	
Allergy, Immunology and Transplantation Research	93.855	-	72,609	MASSACHUSETTS GENERAL HOSPITAL	5R01AI138790-03	72,609	
Allergy, Immunology and Transplantation Research	93.855	-	68,665	EMORY UNIVERSITY	1R01AI148471-04	68,665	
Allergy, Immunology and Transplantation Research	93.855	-	64,445	UNIVERSITY OF MARYLAND	2U19AI110820-07	64,445	
Allergy, Immunology and Transplantation Research	93.855	-	64,033	JOHNS HOPKINS UNIVERSITY	2U01AI069918-16	64,033	
Allergy, Immunology and Transplantation Research	93.855	-	62,288	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	4U01AI118594-06	62,288	
Allergy, Immunology and Transplantation Research	93.855	-	60,578	UNIVERSITY OF CALIFORNIA LOS ANGELES	2UM1AI106716-09	60,578	
Allergy, Immunology and Transplantation Research	93.855	-	57,394	UNIVERSITY OF CALIFORNIA LOS ANGELES	2UM1AI106701-08	57,394	
Allergy, Immunology and Transplantation Research	93.855	-	47,542	FRED HUTCHINSON CANCER RESEARCH CENTER	3UM1AI068614-15S1	47,542	
Allergy, Immunology and Transplantation Research	93.855	-	45,748	FHI 360	UM1AI068619	45,748	
Allergy, Immunology and Transplantation Research	93.855	-	44,699	RTI INTERNATIONAL	1R01AI54549	44,699	
Allergy, Immunology and Transplantation Research	93.855	-	44,577	UNIVERSITY OF ROCHESTER	1U01AI131344-01	44,577	
Allergy, Immunology and Transplantation Research	93.855	-	43,986	UNIVERSITY OF TEXAS HEALTH CENTER AT SAN ANTONIO	5R01AI141877-05	43,986	
Allergy, Immunology and Transplantation Research	93.855	-	43,761	JOHNS HOPKINS UNIVERSITY	5U01AI069918-17	43,761	
Allergy, Immunology and Transplantation Research	93.855	-	43,654	EMORY UNIVERSITY	5UM1AI148684-03	43,654	
Allergy, Immunology and Transplantation Research	93.855	-	42,267	UNIVERSITY OF SOUTHERN CALIFORNIA	5R01AI135122-05	42,267	
Allergy, Immunology and Transplantation Research	93.855	-	41,840	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R56AI154845-01A1	41,840	
Allergy, Immunology and Transplantation Research	93.855	-	41,717	NOVAN INC	4R44AI143022-02	41,717	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Allergy, Immunology and Transplantation Research	93.855	-	36,370	VANDERBILT UNIVERSITY MEDICAL CENTER	5U01AI152967-02	36,370	
Allergy, Immunology and Transplantation Research	93.855	-	35,275	UNIVERSITY OF VIRGINIA	1R01AI129678-01	35,275	
Allergy, Immunology and Transplantation Research	93.855	-	33,702	UNIVERSITY OF PENNSYLVANIA	5R01AI145905-03	33,702	
Allergy, Immunology and Transplantation Research	93.855	-	33,559	UNIVERSITY OF ROCHESTER	1U01AI131344	33,559	
Allergy, Immunology and Transplantation Research	93.855	-	31,385	UNIVERSITY OF MARYLAND	1R01AI125561-01	31,385	
Allergy, Immunology and Transplantation Research	93.855	-	31,367	KAISER FOUNDATION RESEARCH INSTITUTE	1R01AI151072	31,367	
Allergy, Immunology and Transplantation Research	93.855	-	27,950	DISTRICT OF COLUMBIA CENTER FOR AIDS RESEARCH	5P30AI117970-08	27,950	
Allergy, Immunology and Transplantation Research	93.855	-	27,757	EMORY UNIVERSITY	1P01AI125180-01	27,757	
Allergy, Immunology and Transplantation Research	93.855	-	27,066	HARVARD COLLEGE	5P30AI060354-18	27,066	
Allergy, Immunology and Transplantation Research	93.855	-	25,983	FRED HUTCHINSON CANCER RESEARCH CENTER	2UM1AI068614-15	25,983	
Allergy, Immunology and Transplantation Research	93.855	-	23,901	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01AI120790-01	23,901	
Allergy, Immunology and Transplantation Research	93.855	-	23,357	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI068636-16	23,357	
Allergy, Immunology and Transplantation Research	93.855	-	22,623	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	2U01AI113362-08	22,623	
Allergy, Immunology and Transplantation Research	93.855	-	22,497	UNIVERSITY OF SOUTHERN CALIFORNIA	7R01AI149339-03	22,497	
Allergy, Immunology and Transplantation Research	93.855	-	21,708	CHILDREN'S HOSPITAL BOSTON	1R01AI154470-01	21,708	
Allergy, Immunology and Transplantation Research	93.855	-	21,700	FRED HUTCHINSON CANCER RESEARCH CENTER	5UM1AI068614-16	21,700	
Allergy, Immunology and Transplantation Research	93.855	-	21,093	UNIVERSITY OF ROCHESTER	5R01AI129518-05	21,093	
Allergy, Immunology and Transplantation Research	93.855	-	21,047	UNIVERSITY OF CALIFORNIA IN DAVIS	1R01AI143554-01	21,047	
Allergy, Immunology and Transplantation Research	93.855	-	17,239	UNIVERSITY OF ROCHESTER	1R01AI155012-02	17,239	
Allergy, Immunology and Transplantation Research	93.855	-	15,684	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	2UM1AI109565-08	15,684	
Allergy, Immunology and Transplantation Research	93.855	-	15,034	EMORY UNIVERSITY	5P30AI050409-23	15,034	
Allergy, Immunology and Transplantation Research	93.855	-	14,709	INDIANA UNIVERSITY	5R01AI137116-03	14,709	
Allergy, Immunology and Transplantation Research	93.855	-	12,781	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	2UM1AI109565-09	12,781	
Allergy, Immunology and Transplantation Research	93.855	-	9,807	UNIVERSITY OF CALGARY	1R01AI165327-01	9,807	
Allergy, Immunology and Transplantation Research	93.855	-	8,467	EMORY UNIVERSITY	5UM1AI148684-02	8,467	
Allergy, Immunology and Transplantation Research	93.855	-	7,934	TEXAS A&M UNIVERSITY	1R21AI151914-01	7,934	
Allergy, Immunology and Transplantation Research	93.855	-	7,142	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	7R01AI134972-03	7,142	
Allergy, Immunology and Transplantation Research	93.855	-	7,107	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	1D71TW011837-01	7,107	
Allergy, Immunology and Transplantation Research	93.855	-	6,006	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U54AI082973-13	6,006	
Allergy, Immunology and Transplantation Research	93.855	-	5,131	JOHNS HOPKINS UNIVERSITY	1U01AI134591-04	5,131	
Allergy, Immunology and Transplantation Research	93.855	-	4,502	THE GEORGE WASHINGTON UNIVERSITY	5P30AI117970-08	4,502	
Allergy, Immunology and Transplantation Research	93.855	-	4,118	UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01AI137680-03	4,118	
Allergy, Immunology and Transplantation Research	93.855	-	3,748	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	1D71TW011837-02	3,748	
Allergy, Immunology and Transplantation Research	93.855	-	3,543	LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE	1R01AI147321-01	3,543	
Allergy, Immunology and Transplantation Research	93.855	-	3,438	UNIVERSITY OF CALIFORNIA LOS ANGELES	2UM1AI068636-16	3,438	
Allergy, Immunology and Transplantation Research	93.855	-	2,942	INDIANA UNIVERSITY	5R01AI137116-02	2,942	
Allergy, Immunology and Transplantation Research	93.855	-	1,939	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U54AI082973-12 REVISED	1,939	
Allergy, Immunology and Transplantation Research	93.855	-	1,797	DUKE UNIVERSITY	5U01AI152585-02	1,797	
Allergy, Immunology and Transplantation Research	93.855	-	1,650	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01AI113362-09	1,650	
Allergy, Immunology and Transplantation Research	93.855	-	1,615	EMORY UNIVERSITY	5R01AI064060-15	1,615	
Allergy, Immunology and Transplantation Research	93.855	-	1,296	CHILDREN'S HOSPITAL BOSTON	5U01AI163072-02	1,296	
Allergy, Immunology and Transplantation Research	93.855	-	307	EMORY UNIVERSITY	3UM1AI148684-OAS1	307	
Allergy, Immunology and Transplantation Research	93.855	-	12	MAGEE-WOMEN'S RESEARCH INSTITUTE & FOUNDATION	4UM1AI068633-15	12	
Allergy, Immunology and Transplantation Research	93.855	-	(69)	HARVARD COLLEGE	1R01AI145547-02	(69)	
Allergy, Immunology and Transplantation Research	93.855	-	(344)	NORTHWESTERN UNIVERSITY	1P01AI131346-01	(344)	
Allergy, Immunology and Transplantation Research	93.855	-	(11,651)	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5UM1AI109565-07	(11,651)	
Allergy, Immunology and Transplantation Research	93.855	-	(13,365)	UNIVERSITY OF SOUTHERN CALIFORNIA	1R21AI130927-01A1	(13,365)	
93.855 Total		<u>51,594,863</u>	<u>4,780,623</u>			<u>56,375,486</u>	<u>16,369,550</u>
Biomedical Research and Research Training	93.859	6,782,972	-			6,782,972	68,142
Biomedical Research and Research Training	93.859	-	47,189	TRIALTUS BIOSCIENCE, LLC	1R41GM142336-01	47,189	
Biomedical Research and Research Training	93.859	-	34,150	JOHNS HOPKINS UNIVERSITY	1R01GM121404-01A1	34,150	
Biomedical Research and Research Training	93.859	-	11,059	INDIANA UNIVERSITY	1R25GM141507-01	11,059	
Biomedical Research and Research Training	93.859	-	950	NORTHERN ILLINOIS UNIVERSITY	7R25GM129216-02	950	
Biomedical Research and Research Training	93.859	-	(3,055)	UNIVERSITY OF PITTSBURGH	5R01GM101197-03	(3,055)	
93.859 Total		<u>6,782,972</u>	<u>90,293</u>			<u>6,873,265</u>	<u>68,142</u>
Emerging Infections Sentinel Networks	93.860	-	16,287	OLIVE VIEW-UCLA EDUCATION & RESEARCH INSTITUTE, IN	6U01CK00480-05-03	16,287	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Emerging Infections Sentinel Networks	93.860	-	16,008	OLIVE VIEW-UCLA EDUCATION & RESEARCH INSTITUTE, IN	1U01CK000480-01/5U01CK0000480-05-1	16,008	-
93.860 Total		-	32,295			32,295	-
Child Health and Human Development Extramural Research	93.865	9,095,359	-			9,095,359	1,487,793
Child Health and Human Development Extramural Research	93.865	-	663,458	UNIVERSITY OF MIAMI	5R01HD101352-03	663,458	303,606
Child Health and Human Development Extramural Research	93.865	-	479,426	RTI INTERNATIONAL	U10HD34216	479,426	
Child Health and Human Development Extramural Research	93.865	-	350,355	HARVARD COLLEGE	5P01HD103133-02	350,355	
Child Health and Human Development Extramural Research	93.865	-	343,784	THE GEORGE WASHINGTON UNIVERSITY	U24HD036801	343,784	18,092
Child Health and Human Development Extramural Research	93.865	-	334,558	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	1R01HD098175-01A1	334,558	
Child Health and Human Development Extramural Research	93.865	-	237,215	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R01HD089918-05	237,215	
Child Health and Human Development Extramural Research	93.865	-	209,719	RTI INTERNATIONAL	1PL1HD101059-01	209,719	
Child Health and Human Development Extramural Research	93.865	-	147,043	SHARP HEALTHCARE FOUNDATION	5R01HD088646-05	147,043	
Child Health and Human Development Extramural Research	93.865	-	141,556	THE GEORGE WASHINGTON UNIVERSITY	U10HD036801	141,556	
Child Health and Human Development Extramural Research	93.865	-	68,743	RTI INTERNATIONAL	2U24HD069031	68,743	
Child Health and Human Development Extramural Research	93.865	-	54,695	HARVARD COLLEGE	5P01HD103133-03	54,695	
Child Health and Human Development Extramural Research	93.865	-	46,046	UNIVERSITY OF WISCONSIN MILWAUKEE	1R01HD096085-01A1	46,046	
Child Health and Human Development Extramural Research	93.865	-	44,824	UNIVERSITY OF PENNSYLVANIA	7R01HD095248-04	44,824	
Child Health and Human Development Extramural Research	93.865	-	38,664	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U19HD089881-05	38,664	
Child Health and Human Development Extramural Research	93.865	-	36,018	HARVARD COLLEGE	1R01HD101351-01	36,018	
Child Health and Human Development Extramural	93.865	-	35,597	NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDIC	3P01HD067244-08S1	35,597	
Child Health and Human Development Extramural	93.865	-	29,388	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	7R01HD98127-03	29,388	
Child Health and Human Development Extramural	93.865	-	26,991	INDIANA UNIVERSITY	1R01HD101476-01A1	26,991	
Child Health and Human Development Extramural	93.865	-	25,339	RTI INTERNATIONAL	RFA-HD-19-025	25,339	
Child Health and Human Development Extramural	93.865	-	24,898	THE GEORGE WASHINGTON UNIVERSITY	5U54NS115054-03	24,898	
Child Health and Human Development Extramural	93.865	-	24,070	TEMPLE UNIVERSITY	5R01HD103904-02	24,070	
Child Health and Human Development Extramural	93.865	-	18,085	UNIVERSITY OF VIRGINIA	5R01HD087413-04	18,085	
Child Health and Human Development Extramural	93.865	-	15,451	UNIVERSITY OF WASHINGTON	1R01HD101578-01A1	15,451	
Child Health and Human Development Extramural	93.865	-	14,424	FLORIDA STATE UNIVERSITY	5U19HD089875-06	14,424	
Child Health and Human Development Extramural	93.865	-	8,804	UNIVERSITY OF TEXAS AT AUSTIN	7U01HD077384-06	8,804	
Child Health and Human Development Extramural	93.865	-	5,495	SHARP HEALTHCARE FOUNDATION	5R01HD088646-04	5,495	
Child Health and Human Development Extramural	93.865	-	5,491	MEDICAL UNIVERSITY OF SOUTH CAROLINA	R01HD102336-01A1	5,491	
Child Health and Human Development Extramural	93.865	-	2,221	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01HD086139-01A1	2,221	
Child Health and Human Development Extramural	93.865	-	2,028	KESSLER FOUNDATION, INC.	7R01HD091155-03	2,028	
Child Health and Human Development Extramural	93.865	-	339	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R03HD096188-02	339	
Child Health and Human Development Extramural	93.865	-	(471)	MISSISSIPPI STATE UNIVERSITY	1R15HD098660-01	(471)	
Child Health and Human Development Extramural	93.865	-	(1,273)	UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01HD092471-01	(1,273)	
Child Health and Human Development Extramural Research	93.865	-	(7,497)	HARVARD COLLEGE	5U01HD052102-15	(7,497)	
93.865 Total		9,095,359	3,425,484			12,520,843	1,809,491
Aging Research	93.866	16,915,646	-			16,915,646	3,063,808
Aging Research	93.866	-	508,802	UNIVERSITY OF FLORIDA	5R37AG033906-18	508,802	
Aging Research	93.866	-	195,406	PENNINGTON BIOMEDICAL RESEARCH CENTER	1U01AG073204-01	195,406	
Aging Research	93.866	-	166,542	SALK INSTITUTE FOR BIOLOGICAL SCIENCE	1RF1AG068550-01	166,542	
Aging Research	93.866	-	164,484	UNIVERSITY OF PENNSYLVANIA	1R01AG062819-01A1	164,484	
Aging Research	93.866	-	147,667	UNIVERSITY OF CINCINNATI	1R01AG072592-01	147,667	
Aging Research	93.866	-	145,593	MOUNT SINAI SCHOOL OF MEDICINE	5R01AG061186-03	145,593	
Aging Research	93.866	-	140,225	CASE WESTERN UNIVERSITY	5R01AG061388-05	140,225	
Aging Research	93.866	-	94,256	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1R01AG059009	94,256	
Aging Research	93.866	-	92,119	CLEMSON UNIVERSITY	1R56AG073181-01	92,119	
Aging Research	93.866	-	89,976	DUKE UNIVERSITY	5R01AG062502-04	89,976	
Aging Research	93.866	-	88,470	INDIANA UNIVERSITY	1R01AG057703-01	88,470	
Aging Research	93.866	-	83,069	UNIVERSITY OF SOUTHERN CALIFORNIA	1R01AG063689-01	83,069	
Aging Research	93.866	-	79,026	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01AG071032-01	79,026	
Aging Research	93.866	-	77,369	UNIVERSITY OF PENNSYLVANIA	5R01AG062819-03	77,369	
Aging Research	93.866	-	74,469	UNIVERSITY OF WASHINGTON	1R01AG056486-01	74,469	
Aging Research	93.866	-	70,791	UNIVERSITY OF WASHINGTON	5R33AG067069-02	70,791	
Aging Research	93.866	-	69,026	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	1R01AG071803-01	69,026	
Aging Research	93.866	-	67,270	MOUNT SINAI SCHOOL OF MEDICINE	5R01AG061186-04	67,270	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Aging Research	93.866	-	66,303	UNIVERSITY OF MICHIGAN	1RF1AG068410-01	66,303	
Aging Research	93.866	-	65,457	UNIVERSITY OF SOUTHERN CALIFORNIA	R01AG053798	65,457	
Aging Research	93.866	-	62,397	UNIVERSITY OF SOUTHERN CALIFORNIA	5U24AG057437-04	62,397	
Aging Research	93.866	-	55,113	THE JACKSON LAORATORY	1RF1AG063755-01	55,113	
Aging Research	93.866	-	51,578	NORTHERN CALIFORNIA INST FOR RESEARCH AND EDU	1R01AG063887-01	51,578	
Aging Research	93.866	-	50,335	MAYO CLINIC ROCHESTER	5U19AG063911-03	50,335	
Aging Research	93.866	-	45,598	THE GEORGE WASHINGTON UNIVERSITY	1RF1AG069121-01	45,598	
Aging Research	93.866	-	45,111	UNIVERSITY OF SOUTHERN CALIFORNIA	5U19AG02-4904-15	45,111	
Aging Research	93.866	-	42,885	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	5U19AG062882	42,885	
Aging Research	93.866	-	42,006	CALIFORNIA PACIFIC MED. CTR. RES. INST.	5R01AG066671-02	42,006	
Aging Research	93.866	-	41,428	NORTHERN CALIFORNIA INST FOR RESEARCH AND EDU	1R01AG063887	41,428	
Aging Research	93.866	-	39,076	WASHINGTON UNIVERSITY IN ST LOUIS	5R01AG053267-02	39,076	
Aging Research	93.866	-	38,655	BETH ISRAEL DEACONESS MEDICAL CENTER	1R01AG065554-01	38,655	
Aging Research	93.866	-	38,465	WASHINGTON UNIVERSITY IN ST LOUIS	5R01AG053267-04	38,465	
Aging Research	93.866	-	37,349	MAYO CLINIC ROCHESTER	5U19AG063911-02	37,349	
Aging Research	93.866	-	37,075	CASE WESTERN UNIVERSITY	1R01AG067607-01A1	37,075	
Aging Research	93.866	-	34,709	UNIVERSITY OF FLORIDA	3P30AG059297-04S1	34,709	
Aging Research	93.866	-	27,770	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	7RF1AG056111-02	27,770	
Aging Research	93.866	-	27,244	UNIVERSITY OF SOUTHERN CALIFORNIA	5R01AG053798-02	27,244	
Aging Research	93.866	-	27,028	UNIVERSITY OF MICHIGAN	1U19AG063720-01A1	27,028	
Aging Research	93.866	-	25,857	UNIVERSITY OF ALABAMA IN TUSCALOOSA	1R01AG068572-01	25,857	
Aging Research	93.866	-	21,144	JOHNS HOPKINS UNIVERSITY	5R01AG069930-02	21,144	
Aging Research	93.866	-	18,581	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	3RF1AG058067-01A1S2	18,581	
Aging Research	93.866	-	13,127	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01AG057709	13,127	
Aging Research	93.866	-	12,504	UNIVERSITY OF CALIFORNIA IN DAVIS	1U14AG063720-01A1	12,504	
Aging Research	93.866	-	12,062	DUKE UNIVERSITY	1R01AG062502-01A1	12,062	
Aging Research	93.866	-	11,430	EMORY UNIVERSITY	5R34AG058835-02	11,430	
Aging Research	93.866	-	10,416	NORTHWESTERN UNIVERSITY	5P30AG013854-25	10,416	
Aging Research	93.866	-	9,757	UNIVERSITY OF KANSAS MEDICAL CENTER	1R01AG072895-01	9,757	
Aging Research	93.866	-	8,677	SAPERE BIO, INC	1R44AG072994-01A1	8,677	
Aging Research	93.866	-	6,627	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	5R01AG058571-04	6,627	
Aging Research	93.866	-	2,747	CLEMSON UNIVERSITY	7U01AG062370-03	2,747	
Aging Research	93.866	-	2,355	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	1RF1AG067744-01	2,355	
Aging Research	93.866	-	1,072	THE REGENTS OF THE UNIVERSITY OF CALFORNIA	7R01AG056360-02	1,072	
Aging Research	93.866	-	858	UNIVERSITY OF SOUTHERN CALIFORNIA	5R01AG054029-02	858	
Aging Research	93.866	-	278	REGENTS OF THE UNIVERSITY OF COLORADO	1R01AG054366-01A1	278	
Aging Research	93.866	-	(198)	CALIFORNIA PACIFIC MED. CTR. RES. INST.	1R01AG066671-01	(198)	
Aging Research	93.866	-	(398)	UNIVERSITY OF MICHIGAN	5R01AG062582-03	(398)	
93.866 Total		<u>16,915,646</u>	<u>3,387,038</u>			<u>20,302,684</u>	<u>3,063,808</u>
Vision Research	93.867	8,925,019	-			8,925,019	1,406,890
Vision Research	93.867	-	431,883	VANDERBILT UNIVERSITY MEDICAL CENTER	5U24EY029893-04	431,883	
Vision Research	93.867	-	260,038	UNIVERSITY OF FLORIDA	5R01EY028968-04	260,038	
Vision Research	93.867	-	215,526	UNIVERSITY OF FLORIDA	5R01EY024280-07	215,526	
Vision Research	93.867	-	207,064	UNIVERSITY OF CALIFORNIA - BERKELEY	5R01EY023591-09	207,064	
Vision Research	93.867	-	165,163	VANDERBILT UNIVERSITY MEDICAL CENTER	5U54EY032442-02	165,163	
Vision Research	93.867	-	118,235	UNIVERSITY OF PENNSYLVANIA	5R01EY031209-02	118,235	
Vision Research	93.867	-	66,566	UNIVERSITY OF PENNSYLVANIA	1R01EY030192-02S1	66,566	
Vision Research	93.867	-	60,966	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	1R01EY032752-01	60,966	
Vision Research	93.867	-	54,240	UNIVERSITY OF PENNSYLVANIA	3R01EY030192-02S1	54,240	
Vision Research	93.867	-	45,854	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, AT RI	1R21EY033623-01	45,854	
Vision Research	93.867	-	45,136	OKLAHOMA MEDICAL RESEARCH FOUNDATION	5R01EY024944-04	45,136	
Vision Research	93.867	-	39,667	UNIVERSITY OF PENNSYLVANIA	5R01EY015537-15	39,667	
Vision Research	93.867	-	39,147	UNIVERSITY OF WASHINGTON	5R01EY028282-03	39,147	
Vision Research	93.867	-	37,826	UNIVERSITY OF WASHINGTON	1R01EY028282-01A1	37,826	
Vision Research	93.867	-	33,376	UNIVERSITY OF CALIFORNIA IN SAN DIEGO	5R01EY030501-04	33,376	
Vision Research	93.867	-	31,803	JAEB CENTER FOR HEALTH RESEARCH INC	MTS1	31,803	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Vision Research	93.867	-	31,773	JAEB CENTER FOR HEALTH RESEARCH INC	5U10EY011751-20	31,773	
Vision Research	93.867	-	21,051	DOHENY EYE INSTITUTE INC	2R01EY024378-07	21,051	
Vision Research	93.867	-	8,903	DOHENY EYE INSTITUTE INC	1R01EY030501-01A1	8,903	
Vision Research	93.867	-	2,339	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	1R34EY030582-01A1	2,339	
Vision Research	93.867	-	48	VANDERBILT UNIVERSITY MEDICAL CENTER	1U54EY032442-01	48	
Vision Research	93.867	-	(229)	NEW YORK UNIVERSITY MEDICAL SCHOOL	1U10EY026869-01	(229)	
93.867 Total		<u>8,925,019</u>	<u>1,916,375</u>			<u>10,841,394</u>	<u>1,406,890</u>
Medical Library Assistance	93.879	206,986	-			206,986	
93.879 Total		<u>206,986</u>	<u>-</u>			<u>206,986</u>	<u>-</u>
HIV Demonstration, Research, Public and Professional	93.941	-	18,552	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1-U01-PS005236-01-00	18,552	
93.941 Total		<u>-</u>	<u>18,552</u>			<u>18,552</u>	<u>-</u>
International Research and Research Training	93.989	148,795	-			148,795	69,450
International Research and Research Training	93.989	-	52,161	AFRICA HEALTH RESEARCH INSTITUTE AHRI	1R21TW011687-01	52,161	
International Research and Research Training	93.989	-	17,248	UNIVERSIDAD PERUANA CAYETANO HEREDIA	2D43TW009763-08	17,248	
International Research and Research Training	93.989	-	6,180	UNIVERSIDAD PERUANA CAYETANO HEREDIA	2D43TW009763-07	6,180	
International Research and Research Training	93.989	-	22	UNIVERSITY OF PITTSBURGH	7U2RTW010104-06	22	
93.989 Total		<u>148,795</u>	<u>75,611</u>			<u>224,406</u>	<u>69,450</u>
Contract	93.RD	-	1,430,155	WESTAT CORPORATION	OT2HL158287	1,430,155	169,234
Contract #HHSN272201300012I/TO F00131	93.RD	1,377,580	-			1,377,580	892,878
Contract #HHSN272201600018C	93.RD	1,208,379	-			1,208,379	486,845
Contract #HHSN272201600017C	93.RD	1,124,028	-			1,124,028	168,456
Contract #HHSN268201800005I/HHSN26 Opt 3	93.RD	1,091,844	-			1,091,844	318,326
Contract	93.RD	-	1,065,337	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1OT2HL156812-01	1,065,337	
Contract #HHSN268201800005I/75N92020F001	93.RD	525,141	-			525,141	158,565
Contract #HHSN268201800007I TO 01	93.RD	518,424	-			518,424	
Contract #HHSN272201300012I/HHSN27200015	93.RD	508,918	-			508,918	470,217
Contract #HHSN272201300012I/HHSN27200014	93.RD	451,784	-			451,784	261,457
Contract #75N93019D00016 - B07	93.RD	429,368	-			429,368	
Contract	93.RD	-	412,148	ABT ASSOCIATES INC	75D30120C08150	412,148	
Contract #75D30119C06541	93.RD	382,237	-			382,237	88,592
Contract #HHSN272201300012I/HHSN27200016	93.RD	351,470	-			351,470	160,101
Contract #HHSN268201800007I/HHSN26800001	93.RD	333,070	-			333,070	
Contract #75D30120C09617	93.RD	289,438	-			289,438	38,000
Contract #75N91019D00019/75N91019F00131	93.RD	282,682	-			282,682	282,682
Contract	93.RD	-	205,688	LEIDOS BIOMEDICAL RESEARCH, INC	75N91019D00024	205,688	
Contract	93.RD	-	184,298	NEW YORK UNIVERSITY	OT2HL156812	184,298	
Contract #HHSN261201500036I TO 11	93.RD	182,146	-			182,146	182,146
Contract	93.RD	-	162,289	BESHENICH MUIR & ASSOCIATES LLC	75N95021P0036	162,289	
Contract	93.RD	-	131,868	AFRICA HEALTH RESEARCH INSTITUTE AHRI	75N93019C00070	131,868	
Contract	93.RD	-	116,583	ABT ASSOCIATES INC	75D301-20-R-67897	116,583	
Contract #75D30118C02929	93.RD	107,255	-			107,255	
Contract	93.RD	-	99,397	UNIVERSITY OF PENNSYLVANIA	75A50120C00134	99,397	
Contract #HHSN261201500036I TO 10	93.RD	105,132	-			105,132	71,880
Contract #IPA J HYDE - DETECT STUDY	93.RD	61,152	-			61,152	
Contract	93.RD	-	56,960	UNIVERSITY OF UTAH	HHSN275201800009I	56,960	
Contract #IPA AREND REBECCA	93.RD	55,156	-			55,156	
Contract #HHSN272201100038C	93.RD	53,315	-			53,315	
Contract #HHSN261201500036I TO9	93.RD	49,224	-			49,224	49,224
Contract	93.RD	-	38,470	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	HHSN268201800010	38,470	
Contract	93.RD	-	37,601	J. CRAIG VENTER INSTITUTE	75N93019C000076	37,601	
Contract	93.RD	-	36,705	UNIVERSITY OF WISCONSIN IN MADISON	HHSN261201200033I	36,705	
Contract #IPA-MOORE JENNAH	93.RD	33,549	-			33,549	
Contract	93.RD	-	30,392	EASTERN COOPERATIVE ONCOLOGY GROUP	EA1151	30,392	
Contract #75N93019D00016/75N93022F00001	93.RD	29,588	-			29,588	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Contract #HHSN261201500036I TO8	93.RD	29,075	-			29,075	
Contract #HHSN272201300012I/Task F00132	93.RD	26,189	-			26,189	21,323
Contract #HHSN272201300012I/TO F00132	93.RD	20,545	-			20,545	16,299
Contract #HHSN261201500036I	93.RD	19,686	-			19,686	
Contract #HHSN268201800005I Opt 2	93.RD	17,722	-			17,722	16,120
Contract #75N93019D00016 - B05	93.RD	11,203	-			11,203	
Contract	93.RD	-	9,623	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	7200AA22CA00002	9,623	
Contract	93.RD	-	9,370	NATIONAL JEWISH MEDICAL AND RESEARCH CENTER	1OT2HL156812-02	9,370	
Contract	93.RD	-	7,644	WESTAT CORPORATION	HHSN261201600007I	7,644	
Contract	93.RD	-	3,310	AI BIOSCIENCES INC.	75N930019C00018	3,310	
Contract	93.RD	-	3,239	UNIVERSITY OF PENNSYLVANIA	R01-HD-098269-03	3,239	
Contract	93.RD	-	2,651	LEIDOS BIOMEDICAL RESEARCH, INC	75D91019D00024	2,651	
Contract #CDC-22IPA2215787	93.RD	1,624	-			1,624	
Contract	93.RD	-	1,354	NORTHWESTERN UNIVERSITY	HHSN261201200035I	1,354	
Contract	93.RD	-	1,167	JANSSEN RESEARCH AND DEVELOPMENT, LLC	HHSO100201500014C	1,167	
Contract	93.RD	-	1,029	CHILDREN'S HOSPITAL LOS ANGELES	1U01AI126612-01A1	1,029	
Contract	93.RD	-	882	EASTERN COOPERATIVE ONCOLOGY GROUP	EA1183	882	
Contract	93.RD	-	167	CHILDREN'S HOSPITAL OF PHILADELPHIA	N02-CM-62212	167	
Contract	93.RD	-	145	JAEB CENTER FOR HEALTH RESEARCH INC	U10EY011751	145	
Contract	93.RD	-	(352)	BAVARIAN NORDIC A/S	HHSO100201700019C	(352)	
Contract	93.RD	-	(8,760)	CHILDREN'S HOSPITAL BOSTON	75D30119C05584	(8,760)	
Contract	93.RD	-	(11,412)	UNIVERSITY OF MICHIGAN	HHSN268201100026C	(11,412)	
Contract	93.RD	-	(12,664)	SUMMIT OXFORD LIMITED	HHSO100201700014C	(12,664)	
Unknown	93.RD	-	367,612	RTI INTERNATIONAL	1OT2HL156812-01	367,612	209,600
Unknown	93.RD	-	108,223	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG-ACRIN	108,223	8,658
Unknown	93.RD	-	90,419	UNIVERSITY OF PENNSYLVANIA	5UH3HL141736-05	90,419	
Unknown	93.RD	-	41,868	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1OT3HL147154-01	41,868	
Unknown	93.RD	-	35,291	BIRMINGHAM AIDS OUTREACH	CNVAA00055333 (129659-3)	35,291	
Unknown	93.RD	-	29,895	MAYO CLINIC ROCHESTER	HHSN261201200042I	29,895	
Unknown	93.RD	-	22,545	OREGON HEALTH & SCIENCES UNIVERSITY	SWOG	22,545	
Unknown	93.RD	-	13,617	JAEB CENTER FOR HEALTH RESEARCH INC	UG1EY011751	13,617	
Unknown	93.RD	-	11,118	NRG ONCOLOGY INC	NRG NCORP	11,118	
Unknown	93.RD	-	1,422	JOHNS HOPKINS UNIVERSITY	5UM1CA137443-10	1,422	
Unknown	93.RD	-	(100)	UNIVERSITY OF BERN INSTITUTE FOR SOCIALUND PREVENT	5U01AI069924-15	(100)	
Unknown	93.RD	-	(14,099)	EMORY UNIVERSITY	U54NS065701	(14,099)	
93.RD Total		9,676,924	4,723,095			14,400,019	4,070,603
Total Department of Health and Human Services		321,641,764	39,122,373			360,764,137	61,061,070
U. S. Agency for International Development							
USAID Foreign Assistance for Programs Overseas	98.001	-	14,671	NATL ACADEMY OF SCIENCES	AID-263-A-15-00002	14,671	
USAID Foreign Assistance for Programs Overseas	98.001	-	1,208	INTL AIDS VACCINE INITIATIVE	AID-OAA-A-16-00032	1,208	
98.001 Total		-	15,879			15,879	-
Total U. S. Agency for International Development		-	15,879			15,879	-
TOTAL RESEARCH AND DEVELOPMENT CLUSTER		348,263,301	46,157,593			394,420,894	64,209,144
STUDENT FINANCIAL ASSISTANCE CLUSTER							
Department of Education							
Federal Supplemental Education Opportunity Grant	84.007	1,141,592	-			1,141,592	
84.007 Total		1,141,592	-			1,141,592	-
Federal Work-Study Program	84.033	1,000,338	-			1,000,338	
84.033 Total		1,000,338	-			1,000,338	-

The accompanying notes are an integral part of this schedule.

**The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022**

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Federal Perkins Loan - Outstanding loans at fiscal year beginning	84.038	6,350,811	-			6,350,811	-
84.038 Total		6,350,811	-			6,350,811	-
Federal Pell Grant	84.063	23,889,759	-			23,889,759	-
84.063 Total		23,889,759	-			23,889,759	-
Direct Student Loans	84.268	158,008,589	-			158,008,589	-
84.268 Total		158,008,589	-			158,008,589	-
Teacher Education Assistance for College and Higher Education Grants (TEACH)	84.379	29,234	-			29,234	-
84.379 Total		29,234	-			29,234	-
Total Department of Education		190,420,323	-			190,420,323	-
Department of Health and Human Services							
Nurse Faculty Loan Program - Outstanding loans at fiscal year beginning	93.264	3,675,814	-			3,675,814	-
Nurse Faculty Loan Program - New loans issued during fiscal year	93.264	1,008,485	-			1,008,485	-
93.264 Total		4,684,299	-			4,684,299	-
Health Professions Student Loans - Outstanding loans at fiscal year beginning	93.342	1,092,320	-			1,092,320	-
Health Professions Student Loans - New loans issued during fiscal year	93.342	73,383	-			73,383	-
93.342 Total		1,165,703	-			1,165,703	-
Nurse Faculty Loan Program ARRA - Outstanding loans at fiscal year beginning	93.408	53,625	-			53,625	-
93.408 Total		53,625	-			53,625	-
Total Department of Health and Human Services		5,903,627	-			5,903,627	-
TOTAL STUDENT FINANCIAL ASSISTANCE CLUSTER		196,323,950	-			196,323,950	-
DEPARTMENT OF EDUCATION - TRIO CLUSTER							
Department of Education							
TRIO_Student Support Services	84.042	819,830	-			819,830	-
84.042 Total		819,830	-			819,830	-
TRIO_Upward Bound	84.047	884,398	-			884,398	-
84.047 Total		884,398	-			884,398	-
TRIO_Educational Opportunity Centers	84.066	205,152	-			205,152	-
84.066 Total		205,152	-			205,152	-
TRIO_McNair Post-Baccalaureate Achievement	84.217	304,743	-			304,743	-
84.217 Total		304,743	-			304,743	-
Total Department of Education		2,214,123	-			2,214,123	-
TOTAL DEPARTMENT OF EDUCATION - TRIO CLUSTER		2,214,123	-			2,214,123	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES - HEAD START CLUSTER							
Department of Health and Human Services							
Head Start	93.600	1,035,686	-			1,035,686	119,668
COVID-19 Head Start	93.600	26,098	-			26,098	1,245
93.600 Total		1,061,784	-			1,061,784	120,913
Total Department of Health and Human Services		1,061,784	-			1,061,784	120,913

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES - MEDICAID CLUSTER		1,061,784	-			1,061,784	120,913
Department of Health and Human Services							
Medical Assistance Program	93.778	-	55,958	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	1905OH5ADM	55,958	-
93.778 Total		-	55,958			55,958	-
Total Department of Health and Human Services		-	55,958			55,958	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES - MEDICAID CLUSTER		-	55,958			55,958	-
OTHER PROGRAMS							
Department of Agriculture							
Child and Adult Care Food Program	10.558	-	(1,041)	ALABAMA DEPT OF HUMAN RESOURCES	ADS-0000	(1,041)	-
10.558 Total		-	(1,041)			(1,041)	-
Total Department of Agriculture		-	(1,041)			(1,041)	-
Department of Commerce							
Science, Technology, Engineering, and Mathematics (STEM) Talent Challenge Program	11.023	31,528	-			31,528	-
11.023 Total		31,528	-			31,528	-
Total Department of Commerce		31,528	-			31,528	-
Department of Defense							
Contract - Navy Medicine/Dentistry/Optomety	12.U01	811,596	-			811,596	-
Contract - Air Force Medical, Dentistry, Optometry	12.U02	585,094	-			585,094	-
Contract - Army Health Profession Students	12.U03	277,938	-			277,938	-
Contract - Go Army	12.U04	98,500	-			98,500	-
Contract - Air Force Unknown	12.U05	46,236	-			46,236	-
Contract - Army Corp of Engineers	12.U06	18,089	-			18,089	-
Contract - Coast Guard Unknown	12.U07	7,254	-			7,254	-
12 Total		1,844,707	-			1,844,707	-
Total Department of Defense		1,844,707	-			1,844,707	-
Department of Justice							
Drug Court Discretionary Grant Program	16.585	-	158,413	JEFFERSON COUNTY COMMISSION	2018-DC-BX-0025	158,413	-
Drug Court Discretionary Grant Program	16.585	-	131,446	JEFFERSON COUNTY COMMISSION	2020-VC-BX-0053	131,446	-
16.585 Total		-	289,859			289,859	-
Comprehensive Opioid Abuse Site-Based Program	16.838	-	312,857	JEFFERSON COUNTY COMMISSION	2020-AR-BX-0138	312,857	-
Comprehensive Opioid Abuse Site-Based Program	16.838	-	66	JEFFERSON COUNTY COMMISSION	2018-AR-BX-K013	66	-
16.838 Total		-	312,923			312,923	-
Contract	16.U08	-	35,159	JEFFERSON COUNTY COMMISSION	15PBJA-21-GG-04127-D	35,159	-
16. Total		-	35,159			35,159	-
Total Department of Justice		-	637,941			637,941	-
Department of Labor							
H-1B Job Training Grants	17.268	481,793	-			481,793	449,399
17.268 Total		481,793	-			481,793	449,399

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Total Department of Labor		<u>481,793</u>	<u>-</u>			<u>481,793</u>	<u>449,399</u>
Department of State							
Academic Exchange Programs - Undergraduate Programs	19.009	-	4,196	WORLD LEARNING	SECAGD19CA0115	4,196	-
19.009 Total		<u>-</u>	<u>4,196</u>			<u>4,196</u>	<u>-</u>
Total Department of State		<u>-</u>	<u>4,196</u>			<u>4,196</u>	<u>-</u>
Department of Transportation							
Highway Training and Education	20.215	30,612	-			30,612	-
20.215 Total		<u>30,612</u>	<u>-</u>			<u>30,612</u>	<u>-</u>
Contract	20.U09	-	37,732	ALABAMA DEPT OF TRANSPORTATION	K-15-1884	37,732	-
Contract	20.U10	-	(4,403)	ALABAMA DEPT OF TRANSPORTATION	DBE/SS	(4,403)	-
20. Total		<u>-</u>	<u>33,329</u>			<u>33,329</u>	<u>-</u>
Total Department of Transportation		<u>30,612</u>	<u>33,329</u>			<u>63,941</u>	<u>-</u>
Department of the Treasury							
COVID-19 Coronavirus Relief Fund	21.019	-	45,321	STATE OF ALABAMA DEPARTMENT OF FINANCE	SLT0002/SLT0223	45,321	-
21.019 Total		<u>-</u>	<u>45,321</u>			<u>45,321</u>	<u>-</u>
COVID-19 Coronavirus State and Local Fiscal Recovery Funds	21.027	-	5,962,350	ALABAMA HEALTH RESEARCH AND EDUCATION FOUNDATION,	ARPA PL 117-2	5,962,350	-
21.027 Total		<u>-</u>	<u>5,962,350</u>			<u>5,962,350</u>	<u>-</u>
Total Department of the Treasury		<u>-</u>	<u>6,007,671</u>			<u>6,007,671</u>	<u>-</u>
Appalachian Regional Commission							
Appalachian Research, Technical Assistance, and Demonstration Projects	23.011	2,489	-			2,489	-
23.011 Total		<u>2,489</u>	<u>-</u>			<u>2,489</u>	<u>-</u>
Total Appalachian Regional Commission		<u>2,489</u>	<u>-</u>			<u>2,489</u>	<u>-</u>
Small Business Administration							
Shuttered Venue Operators Grant Program	59.075	971,494	-			971,494	-
59.075 Total		<u>971,494</u>	<u>-</u>			<u>971,494</u>	<u>-</u>
Total Small Business Administration		<u>971,494</u>	<u>-</u>			<u>971,494</u>	<u>-</u>
Department of Veterans Affairs							
Contract #36C24722P0567	64.U11	454	-			454	-
64. Total		<u>454</u>	<u>-</u>			<u>454</u>	<u>-</u>
Total Department of Veterans Affairs		<u>454</u>	<u>-</u>			<u>454</u>	<u>-</u>
Department of Education							
Graduate Assistance in Areas of National Need	84.200	96,363	-			96,363	-
84.200 Total		<u>96,363</u>	<u>-</u>			<u>96,363</u>	<u>-</u>
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325	350,619	-			350,619	-
84.325 Total		<u>350,619</u>	<u>-</u>			<u>350,619</u>	<u>-</u>
Gaining Early Awareness and Readiness for Undergraduate Programs	84.334	1,222,201	-			1,222,201	130,202
84.334 Total		<u>1,222,201</u>	<u>-</u>			<u>1,222,201</u>	<u>130,202</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Child Care Access Means Parents in School	84.335	264,652	-			264,652	-
84.335 Total		264,652	-			264,652	-
English Language Acquisition State Grants	84.365	416,947	-			416,947	-
84.365 Total		416,947	-			416,947	-
Improving Teacher Quality State Grants	84.367	-	224,504	ALABAMA DEPT OF EDUCATION	PL 107-110	224,504	-
84.367 Total		-	224,504			224,504	-
Investing in Innovation (I3) Fund	84.411	-	10,008	NATIONAL WRITING PROJECT	U411A160004	10,008	-
84.411 Total		-	10,008			10,008	-
COVID-19 Elementary and Secondary School Emergency	84.425D	-	287,749	ALABAMA DEPT OF EDUCATION	PL 116-136	287,749	-
COVID-19 Elementary and Secondary School Emergency	84.425D	-	21,034	ALABAMA DEPT OF EDUCATION	PL 117-2	21,034	-
COVID-19 Higher Education Relief Fund (HEERF) - Student Aid Portion	84.425E	487,611	-			487,611	-
COVID-19 Higher Education Relief Fund (HEERF) - Institutional Portion	84.425F	20,229,811	-			20,229,811	-
COVID-19 Higher Education Relief Fund (HEERF) - COVID-19 Strengthening Institutions Program	84.425M	1,590,188	-			1,590,188	-
84.425 Total		22,307,610	308,783			22,616,393	-
Total Department of Education		24,658,392	543,295			25,201,687	130,202
Consumer Product Safety Commission							
Contract #61320619N0138 Option1/5A732068	87.U12	134,677	-			134,677	-
Contract #61320619N0138 opt 3 5A732068	87.U13	22,976	-			22,976	-
87. Total		157,653	-			157,653	-
Total Consumer Product Safety Commission		157,653	-			157,653	-
Department of Health and Human Services							
Training in General, Pediatric, and Public Health Dentistry	93.059	210,235	-			210,235	67,004
93.059 Total		210,235	-			210,235	67,004
Global AIDS	93.067	-	80,832	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	5NU2GGH002251-02-00	80,832	-
93.067 Total		-	80,832			80,832	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	376,479	-			376,479	35,969
93.084 Total		376,479	-			376,479	35,969
Enhance Safety of Children Affected by Substance Abuse	93.087	492,671	-			492,671	6,903
93.087 Total		492,671	-			492,671	6,903
Area Health Education Centers Point of Service Maintenance and Enhancement Awards	93.107	769,327	-			769,327	537,247
93.107 Total		769,327	-			769,327	537,247
Maternal and Child Health Federal Consolidated Programs	93.110	1,057,478	-			1,057,478	20,000
Maternal and Child Health Federal Consolidated Programs	93.110	-	55,432	ALABAMA DEPT OF MENTAL HEALTH	5U4CM32312-04-00	55,432	-
Maternal and Child Health Federal Consolidated Programs	93.110	-	31,461	AMERICAN COLLEGE OF OBSTETRICS & GYNECOLOGY	2UC4MC280420500	31,461	-
Maternal and Child Health Federal Consolidated Programs	93.110	-	22,091	GEORGETOWN UNIVERSITY	2UE8MC25742-09-00	22,091	-
Maternal and Child Health Federal Consolidated Programs	93.110	-	4,758	ASSOCIATION OF PUBLIC HEALTH LABORATORIES	UG8MC31893	4,758	-
93.110 Total		1,057,478	113,742			1,171,220	20,000
Project Grants and Cooperative Agreements for Tuberculosis Control Programs	93.116	-	122,823	ALABAMA DEPT OF PUBLIC HEALTH	6NU52PS910194	122,823	-
Project Grants and Cooperative Agreements for Tuberculosis Control Programs	93.116	-	35,315	ALABAMA DEPT OF PUBLIC HEALTH	C10114110-6NU52PS910194	35,315	-
93.116 Total		-	158,138			158,138	-

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Nurse Anesthetist Traineeships	93.124	84,257	-			84,257	-
93.124 Total		<u>84,257</u>	<u>-</u>			<u>84,257</u>	<u>-</u>
Emergency Medical Services for Children	93.127	-	246,489	ALABAMA DEPT OF PUBLIC HEALTH	5H33MC06713-16	246,489	-
Emergency Medical Services for Children	93.127	-	(5,988)	ALABAMA DEPT OF PUBLIC HEALTH	C10114143 -H33MC06713	(5,988)	-
93.127 Total		<u>-</u>	<u>240,501</u>			<u>240,501</u>	<u>-</u>
Centers for Research and Demonstration for Health	93.135	620,256	-			620,256	13,405
COVID-19 Centers for Research and Demonstration for	93.135	323,483	-			323,483	-
93.135 Total		<u>943,739</u>	<u>-</u>			<u>943,739</u>	<u>13,405</u>
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	790,596	-			790,596	100,000
COVID-19 Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	12,215	-			12,215	-
93.153 Total		<u>802,811</u>	<u>-</u>			<u>802,811</u>	<u>100,000</u>
Disabilities Prevention	93.184	3,866,863	-			3,866,863	1,305,686
93.184 Total		<u>3,866,863</u>	<u>-</u>			<u>3,866,863</u>	<u>1,305,686</u>
Family Planning_Services	93.217	-	102,641	ALABAMA DEPT OF PUBLIC HEALTH	FPHPA006461	102,641	-
Family Planning_Services	93.217	-	9,275	ALABAMA DEPT OF PUBLIC HEALTH	FPHPA006556-01-00	9,275	-
93.217 Total		<u>-</u>	<u>111,916</u>			<u>111,916</u>	<u>-</u>
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	731,644	-			731,644	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	429,066	JEFFERSON COUNTY COMMISSION	1H79TI082946-02	429,066	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	295,959	JEFFERSON COUNTY COMMISSION	1H79TI081163-01	295,959	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	32,696	ALABAMA DEPT OF EDUCATION	1H79SM080971	32,696	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	6,109	ALABAMA DEPT OF PUBLIC HEALTH	C10114080-5H79SM062921-05	6,109	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	5,066	ALABAMA DEPT OF MENTAL HEALTH	HRSA-18-122	5,066	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	4,978	ALABAMA DEPT OF EDUCATION	1H79SM080971-01	4,978	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	(72)	ALABAMA DEPT OF PUBLIC HEALTH	C00119028-5H79SM062921-03	(72)	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	(151)	ALABAMA DEPT OF PUBLIC HEALTH	C801103060-5H79SM062921-02	(151)	-
93.243 Total		<u>731,644</u>	<u>773,651</u>			<u>1,505,295</u>	<u>-</u>
Advanced Nursing Education Grant Program	93.247	808,004	-			808,004	-
93.247 Total		<u>808,004</u>	<u>-</u>			<u>808,004</u>	<u>-</u>
Universal Newborn Hearing Screening	93.251	-	47,257	ALABAMA DEPT OF PUBLIC HEALTH	H61MC00054	47,257	-
93.251 Total		<u>-</u>	<u>47,257</u>			<u>47,257</u>	<u>-</u>
CSELS Partnership: Strengthening Public Health Laboratories	93.322	-	13	ASSOCIATION OF PUBLIC HEALTH LABORATORIES	1U60OE000103	13	-
93.322 Total		<u>-</u>	<u>13</u>			<u>13</u>	<u>-</u>
COVID-19 Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	-	23,849,409	ALABAMA DEPT OF PUBLIC HEALTH	C10114200-6NU50CK000545-02-06	23,849,409	-
COVID-19 Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	-	703,899	ALABAMA DEPT OF PUBLIC HEALTH	C10114058B-NU50CK000545	703,899	-

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
COVID-19 Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) 93.323 Total	93.323	-	571,903	ALABAMA DEPT OF PUBLIC HEALTH	C10114183-1NU50CK000545-01-00	571,903	-
		-	25,125,211			25,125,211	-
Paralysis Resource Center 93.325 Total	93.325	-	120	CHRISTOPHER & DANA REEVE FOUNDATION	90PRRC0002-02-00	120	-
		-	120			120	-
Behavioral Risk Factor Surveillance System 93.336 Total	93.336	-	234,064	ALABAMA DEPT OF PUBLIC HEALTH	NU58DP006852	234,064	-
		-	234,064			234,064	-
Cooperative Agreement for Emergency Response: Public Health Crisis Response 93.354 Total	93.354	-	34,325	ALABAMA DEPT OF PUBLIC HEALTH	1NU90TP922134	34,325	-
		-	34,325			34,325	-
Nurse Education, Practice Quality and Retention Grants 93.359 Total	93.359	1,272,757	-			1,272,757	-
		1,272,757	-			1,272,757	-
Sickle Cell Treatment Demonstration Program 93.365	93.365	867,075	-			867,075	564,549
Sickle Cell Treatment Demonstration Program 93.365	93.365	-	17,197	CAROLINAS HEALTHCARE SYSTEM	6U1EMC31108-02-01	17,197	
Sickle Cell Treatment Demonstration Program 93.365 Total	93.365	-	12,104	CAROLINAS HEALTHCARE SYSTEM	6 U1EMC3110804-02	12,104	
		867,075	29,301			896,376	564,549
Improving Health of Americans through Prevention/Management of Diabetes/Heart Disease/Stroke 93.426	93.426	-	48,493	ALABAMA DEPT OF PUBLIC HEALTH	C10114203-NU58DP006527	48,493	
Improving Health of Americans through Prevention/Management of Diabetes/Heart Disease/Stroke 93.426 Total	93.426	-	(249)	ALABAMA DEPT OF PUBLIC HEALTH	C10114129-NU58DP006527	(249)	
		-	48,244			48,244	-
Every Student Succeeds Act/Preschool Development 93.434	93.434	-	239,804	ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION	90TP0065-01-00	239,804	
Every Student Succeeds Act/Preschool Development 93.434	93.434	-	62,676	ALABAMA DEPT OF EDUCATION	90TP0065-01-00	62,676	8,803
Every Student Succeeds Act/Preschool Development 93.434 Total	93.434	-	3,121	UNIVERSITY OF ALABAMA IN TUSCALOOSA	90TP0065-03-00	3,121	
		-	305,601			305,601	8,803
COVID-19 Testing for the Uninsured 93.461 Total	93.461	2,425,816	-			2,425,816	-
		2,425,816	-			2,425,816	-
COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution 93.498 Total	93.498	9,238,513	-			9,238,513	-
		9,238,513	-			9,238,513	-
Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support 93.516	93.516	-	84,450	EMORY UNIVERSITY	5U86HP31680-04-00	84,450	
Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support 93.516 Total	93.516	-	16,270	EMORY UNIVERSITY	6UB6HP31680-05-00	16,270	
		-	100,720			100,720	-
ACA - State Innovation Models: Funding for Model Design and Model Testing Assistance 93.624 Total	93.624	362,261	-			362,261	-
		362,261	-			362,261	-
University Centers for Excellence in Developmental Disabilities Education, Research, and Service 93.632	93.632	451,979	-			451,979	
COVID-19 University Centers for Excellence in Developmental Disabilities Education, Research, and Service 93.632	93.632	31,869	-			31,869	

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
93.632 Total		<u>483,848</u>	<u>-</u>			<u>483,848</u>	<u>-</u>
Foster Care Title IV-E	93.658	-	87,645	UNIVERSITY OF ALABAMA IN TUSCALOOSA	C220161203	87,645	-
93.658 Total		<u>-</u>	<u>87,645</u>			<u>87,645</u>	<u>-</u>
Medical Student Education	93.680	6,220,756	-			6,220,756	430,616
93.680 Total		<u>6,220,756</u>	<u>-</u>			<u>6,220,756</u>	<u>430,616</u>
Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Parts A and B	93.686	-	130,000	ALABAMA DEPT OF PUBLIC HEALTH	C00119147-UT8HA33956	130,000	-
Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Parts A and B	93.686	-	100,000	ALABAMA DEPT OF PUBLIC HEALTH	C20115141-UT8HA33956	100,000	-
93.686 Total		<u>-</u>	<u>230,000</u>			<u>230,000</u>	<u>-</u>
PPHF-2012 Mental and Behavioral Health Education and Training Grants	93.732	888,620	-			888,620	-
93.732 Total		<u>888,620</u>	<u>-</u>			<u>888,620</u>	<u>-</u>
Children's Health Insurance Program	93.767	-	66,130	ALABAMA DEPT OF PUBLIC HEALTH	C20115194	66,130	-
Children's Health Insurance Program	93.767	-	59,499	ALABAMA DEPT OF PUBLIC HEALTH	C80113063-7500515	59,499	-
Children's Health Insurance Program	93.767	-	25,494	ALABAMA DEPT OF PUBLIC HEALTH	C00119199-PL 111-148	25,494	20,822
Children's Health Insurance Program	93.767	-	(12,670)	ALABAMA DEPT OF PUBLIC HEALTH	C60118063	(12,670)	-
93.767 Total		<u>-</u>	<u>138,453</u>			<u>138,453</u>	<u>20,822</u>
Opioid STR	93.788	-	240,283	ALABAMA DEPT OF MENTAL HEALTH	OPIOID USE DISORDER	240,283	-
Opioid STR	93.788	-	2,553	ALABAMA DEPT OF MENTAL HEALTH	H79T1083325	2,553	-
93.788 Total		<u>-</u>	<u>242,836</u>			<u>242,836</u>	<u>-</u>
Hospital Preparedness Program (HPP) Ebola	93.817	-	(3,689)	ALABAMA DEPT OF PUBLIC HEALTH	C90116244-1U3REP150509	(3,689)	-
93.817 Total		<u>-</u>	<u>(3,689)</u>			<u>(3,689)</u>	<u>-</u>
Maternal, Infant and Early Childhood Home visiting Grant Program	93.870	-	125,687	ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION	X10MC33563	125,687	-
Maternal, Infant and Early Childhood Home visiting Grant Program	93.870	-	659	ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION	X10MC32174AND X10MC39669	659	-
93.870 Total		<u>-</u>	<u>126,346</u>			<u>126,346</u>	<u>-</u>
Strengthening the Public Health System in US-affiliated Pacific Islands (Non-PPHF)	93.874	-	64,784	UNIVERSITY OF HAWAII	6NU38OT000253-04-01	64,784	-
93.874 Total		<u>-</u>	<u>64,784</u>			<u>64,784</u>	<u>-</u>
Autism Collaboration, Accountability, Research, Education, and Support	93.877	672,189	-			672,189	-
93.877 Total		<u>672,189</u>	<u>-</u>			<u>672,189</u>	<u>-</u>
Grants for Primary Care Training and Enhancement	93.884	241,750	-			241,750	-
93.884 Total		<u>241,750</u>	<u>-</u>			<u>241,750</u>	<u>-</u>
Cancer Prevention and Control Programs for State,	93.898	-	9,964	ALABAMA DEPT OF PUBLIC HEALTH	C20115108 NU58DP006301	9,964	-
93.898 Total		<u>-</u>	<u>9,964</u>			<u>9,964</u>	<u>-</u>
HIV Care Formula Grants	93.917	-	(333)	UNITED WAY OF CENTRAL ALABAMA INC	X07HA00049	(333)	-
93.917 Total		<u>-</u>	<u>(333)</u>			<u>(333)</u>	<u>-</u>
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	154,098	-			154,098	-
COVID-19 Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	37,600	-			37,600	-
93.918 Total		<u>191,698</u>	<u>-</u>			<u>191,698</u>	<u>-</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
HIV Prevention Activities_Health Department Based	93.940	-	443,088	ALABAMA DEPT OF PUBLIC HEALTH	C20115042 NU62PS924533	443,088	
HIV Prevention Activities_Health Department Based	93.940	-	328,155	ALABAMA DEPT OF PUBLIC HEALTH	C10114046-NU62PS924533	328,155	
HIV Prevention Activities_Health Department Based	93.940	-	324,855	ALABAMA DEPT OF PUBLIC HEALTH	C10114047-NU62PS924533	324,855	
HIV Prevention Activities_Health Department Based	93.940	-	100,000	ALABAMA DEPT OF PUBLIC HEALTH	C20115016 NU62PS924533	100,000	
HIV Prevention Activities_Health Department Based	93.940	-	90,000	ALABAMA DEPT OF PUBLIC HEALTH	C10114013-NU62PS924533	90,000	
HIV Prevention Activities_Health Department Based	93.940	-	80,722	ALABAMA DEPT OF PUBLIC HEALTH	C20115018 NU62PS924533	80,722	
HIV Prevention Activities_Health Department Based	93.940	-	45,639	ALABAMA DEPT OF PUBLIC HEALTH	C10114048-NU62PS924533	45,639	
93.940 Total		-	1,412,459			1,412,459	-
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	-	23,308	MONTANA DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERV	20-25-5-01-301-0 PRAMS	23,308	
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	-	21,768	ALABAMA DEPT OF PUBLIC HEALTH	C10114190 1U01DP006600-01-00	21,768	
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	-	1,404	ALABAMA DEPT OF PUBLIC HEALTH	C10119151-5U01DP006235-05-00	1,404	
93.946 Total		-	46,480			46,480	-
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	576,299	-			576,299	152,799
93.978 Total		576,299	-			576,299	152,799
Preventive Health and Health Services Block Grant	93.991	-	6,780	ALABAMA DEPT OF PUBLIC HEALTH	C20115008 1NB01OT009404-01	6,780	
93.991 Total		-	6,780			6,780	-
Maternal and Child Health Services Block Grant to the States	93.994	-	177,662	ALABAMA DEPT OF PUBLIC HEALTH	C10114267 GC-21-455	177,662	
Maternal and Child Health Services Block Grant to the States	93.994	-	5,365	ALABAMA DEPT OF PUBLIC HEALTH	C20115073 B04MC40113	5,365	
Maternal and Child Health Services Block Grant to the States	93.994	-	500	ALABAMA DEPT OF PUBLIC HEALTH	C10114051-B04MC33819	500	
93.994 Total		-	183,527			183,527	-
Contract	93.U14	-	76,324	CHILDREN'S HOSPITAL BOSTON	75D30121C10297	76,324	
Contract	93.U15	-	12,716	JEFFERSON COUNTY BOARD OF HEALTH	DC-169	12,716	
Contract	93.U16	-	5,702	UNIVERSITY OF NEW MEXICO	75Q80120C00003	5,702	
Contract	93.U17	-	92	BAVARIAN NORDIC A/S	HHSO100201700019C	92	
Unknown	93.U18	-	451,725	ALABAMA DEPT OF PUBLIC HEALTH	C20115138 6NU50CK000545-03-02	451,725	
Unknown	93.U19	-	127,389	ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION	X10MC39669/X10MC43564	127,389	
Unknown	93.U20	-	23,833	ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION	X11MC41937	23,833	
Unknown	93.U21	-	(340)	ALABAMA MEDICAID AGENCY	C200629856	(340)	
93. Total		-	697,441			697,441	-
Total Department of Health and Human Services		33,585,090	30,646,329			64,231,419	3,263,803
Corporation for National and Community Services							
Volunteers in Service to America	94.013	281,409	-			281,409	
94.013 Total		281,409	-			281,409	-
Total Corporation for National and Community Services		281,409	-			281,409	-
TOTAL OTHER PROGRAMS		62,045,621	37,871,720			99,917,341	3,843,404
SPECIAL FEDERAL APPROPRIATIONS							
Miscellaneous							

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham
Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2022

Federal Program	ALN	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Lister Hill Center for Health Policy	93.U22	472,130	-			472,130	
John J. Sparkman Center	93.U23	431,931	-			431,931	
93 Total		<u>904,061</u>	<u>-</u>			<u>904,061</u>	<u>-</u>
Total Miscellaneous		<u>904,061</u>	<u>-</u>			<u>904,061</u>	<u>-</u>
TOTAL SPECIAL FEDERAL APPROPRIATIONS		<u>904,061</u>	<u>-</u>			<u>904,061</u>	<u>-</u>
TOTAL FEDERAL EXPENDITURES		<u>\$ 610,812,840</u>	<u>\$ 84,085,271</u>			<u>\$ 694,898,111</u>	<u>\$ 68,173,461</u>

The accompanying notes are an integral part of this schedule.

The University of Alabama at Birmingham

Notes to Schedule of Expenditures of Federal Awards

Year Ended September 30, 2022

1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the federal expenditures of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, under programs of the federal government for the year ended September 30, 2022. Other campuses of The University of Alabama System are presented in separate reports. The amounts reported as federal expenditures were obtained from UAB's general ledger. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this Schedule may differ from amounts presented in, or used in the preparation of, the statements of net position, of revenues, expenses, and changes in net position and of cash flows of UAB. The federal expenditures of Southern Research Institute ("SRI"), a discretely presented component unit of UAB, have not been included within the Schedule.

The blended component units of UAB include UAB Research Foundation, UAB Athletics Foundation, UAB Hospital Management, L.L.C, and Triton Health Systems, L.L.C. These component units do not expend federal awards and therefore are not subject to requirements of the Uniform Guidance.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between UAB and agencies and departments of the federal government and all subawards to UAB by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years. Complete assistance listing numbers and pass-through numbers are provided when available.

2. Summary of Significant Accounting Policies

For purposes of the Schedule, expenditures for federal award programs are recognized on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance where certain types of expenditures are not allowable or are limited to reimbursement.

3. Facilities and Administrative Costs ("F&A Costs")

UAB applies its predetermined approved facilities and administrative rate when charging indirect cost to federal awards rather than the 10% de minimis cost rate described in Section 200.414 of the Uniform Guidance. UAB operates under predetermined fixed F&A cost rates which are effective from October 1, 2019 through September 30, 2023. The predetermined fixed rates were based on 2014 financial information. The base rate for on-campus research is 48.5% for the year ended September 30, 2022. Base rates for other F&A cost recoveries range from 5.4% to 45% for the year ended September 30, 2022.

The University of Alabama at Birmingham
Notes to Schedule of Expenditures of Federal Awards
Year Ended September 30, 2022

4. Provider Relief Funds (PRF)

The Schedule includes grant activity related to the Department of Health and Human Services ("HHS") Provider Relief Fund and American Rescue Plan (ARP) Distribution Assistance Listing #93.498. As required based on guidance in the 2022 OMB Compliance Supplement, the Schedule includes all Period 2 funds received between July 1, 2020 and December 31, 2020 and expended by December 31, 2021 as reported to the Health Resources & Services Administration (HRSA) via the PRF Reporting Portal. The Schedule thus includes \$9,238,513 of direct expenditures for Period 2. No funds were received for Period 3 (January 1, 2021 to June 30, 2021).

5. Federal Student Loan Programs

Direct Loan Programs

The Perkins, Health Professions Student Loan ("HPSL"), Nurse Faculty Loan Program ("NFLP"), and Loans to Disadvantaged Students ("LDS") programs are administered directly by UAB, and balances and transactions relating to these programs are included in UAB's basic financial statements.

The balances of loans outstanding at September 30, 2022 under the federal student loan programs are summarized as follows:

	Perkins (ALN 84.038)	HPSL (ALN 93.342)	NFLP (ALN 93.264)	LDS (ALN 93.342)	NFLP-ARRA (ALN 93.408)	Total
Total loan balance outstanding, September 30, 2022	\$ 4,521,206	\$ 1,008,849	\$ 4,384,514	\$ 64,953	\$ 42,859	\$ 10,022,381

Federal Direct Loans

The Federal Direct Student Loan (FDSL) program (Assistance Listing #84.268) was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSL enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through UAB rather than through private lenders. UAB began participation in the FDSL on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan origination process, including funds management and promissory note functions. UAB is not responsible for collection of these loans.

Part II
Schedule of Findings and Questioned Costs

The University of Alabama at Birmingham

Schedule of Findings and Questioned Costs

Year Ended September 30, 2022

Section I – Summary of Auditor’s Results

Financial Statements

Type of auditor’s report issued Unmodified opinion

Internal control over financial reporting

Material weakness(es) identified? __yes no

Significant deficiency(ies) identified that are not considered to be material weaknesses? __yes none reported

Noncompliance material to financial statements noted? __yes no

Federal Awards

Internal control over major programs

Material weakness(es) identified? __yes no

Significant deficiency(ies) identified that are not considered to be material weaknesses? __yes none reported

Type of auditor’s report issued on compliance for major programs Unmodified

Any audit findings disclosed that are required to be reported in accordance the with 2 CFR 200.516(a)? __x yes __no

Identification of major programs:

Assistance Listing Number(s)	Name of Federal Program or Cluster
Various	Research and Development Cluster
21.027	COVID-19 Coronavirus Recovery Programs
84.425D, 84.425E, 84.425F and 84.425M	COVID-19 Elementary and Secondary School Emergency Relief (ESSER) Fund, COVID-19 Higher Education Emergency Relief Fund (HEERF) Student Portion, COVID-19 Higher Education Emergency Relief Fund (HEERF) Institutional Portion and COVID-19 Higher Education Emergency Relief Fund (HEERF) Strengthening Institutions Program
93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
93.323	COVID-19 Infectious Diseases
93.680	Medical Student Education
93.600	Head Start Cluster

Dollar threshold used to distinguish between Type A and Type B Programs \$ 3,000,000

Auditee qualified as low-risk auditee? __x yes __no

Section II – Financial Statement Findings

No matter were noted.

Section III – Federal Award Findings and Questioned Costs

Refer to the following page.

Finding 2022-001 – Return of Interest Earned on Advance Payments

Cluster: Research & Development

Federal Agency: Department of Defense

Assistance Listing Program Title and Number: Military Medical Research and Development – 12.420

Award Name: Beta Blockers for the Prevention of Acute Exacerbations of COPD

Award Identifying Numbers: W81XWH-15-1-0705

Award Year: 2021-2022

Criteria: UAB is subject to cash management compliance requirements pertaining to the use of advanced funds. 2 CFR section 200.305(b)(9) requires that interest earned by non-federal entities other than states on advances of federal funds be remitted annually to the US Department of Health and Human Services, Payment Management System. Up to \$500 per year may be kept for administrative expenses.

Condition: While testing UAB’s compliance with Cash Management compliance requirements for the R&D cluster, we identified that UAB had earned interest in excess of \$500 (approximately \$51,000 in total) on funds associated with one of only two advance payment method awards, but that this interest had not been remitted to the PMS system as required.

Questioned Costs: \$50,753

Cause: Although UAB does have a process to identify and remit interest earned on advanced payment awards in excess of \$500, this process was interrupted by both an award extension request and staff turnover.

Effect: Interest earned on advanced funds was not returned in a timely manner.

Recommendation: The University should establish procedures to ensure that interest earned on advanced funds is identified and returned annually in accordance with 2 CFR section 200.305(b)(9).

View of Responsible Officials: Refer to Management’s Corrective Action Plan for management’s view and corrective action plan for the finding described above.



THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESPONSE TO THE UNIFORM GUIDANCE AUDIT

The following is the University of Alabama at Birmingham's Response to the audit of Federal programs in accordance with the Uniform Guidance for the year ending September 30, 2022.

Finding 2022-001- Return of Interest Earned on Advance Payments

Program: Research and Development Cluster

Awards: Beta Blockers for the Prevention of Acute Exacerbations of COPD – 12.420

Management understands the requirement to remit interest earned on advance payments in excess of \$500 annually to the Department of Health and Human Services (HHS). Advance payment on awards are uncommon at our institution with only two such awards active during the period under audit. Management acknowledges and agrees with the finding as presented.

The Grants and Contracts Department (Department) tracked the monthly interest earned on the advance payment received from the DOD. The department requested clarification from the DOD as to what constitutes "annually". There was no clarification provided at the time from DOD, as such the department used the fiscal year-end. During the fiscal year 2022, the award went through a request for an extension which coincided with the award end period. The department elected to hold off on remitting the earned interest until a final resolution on the award extension period was received. The award closeout process would include the remittance interest earned. The award was extended for an additional 12 months, but the interest earned was not remitted timely. The department also experienced turnover of a manager and an accountant during fiscal year 2022, both were actively involved in the maintenance of the award in question. The interest earned has since been remitted to HHS.

Management notes that award will end September 29, 2023 with no option to extend. Interest earned will be tracked by the department and remitted with closeout documents. The University of Alabama at Birmingham expects to have this item completed by October 2023. For follow-up questions and information, contact Bernard Mays, University Controller at bmaysjr@uab.edu.

Sincerely,

Bernard Mays Jr.
UAB Controller and Assistant Vice President for Financial Affairs

FINANCE & ADMINISTRATION

Office of Financial Affairs

Part III
Summary Schedule of Prior Audit Findings and Status

The University of Alabama at Birmingham

Summary Schedule of Prior Audit Findings and Status

Year Ended September 30, 2022

Finding 2021-001: Student Financial Assistance – Return of Title IV Funds

Federal Agency: U.S. Department of Education

Program: Student Financial Assistance Cluster

Award(s) and Assistance Listing Numbers: Direct Loans (84.268) & Federal Pell Grant (84.063)

Award Year: Academic year 2020-2021

Through return of Title IV Funds testing, PwC noted that three students began attendance but subsequently withdrew and their unearned title IV funds were not returned within 45 days of the withdrawal date. Two students related to direct loans in the amount of \$1,731 & \$1,864 which were returned 48 days and 57 days after the withdrawal date. The third student related to the Federal Pell Grant in the amount of \$149 which was returned 82 days after the withdrawal date.

PwC recommended the University enhance its controls and incorporate multiple individuals in the process to ensure that Title IV refunds are made timely.

Status

Management implemented a new all-inclusive withdrawal report, with the help of information technology, instead of having to identify students from a number of different reports to ensure students who have full term withdrawals are found in a timely manner. The reports have been made available to Student Account Services to further ensure all students who have full term withdrawals are identified and funds returned in a timely manner as evidenced through proper review.

Part IV
2022 Financial Report

UAB

2022 Financial Report
University of Alabama at Birmingham



UAB is an equal education opportunity institution,
and an equal employment opportunity employer.

This report is published by the UAB Senior Vice President
for Finance and Administration. Obtain additional copies
by writing:

Senior Vice President for Finance and Administration
The University of Alabama at Birmingham
Birmingham, Alabama 35294

University of Alabama at Birmingham

2021-2022 Annual Financial Report

Table of Contents

Financial Section	
Management's Responsibility for Financial Reporting	2
Report of Independent Auditors	3
Management's Discussion and Analysis (Unaudited)	5
Financial Statements	
Statements of Net Position	23
Statements of Revenues, Expenses, and Changes in Net Position	25
Statements of Cash Flows	26
Discretely Presented Component Unit	
Statements of Net Position	28
Statements of Revenues, Expenses, and Changes in Net Position	29
Notes to Financial Statements	
Note 1 Organization and Summary of Significant Accounting Policies	30
Note 2 Component Units	36
Note 3 Cash and Cash Equivalents	39
Note 4 Investments	39
Note 5 Receivables	49
Note 6 Capital Assets	51
Note 7 Long-term Debt	53
Note 8 Self-insurance	59
Note 9 Employee Benefits	60
Note 10 Post-Employment Benefits	64
Note 11 Federal Direct Student Loan Program	71
Note 12 Grants and Contracts	72
Note 13 Operating Expenses by Function	72
Note 14 Contingencies and Commitments	73
Note 15 Segment Reporting	73
Note 16 Health Care Services	76
Note 17 Recently Issued Pronouncements	79
Required Supplementary Information (Unaudited)	81
UAB Administration (Unaudited)	85
The Board of Trustees of The University of Alabama (Unaudited)	86

Management's Responsibility for Financial Reporting


The accompanying financial statements of the University of Alabama at Birmingham (UAB) for the years ended September 30, 2022 and 2021 were prepared by UAB's management in conformity with accounting principles generally accepted in the United States of America.

The management of UAB is responsible for the integrity and objectivity of these financial statements, which are presented on the accrual basis of accounting and, accordingly, include some amounts based upon judgement. Other financial information in the annual report is consistent with that in the financial statements. Our system of internal accounting controls is designed to help ensure that the financial reports and the books properly reflect the transactions of the institution, in accordance with established policies and procedures as implemented by qualified personnel.

The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the financial and accounting operations of the institution, including the review and discussion of periodic financial statements and the evaluation and adoption of budgets. The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the basis of engagement and reporting of independent auditors.



Brian D. Burnett, PhD
Senior Vice President for Finance and Administration



Stephanie Mullins
UAB Chief Financial Officer
Associate Vice President for Financial Affairs



Report of Independent Auditors

To the Board of Trustees of The University of Alabama

Report on the Audit of the Financial Statements

Opinions

We have audited the accompanying financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, a component unit of the State of Alabama, which comprise the statements of net position as of September 30, 2022 and 2021, and the related statements of revenues, expenses, and changes in net position, and of cash flows (where applicable) for the years then ended, including the related notes (collectively referred to as the "financial statements").

In our opinion, based on our audit and the report of other auditors, the accompanying financial statements present fairly, in all material respects, the respective financial position of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham as of September 30, 2022 and 2021, and the respective changes in financial position and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

We did not audit the financial statements of Southern Research Institute, UAB's discretely presented component unit, which statements reflect total assets of \$124.1 million and \$125.5 million as of December 31, 2021 and January 1, 2021, and changes in net position of \$9.7 million and \$12.1 million for the years then ended. Those statements were audited by other auditors whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for the discretely presented component unit, is based solely on the report of the other auditors.

Basis for Opinions

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of UAB and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

The financial statements of Southern Research Institute and Triton Health Systems, L.L.C., UAB Athletics Foundation, and UAB Research Foundation, UAB's blended component units, were not audited in accordance with *Government Auditing Standards*.

Emphasis of Matters

As discussed in Note 1 to the financial statements, UAB changed the manner in which it accounts for leases in 2022. Our opinions are not modified with respect to this matter.



As discussed in Note 1, the financial statements of UAB are intended to present the financial position, the changes in financial position, and the cash flows of only that portion of the business-type activities of the financial reporting entity of The University of Alabama System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of The University of Alabama System as of September 30, 2022 and 2021, the changes in its financial position, or its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America. Our opinions are not modified with respect to this matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinions. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



Required Supplemental Information

Accounting principles generally accepted in the United States of America require that the accompanying management's discussion and analysis on pages 5 through 22 and the required supplementary information for the pension plan and postemployment benefits on pages 81 and 84 be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is

required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated January 24, 2023 on our consideration of UAB's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering UAB's internal control over financial reporting and compliance and other matters.

PricewaterhouseCoopers LLP

Birmingham, Alabama
January 24, 2023

The University of Alabama at Birmingham

Management's Discussion and Analysis (Unaudited)

The objective of management's discussion and analysis ("MD&A") is to help readers of The University of Alabama at Birmingham ("UAB")'s financial statements better understand the financial position and operating activities for the fiscal years ended September 30, 2022 and 2021. This discussion has been prepared by management along with the financial statements and related note disclosures and should be read in conjunction with the financial statements and notes. The financial statements, notes, required supplementary information, and this discussion are the responsibility of management. In January 2020, the World Health Organization declared the novel Coronavirus ("COVID-19") a Public Health Emergency of International Concern. The outbreak of COVID-19 caused domestic and global disruption in operations for institutions of higher education and healthcare organizations and impacted several areas of UAB and University Hospital's financial statements as further discussed within the MD&A and Note 1.

History, Mission and Governance

The University of Alabama at Birmingham ("UAB") became an autonomous campus within The University of Alabama System in 1969 and, in the five decades since, has grown into a world-renowned research university and medical center, occupying more than 105 city blocks in Alabama's largest metropolitan area. UAB is the state's largest single-site employer with more than 26,000 employees. *Forbes* ranked UAB the number one Best Large Employer in America (above the likes of Mayo Clinic, NASA and Google) in 2021 and the number one best employer for diversity among colleges and universities.

UAB's mission is to serve students, patients, the community and the global need for discovery, knowledge dissemination, education, creativity and the application of groundbreaking solutions. UAB is a leader among comprehensive public urban research universities with academic medical centers.

As of 2017, UAB had an economic impact on Alabama that exceeds \$7.15 billion annually and is key in growing a robust tech and knowledge-based economy for the Birmingham region and Alabama. The UAB Harbert Institute for Innovation and Entrepreneurship generated \$5.6 million in revenue, 106 intellectual property disclosures, 39 licenses and eight U.S. patents in FY2022 alone - the Institute's eighth straight year to achieve a positive bottom line (among only 20 percent of university tech transfer offices nationally to do so). UAB's research partner, a discretely presented component unit, Southern Research Institute ("SRI") broke ground in May 2022 on a state-of-the-art biotech innovation center (and anchor of a future urban research park in Birmingham's Southside) that will double its lab space to study infectious diseases, expand capacity to research chronic diseases, grow 150 new scientific and professional jobs, and double a current annual economic impact to \$300M.

At UAB, we have never settled on merely finding what's next - we have helped build the future through new ideas and initiatives in the classroom, the laboratory, the studio and the clinic. UAB's vision, mission and shared values provide a foundation for the strategic plan, Forging the Future.

UAB is accredited by the Southern Association of Colleges and Schools Commission on Colleges to award baccalaureate, masters, doctorate, and professional degrees. UAB's accreditation was reaffirmed during the 2015 cycle. UAB's next reaffirmation will occur in the 2025 cycle. UAB offers Baccalaureate, Master's, Specialist, Doctoral, D.M.D., M.D., and O.D. degrees. At the same time, UAB continues to offer students unrivaled research opportunities and novel academic programs, such as a new Bachelor of Science in Entrepreneurialism that has enrolled more than 108 students in its first two years and earned the 2022 Model Emerging Program Award from the U.S. Association for Small Business and Entrepreneurship. UAB graduate programs continue to rank highly in *US News & World Report*, with 16 programs in the top 25, including a Master's in Health Administration that is number one nationally and six nursing programs in the top 10.

UAB is governed by The Board of Trustees of The University of Alabama (the "Board"), a body corporate under Alabama Law. The Board also governs The University of Alabama and The University of Alabama in Huntsville, which, along with UAB, make up The University of Alabama System (the "System"). The Board determines policy and approves operating budgets, educational programs, facilities and capital financings for each university, and sets the separate tuition and fee schedules applicable at each university. Oversight responsibilities of the Alabama Commission on Higher Education ("ACHE") and annual requests for appropriations from the Alabama legislature are coordinated for each campus by the Chancellor of the System with the approval of the Board.

UAB Awards, Accomplishments and Accolades

University:

UAB's research enterprise is more competitive than ever. In FY2022, research awards topped \$700 million for the first time with a record \$715 million--marking a 50 percent increase since FY2017 and continuing the most successful era of research funding in the university's history. Among public universities, UAB ranks 17th (top 4 percent) in federal research funding and 11th (top 4 percent) in NIH funding. *U.S. News & World Report* recently ranked UAB among the top eight percent of higher education institutions globally for academic research and reputation.

As a globally respected academic medical center, UAB excels at translating research into leading-edge patient care. UAB is home to the eighth largest hospital in the U.S. (1,207 beds), the state's only accredited Level 1 Adult Trauma Center, and the only National Cancer Institute-designated comprehensive cancer center in Alabama and a four-state region. In *U.S. News & World Report Best Hospitals (2022-23)*, UAB was again named the top hospital in Alabama with eight specialties in the nation's top 50. Three faculty from the Heersink School of Medicine were named to the prestigious national Academy of Medicine ("NAM") in 2022, making for a total of 17 NAM members in UAB history.

University Hospital:

This year's *U.S. News and World Report's* "Best Hospitals" special edition issue ranked eight UAB Medicine specialties among the nation's top 50 and ranked University Hospital as the top hospital in Alabama. *U.S. News and World Report* also ranked hospitals in adult procedures and conditions. University Hospital is ranked high performing, which is the highest ranking conferred, in 3 specialties and 17 adult procedures and conditions. *Becker's Hospital Review* named University Hospital on its most recent list of the "100 Great Hospitals in America," a compilation of hospitals that are considered industry innovators and known nationally for excellence in clinical care and, in 2022, the eighth largest hospital in America. University Hospital has been named a Magnet-designated organization for the fifth consecutive time by the American Nurses Credentialing Center Magnet Recognition Program®. University Hospital is only the 21st hospital worldwide to receive this designation five consecutive times. Magnet hospitals are recognized for excellence in nursing care and patient outcomes. UAB Medicine also ranked among the highest in the nation on the Consumer Loyalty list, based on results from *NRC Health's Market Insights* survey, the largest database of health care consumer responses in the country. For the third year in a row, the UAB Medicine eMedicine program was recognized with Hicuity Health's 2022 WE SEE YOU CARE Award for its innovation, leadership, and partnership in implementing a shared services model of tele-ICU care. UAB Medicine received nine Women's Choice Awards in 2022, including among the highest ranked in the Best Hospitals and Patient Experience categories. The Women's Choice Award is an independent referral source for women, aiming to empower women to make better health care choices. For the sixth time since 2016, UAB Medicine has received the LGBTQ Healthcare Equality Leader designation from the Human Rights Campaign Foundation, scoring a perfect 100 in the organization's five criteria.

Overview of Financial Statements

UAB's financial report includes three financial statements: the Statement of Net Position; the Statement of Revenues, Expenses and Changes in Net Position; and the Statement of Cash Flows. These financial statements are prepared in accordance with Governmental Accounting Standards Board ("GASB") principles, which establish standards for external financial reporting for public colleges and universities. The financial statements present comparative financial information of the University, the University of Alabama Hospital ("University Hospital"), and UAB's blended component units. The University Hospital's condensed financial information is presented at Note 15. The blended component units included within the financial information of UAB are UAB Research Foundation ("UABRF"), UAB Athletics Foundation ("UABAF"), Hospital Management L.L.C. ("LLC"), and Triton Health Systems, L.L.C. ("Triton"). In addition to the blended component units, UAB has one discretely presented component unit in the Southern Research Institute ("SRI"). The financial information of SRI does not form part of UAB's MD&A, UAB's financial statements, or UAB's footnotes. However, SRI's Statement of Net Position and Statements of Revenues, Expenses, and Changes in Net Position are disclosed separately on pages 27-28.

During fiscal year 2022, the UAB adopted GASB Statement No. 87, *Leases*, which establishes a single model for lease accounting based on the principle that leases serve to finance the right to use an underlying asset. The statement requires lessees to recognize right-to-use assets and related liabilities, and lessors to recognize receivables and corresponding deferred inflows of resources, for leases that were previously classified as operating and recognized as inflows or outflows of resources. The adoption of GASB Statement No. 87 has been reflected at the beginning of the earliest period presented in the financial statements, or October 1, 2020. For purposes of the MD&A, fiscal year 2020 information does not reflect the adoption of GASB Statement No. 87.

UAB's overall financial position remained strong, as assets totaled \$6.40, \$6.89, and \$5.93 billion at September 30, 2022, 2021, and 2020, respectively. The decrease of \$495.3 million or 7.2% from September 30, 2021 to September 30, 2022 was primarily due to decreases in the fair market value of the investments held offset by increases in capital assets, net of accumulated depreciation and in cash from debt proceeds. Increases of \$959.1 million or 16.2% from September 30, 2020 to September 30, 2021 were primarily due to increases in the fair market value of the investments held.

Total liabilities decreased \$544.5 million or 13.3% from September 30, 2021 to September 30, 2022. The decrease results primarily from a reduction in pension and OPEB liability due to changes in actuarial evaluations. Total liabilities increased \$638.1 million or 18.5% from September 30, 2020 to September 30, 2021. The increase results primarily from pension and OPEB liability growth due to changes in actuarial evaluations.

The change in net position reflects the operating, nonoperating and other activity of UAB, which results from revenues, expenses, and gains and losses, and is summarized for the years ended September 30, 2022, 2021, and 2020, as follows:

	2022	2021	2020
TOTAL OPERATING REVENUES	\$ 4,358,101,318	\$ 4,133,641,841	\$ 3,712,470,836
TOTAL OPERATING EXPENSES	4,672,591,992	4,348,737,086	3,953,876,475
NET OPERATING LOSS	(314,490,674)	(215,095,245)	(241,405,639)
TOTAL NONOPERATING (LOSS) INCOME, CAPITAL, ENDOWMENT AND OTHER ACTIVITIES	(87,063,705)	1,045,051,799	450,349,699
(DECREASE) INCREASE IN NET POSITION	\$ (401,554,379)	\$ 829,956,554	\$ 208,944,060

Statements of Net Position

The statement of net position presents the financial position of UAB at the end of the fiscal year, and includes all assets, deferred outflows, liabilities, and deferred inflows recorded on the accrual basis of accounting. The changes in net position are indicators of whether the overall financial condition of UAB has improved or worsened during the year. A summarized comparison of UAB's assets, deferred outflows, liabilities, deferred inflows, and net position at September 30, 2022, 2021, and 2020, is as follows:

	2022	2021	2020
ASSETS AND DEFERRED OUTFLOWS OF RESOURCES			
Current assets	\$ 2,588,374,852	\$ 2,856,565,711	\$ 2,502,144,919
Capital assets, net	1,918,644,336	1,896,543,024	1,784,230,411
Other assets	1,888,302,417	2,137,550,819	1,645,174,783
TOTAL ASSETS	6,395,321,605	6,890,659,554	5,931,550,113
Deferred outflows from debt refundings	15,092,272	12,081,090	13,336,713
Deferred outflows pension and OPEB related	716,467,779	850,533,926	305,494,017
TOTAL DEFERRED OUTFLOWS OF RESOURCES	731,560,051	862,615,016	318,830,730
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 7,126,881,656	\$ 7,753,274,570	\$ 6,250,380,843
LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION			
Current liabilities	634,403,041	802,155,961	800,205,475
Noncurrent liabilities	2,900,237,877	3,277,031,877	2,640,898,752
TOTAL LIABILITIES	3,534,640,918	4,079,187,838	3,441,104,227
Deferred inflows from leases	29,984,253	31,345,123	—
Deferred inflows pension and OPEB related	846,514,810	525,445,555	521,937,116
TOTAL DEFERRED INFLOWS OF RESOURCES	876,499,063	556,790,678	521,937,116
Net position	2,715,741,675	3,117,296,054	2,287,339,500
TOTAL LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION	\$ 7,126,881,656	\$ 7,753,274,570	\$ 6,250,380,843

The major categories of current assets consist of cash and cash equivalents, short-term investments, and accounts receivable and are used to support UAB's normal operations. At September 30, 2022, the major categories totaled \$2.43 billion of the \$2.59 billion. Total current assets decreased \$268.2 million or 9.4% from 2021. This decrease resulted from a decline in unrealized gains due to poor investment performance during the middle and later part of 2022. The decrease was offset by a increase in net receivables from sponsoring agencies. At September 30, 2021, the major categories totaled \$2.71 billion of the \$2.86 billion and increased \$354.4 million or 14.2% from 2020. This increase resulted from the contributions made to the Liquidity and Capital Reserve Pool ("LCRP") throughout the year, reinvesting gains during a period of poor market performance at the start of the year, followed by growth in unrealized gains due to improved investment performance during the middle and later part of 2021. The increase was offset by a decrease in both cash and cash equivalents and net receivables.

Deferred outflows represent the consumption of net assets attributable to a future period and consists of bond deferred refunding amounts (Note 7), pension obligations (Note 9), and other post-employment benefits ("OPEB") obligations (Note 10). At September 30, 2022, deferred outflows from debt refundings increased \$3.0 million to \$15.1 million due to new debt issuances during the year. Deferred outflows related to the pension obligations decreased \$30.1 million to \$270.3 million. The decrease in deferred outflows related to the pension obligations is a result of a decrease in net difference between projected and actual earnings on pension plan investments offset by an increase in changes in assumptions. Deferred outflows related to the OPEB obligations decreased \$104.0 million to \$446.2 million. The decrease in the deferred outflows related to the OPEB obligations is a result of a decrease in actuarial assumptions and changes in proportion and differences between employer contributions and proportionate share of contributions. At September 30, 2021, deferred outflows from refundings decreased \$1.3 million to 12.1 million due to the annual amortization of the refundings. Deferred outflows related to the pension obligations increased \$101.7 million to \$300.3 million in deferred outflows related to the pension obligations is a result of an increase in net difference between projected and actual earnings on pension plan investments and difference between expected and actual experience offset by a decrease in changes in actuarial assumptions. Deferred outflows related to the OPEB obligations increased \$443.3 million to \$550.2 million is a result of an increase in changes in actuarial assumptions and an increase in proportion and differences between employer contributions and proportionate share of contributions.

Current liabilities consist primarily of accounts payable, accrued payroll and related benefits, unearned revenue, and current portion of long-term debt. At September 30, 2022, current liabilities decreased \$167.8 million to \$634.4 million. The decrease is due to University Hospital's Due to third-party payors and advances payable related to repayment of advance payments received in fiscal year 2020 from the Centers for Medicare and Medicaid Services ("CMS") Accelerated and Advance Payments Program. At September 30, 2021, current liabilities increased \$2.0 million to \$802.2 million. The increase is due to University Hospital's Due to third-party payors and advances payable related to repayment of advance payments received in fiscal year 2020 from the Centers for Medicare and Medicaid Services ("CMS") Accelerated and Advance Payments Program.

Deferred inflows represent the acquisition of net assets attributable to a future period and are associated future lease payments, pension obligations (Note 9) and other post-employment benefits ("OPEB") obligations (Note 10). At September 30, 2022, deferred inflows related to leases decreased \$1.4 million to \$30.0 million. The decrease is due to future lease payments received during the fiscal year. At September 30, 2022, deferred inflows related to the pension obligations increased \$296.9 million to \$356.3 million. The increase in deferred inflows related to the pension obligations is the result of an increase change in net difference between projected and actual earnings on pension plan investments offset by a decrease in changes in assumptions. Deferred inflows related to the OPEB obligations increased \$24.1 million to \$490.3 million. The increase in deferred inflows related to the OPEB obligations is a result an increase in changes of assumptions offset by a decrease in differences between expected and actual experiences. At September 30, 2021 deferred inflows related to the pension obligations decreased \$30.9 million to \$59.3 million. The decrease in deferred inflows related to the pension obligations is the result of a decrease in differences between expected and actual experience, changes in proportion, and differences between employer contributions and proportionate share of total contributions. Deferred inflows related to the OPEB obligations increased \$34.4 million to \$466.1 million. The increase in deferred inflows related to the OPEB obligations is a result of an increase in differences between expected and actual experiences, a change in proportion, and differences between employer contributions and proportionate share of total contributions.

Endowment, Life Income and Other Investments

The composition of UAB's endowment, life income and other investments at September 30, 2022, 2021, and 2020, is summarized as follows:


	2022	2021	2020
Endowment and Life income investments	\$ 673,323,752	\$ 711,622,472	\$ 539,974,716
Investment in Professional Liability Trust Fund	40,809,631	69,880,913	59,920,845
Other long-term investments	142,971,739	117,568,898	107,735,412
TOTAL ENDOWMENT, LIFE INCOME AND OTHER INVESTMENTS	\$ 857,105,122	\$ 899,072,283	\$ 707,630,973

UAB's endowment funds are invested in an investment pool established by the Board. UAB's endowment funds held within the investment pool consists of both permanent and quasi-endowments. Permanent endowment funds are those funds received from donors with the requirement that the principal remain unspent and invested in perpetuity to produce income to be expended for the purposes specified by the donor. Quasi-endowments consist of restricted or unrestricted funds that have been set aside by actions of the Board to produce income for an established purpose or until the time the Board reverses its action. Endowment income supports scholarships, fellowships, professorships, research efforts, and other programs and activities of UAB.

UAB uses its endowment funds to support operations in a way that strikes a balance between generating a predictable stream of annual support for current needs and preserving the purchasing power of the endowment funds for future periods. UAB held 2,028, 1,884, and 1,790 individual endowment funds within the pool at September 30, 2022, 2021, and 2020, respectively, the majority of which are restricted for specific purposes. UAB made contributions to the endowment funds totaling \$62.8, \$22.7, and \$20.0 million for the years ended September 30, 2022, 2021, and 2020, respectively.

The Board-approved spending rule provides for distributions from the pool to UAB. The annual distribution rate is 4.5 percent and is based on a moving five-year average of the market (unit) value. This spending rule is one element of an ongoing financial management strategy that has allowed UAB to effectively weather the uncertainties of challenging economic environments. Endowment spending rate distributions totaled \$27.4, \$26.0, and \$24.9 million for the years ended September 30, 2022, 2021, and 2020, respectively.

**Endowment Cost and Market Value
Fiscal Years Ending September 30**



UAB's endowment and life income investments decreased \$38.3 million to \$673.3 million from September 30, 2021 to September 30, 2022. This decrease resulted from a weak investment performance offset by establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments throughout the year. UAB's endowment and life income investments increased \$171.6 million to \$711.6 million from September 30, 2020 to

September 30, 2021. This increase resulted from the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments throughout the year, reinvesting of underwater endowment gains during a period of poor market performance at the start of the year, followed by growth in unrealized gains due to improved investment performance during the middle and later part of 2021.

University Hospital participates in The University of Alabama Professional Liability Trust Fund (the "PLTF"). The PLTF uses contributions from University Hospital and other contributing entities, together with the earnings thereon, to pay liabilities arising from performance of certain professional services by employees of these entities. University Hospital reports its share of the net position of the PLTF as a joint venture investment using the equity method in the accompanying statements of net position. At September 30, 2022, 2021, and 2020, University Hospital's investment in the PLTF totaled approximately \$40.8, \$69.9, and \$59.9 million, respectively.

At September 30, 2022, 2021, and 2020, UAB's other investments totaled \$143.0, \$117.6, and \$107.7 million, respectively. Other investments primarily consisted of investments held by UAB's blended component unit Triton Health Systems, L.L.C. ("Triton"), which totaled \$142.4, \$117.0, and \$107.2 million, respectively.

Capital and Debt Activities

An aspect of UAB's continued growth is an emphasis on the expansion and maintenance of capital assets. UAB continues to implement its long-range capital plan to modernize its existing infrastructure and strategically invest in new construction. Capital assets primarily include land, buildings, fixed equipment systems, and inventoried equipment.

Construction in progress additions totaled \$84.0 million and \$32.9 million at September 30, 2022 and 2021, respectively. Capital projects in process at September 30, 2022 include Altec/Styslinger Genomic Medicine & Data Sciences and Science and Engineering Building. Capital projects in process at September 30, 2021 include Altec/Styslinger Genomic Medicine & Data Sciences, Central Utilities, McCallum Building renovations, and the Science and Engineering Building.

Capital asset additions totaled \$153.3 million in 2022 as compared to \$208.5 million in 2021. Capital asset additions primarily represent renovation and new construction of academic, research, clinical and athletic facilities, as well as significant investments in equipment, including information technology. Current year capital asset additions were funded with debt proceeds designated for capital purchases of \$166.0 million and \$35.2 million, and capital funds, grants, gifts totaling \$39.2 million and \$5.3 million, in 2022 and 2021, respectively.

During fiscal year 2022, S&P Global, formerly known as Standard & Poor's Ratings Services, raised its rating on UAB's general revenue bonds from AA to AA+ with a stable outlook. Long-term debt activity for the years ended September 30, 2022 and September 30, 2021 is summarized as follows:

2022

	<u>Beginning Balance</u>	<u>Additions</u>	<u>Repayments</u>	<u>Ending Balance</u>
Direct borrowing and direct placement	204,410,664	99,757,259	22,273,231	281,894,692
General receipt bonds	962,481,000	231,245,000	178,742,000	1,014,984,000
	<u>\$ 1,166,891,664</u>	<u>\$ 331,002,259</u>	<u>\$ 201,015,231</u>	<u>\$ 1,296,878,692</u>

2021

	<u>Beginning Balance</u>	<u>Additions</u>	<u>Repayments</u>	<u>Ending Balance</u>
Direct borrowing and direct placement	164,033,008	60,349,379	19,971,723	204,410,664
General receipt bonds	998,471,000	—	35,990,000	962,481,000
	<u>\$ 1,162,504,008</u>	<u>\$ 60,349,379</u>	<u>\$ 55,961,723</u>	<u>\$ 1,166,891,664</u>

UAB's long-term debt consists of leases, a note payable, and general revenue bonds. Long-term debt increased \$130.0 million to \$1.30 billion from September 30, 2021 to September 30, 2022. The increase in debt is due to the issuances of Series 2022 bonds during the year (Note 7). Long-term debt increased \$4.4 million to \$1.17 billion from September 30, 2020 to September 30, 2021. The increase in debt is the result of entering into new leases of \$42.7 million, offset by principal payments made in accordance with the debt instruments.

During 2022, the University issued \$311.5 million of general revenue bonds with a net original issue premium of \$12.0 million. Total bond proceeds of \$323.5 million were utilized to finance the cost of certain capital improvements to the

facilities of UAB and refund existing Series 2010A, Series 2010C, Series 2013A2, and Series 2013D2 bonds, totaling \$6.2 million, \$3.8 million, \$58.4 million and \$75.9 million, respectively. The University deposited the funds received in an escrow trust for the purpose of making subsequent payment of principal and interest on the defeased indebtedness. Under the trust agreements, funds deposited in the trust accounts were invested in obligations of the U.S. Government. The University estimates that the amounts on deposit will be sufficient to satisfy the debt service requirements on the defeased indebtedness and that the defeasance will result in lower overall debt service payments. The University remains legally obligated for the repayment of the defeased indebtedness. Neither the assets of the trust accounts nor the defeased indebtedness are included in the accompanying statements of net position. The principal outstanding on defeased indebtedness at September 30, 2022 is approximately \$139.2 million.

Effective interest rates on the University general revenue bonds averaged 2.83% percent and 3.18% percent in 2022 and 2021, respectively. Interest expense on general revenue bonds totaled \$44.7 million and \$37.6 million in 2022 and 2021, respectively.

Obligations For Pension and Post-employment Benefits

GASB Statements No. 68 and 75 require governmental employers participating in multi-employer cost-sharing pension and healthcare benefit plans to recognize liabilities for their proportionate share of the unfunded liability for plans whose actuarial liabilities exceed the plan's net assets. As required by Alabama statute, all eligible employees of a qualifying public educational employer must be a member of the Teacher's Retirement System of Alabama ("TRS"). As a qualifying employer, UAB is required to make certain employer contributions on behalf of its employees participating in TRS's defined benefit pension plan (the "Plan"). Additionally, Alabama statutes permitted UAB to opt-in to provide its eligible retirees with healthcare benefits through the Public Education Employees' Health Insurance Plan ("PEEHIP").

The employer contribution rates for both plans are established annually by TRS and PEEHIP, and adopted by the Alabama Legislature. Both the TRS employer contribution rate and the employer's PEEHIP cost for retiree coverage are based upon the actuarial valuations performed by TRS and PEEHIP, respectively. Although the liabilities recognized under GASB 68 and 75 meet GASB's definition of a liability within GASB's framework for accounting standards, UAB does not believe that the associated recorded liabilities associated with the TRS and PEEHIP constitute legal liability for UAB, nor do they open UAB to other claims on its resources.

Using current actuarial assumptions, and presuming a continuation of the current level of benefits, UAB's obligations for pension benefits as prescribed by GASB 68 totaled \$1.05 billion at September 30, 2022, as compared to \$1.41 billion and \$1.25 billion at September 30, 2021 and 2020, respectively. The decrease in the reported liability at September 30, 2022 was driven by a decrease in the UAB's proportionate share of the collective net pension liability. The increase in the reported liability at September 30, 2021 was driven by an increase in UAB's proportionate share of a larger collective net pension liability compared to September 30, 2020.

Using current actuarial assumptions, and presuming a continuation of the current level of benefits, UAB's obligations for postemployment benefits through PEEHIP as prescribed by GASB 75 totaled \$546.6 million at September 30, 2022, as compared to \$680.4 million and \$265.2 million at September 30, 2021 and 2020, respectively. The decrease in the reported liability at September 30, 2022 was driven primarily by a increase in the discount rate and an decrease in UAB's proportionate share of the collective net OPEB liability. The increase in the reported liability at September 30, 2021 was driven primarily by a decrease in the discount rate and an increase in UAB's proportionate share of the collective net OPEB liability.

UAB also administers a single-employer plan which offers its members hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit. The health care benefits cover medical and hospitalization costs for retirees and their dependents. UAB retired employees make contributions to the plan by making premium payments associated with their selected health plan option. Eligible disabled retirees are responsible for only the employee portion of those premiums and UAB is responsible for the employer portion. All other UAB retirees are responsible for the full premium cost of the plan and in no case does the employer contribute to the plan.

Using current actuarial assumptions, and presuming a continuation of the current level of benefits, UAB's obligations for postemployment benefits through UAB plan totaled \$7.2 million at September 30, 2022, as compared to \$5.3 million and \$6.3 million at September 30, 2021 and 2020, respectively. The increase in the reported liability at September 30, 2022 was driven primarily by changes of assumptions. The decrease in the reported liability at September 30, 2021 was driven primarily by differences between expected and actual experience, changes in actuarial assumptions and benefit payments.

Net Position

Net position represents the residual interest in UAB's assets and deferred outflows after liabilities and deferred inflows are deducted. The UAB's net position decreased \$401.6 million during fiscal year 2022, reaching \$2.72 billion. This decrease reflects the UAB's current year's operations including increased net patient revenue, grants and contracts revenue, and net auxiliary revenue offset by increased in operating expenses and weaker investment performance. During fiscal year 2021 net position increased \$830.0 million, totaling \$3.12 billion, which reflects UAB's operations including an increase in net patient revenue, nonoperating grants and contracts revenue and investment income. UAB's net position at September 30, 2022, 2021, and 2020, is summarized as follows:

	2022	2021	2020
NET INVESTMENT IN CAPITAL ASSETS	\$ 785,417,963	\$ 786,585,310	\$ 769,281,767
RESTRICTED			
Nonexpendable	435,778,701	390,793,182	405,615,948
Expendable	466,127,882	600,618,098	353,055,159
UNRESTRICTED	1,028,417,129	1,339,299,464	759,386,626
TOTAL NET POSITION	\$ 2,715,741,675	\$ 3,117,296,054	\$ 2,287,339,500

Net position invested in capital assets represent UAB's capital assets, net of accumulated depreciation and outstanding principal of debt in excess of related bond proceeds attributable to the acquisition, construction, or improvement of those assets. The \$1.2 million decrease in 2022 reflects an increase in total debt related to the Series 2022 bond issuance during the year offset by growth in capital assets net of annual depreciation expense. The \$17.3 million increase in 2021, reflects the growth in capital assets net of annual depreciation expense, along with the decrease in total debt related to the annual principal payments.

Restricted nonexpendable net position includes UAB's permanent endowment funds, annuity and life income assets that will ultimately become pure endowment funds. The changes relate primarily to contributions made during the fiscal year.

Restricted expendable net position is subject to externally imposed restrictions governing its use. Restricted expendable net position includes UAB's assets whose use is restricted by an external restriction. The \$134.5 million decrease in 2022 is the result of the decline in investment market value offset by an increase in new gifts during the year. The \$247.6 million increase in 2021 is the result of the growth in investment market value and an increase in new gifts during the year.

Unrestricted net position includes UAB's assets whose use is not restricted by an external entity. Although unrestricted net position is not subject to externally imposed restrictions, UAB has designated available unrestricted net position to be used for academic and research programs as well as capital projects. Unrestricted net position decreased by \$310.9 million in 2022, primarily due to an increase in operating expenses coupled with a decrease in investment income. Unrestricted net position increased by \$579.9 million in 2021, primarily due to an increase in net patient revenues.

Statements of Revenues, Expenses, and Changes in Net Position

The statement of revenues, expenses, and changes in net position ("SRECNP") presents UAB's results of operations, as well as the nonoperating revenues and expenses. Primary components of UAB's operating revenue sources are tuition and fees, grants and contracts, and sales and services. Sales and services revenues is comprised of revenues from University Hospital operations (Hospital sales and services), revenues generated from both self-supporting departments (including intercollegiate Athletics, residence halls, food service operations) and Triton Health Systems, L.L.C. revenues (a blended component unit) (Auxiliary sales and services). Other significant revenue sources, which are considered nonoperating as defined by the GASB, include State educational appropriations, private gifts, and investment income.

Operating expenses are those incurred in conjunction with the fulfillment of the UAB's mission and include salaries, wages and benefits; supplies and services; depreciation; and scholarships and fellowships. The SRECNP also includes other changes affecting its net position including capital gifts and grants, additions to permanent endowments, and intragovernmental transfers between the University, University Hospital, and UAB Athletics Foundation. During fiscal year 2022, intragovernmental transfers to related governmental entities totaled \$48.6 million.


Annual state appropriations are classified as nonoperating revenues according to governmental accounting standards, even though the state-appropriated funds are used to support the operations of UAB. Without the nonoperating revenues, in particular the state appropriations and private gifts, UAB would not be able to cover its costs of operations.

A summarized comparison of UAB's revenues, expenses and changes in net position for the years ended September 30, 2022, 2021, and 2020 is presented below:


	2022	2021	2020
OPERATING REVENUES			
Student tuition and fees, net	\$ 238,778,078	\$ 243,476,387	\$ 244,929,737
Grants and contracts	572,438,335	526,727,011	483,921,582
Sales and services	3,519,577,463	3,322,823,875	2,931,632,967
Other revenues	27,307,442	40,614,568	51,986,550
TOTAL OPERATING REVENUES	4,358,101,318	4,133,641,841	3,712,470,836
OPERATING EXPENSES			
Operating expenses	4,672,591,992	4,348,737,086	3,953,876,475
OPERATING LOSS	(314,490,674)	(215,095,245)	(241,405,639)
NONOPERATING REVENUES (EXPENSES)			
Economic relief funds	21,209,457	412,719	71,281,070
State educational appropriations	332,448,930	314,953,056	306,964,712
Grants and contracts	61,949,289	105,093,454	57,856,589
Private gifts	37,066,668	61,112,310	18,705,016
Investment income	(521,865,832)	555,919,121	15,735,962
Interest expense	(41,794,231)	(38,235,066)	(40,126,392)
Net other nonoperating revenue	(11,570,614)	7,377,048	322,621
NET NONOPERATING (EXPENSES) REVENUES	(122,556,333)	1,006,632,642	430,739,578
OTHER CHANGES IN NET POSITION	35,492,628	38,419,157	19,610,121
(DECREASE) INCREASE IN NET POSITION	(401,554,379)	829,956,554	208,944,060
Net Position, beginning of year	3,117,296,054	2,287,339,500	2,078,395,440
NET POSITION, END OF YEAR	\$ 2,715,741,675	\$ 3,117,296,054	\$ 2,287,339,500

The following are graphic illustrations of revenues by source, both operating and nonoperating, which are used to fund UAB's operating activities for the years ended September 30, 2022 and September 30, 2021, respectively. Certain recurring sources of the University's revenues are considered nonoperating, as defined by Governmental Accounting Standards Board ("GASB"), such as state appropriations, distributions from investments, private gifts and federal Pell grants.

Revenue Streams 2022



Revenue Streams 2021



Student Tuition and Fees, Net

Tuition and fees funding make up a large portion of the University's academic programs. Factors that impact gross tuition revenue include enrollment growth and changes in rates. Enrollment for the fall semester of the 2021-2022 school year is outlined in the following table.

	Fall 2021			TOTAL
	UNDERGRADUATE	GRADUATE	FIRST PROFESSIONAL/ ADVANCED PROFESSIONAL *	
SCHOOL OF ARTS AND SCIENCES	6,713	651	276	7,640
SCHOOL OF BUSINESS	2,526	995	—	3,521
SCHOOL OF EDUCATION	1,073	609	94	1,776
SCHOOL OF ENGINEERING	857	443	103	1,403
UNCLASSIFIED	—	145	4	149
SUBTOTAL	11,169	2,843	477	14,489
ACADEMIC HEALTH CENTER:				
SCHOOL OF MEDICINE	—	—	1,900	1,900
SCHOOL OF DENTISTRY	13	1	405	419
SCHOOL OF OPTOMETRY	—	1	236	237
SCHOOL OF NURSING	924	1,136	668	2,728
SCHOOL OF HEALTH PROFESSIONS	1,153	940	435	2,528
SCHOOL OF PUBLIC HEALTH	288	587	105	980
JOINT HEALTH SCIENCES	—	52	413	465
SUBTOTAL, ACADEMIC HEALTH CENTER	2,378	2,717	4,162	9,257
TOTAL ENROLLMENT	13,547	5,560	4,639	23,746

* Includes 1,146 first professionals and 1,457 advanced professionals.

In fall 2021 UAB continued its record enrollment trend with 22,289 students, of which 2,415 students were first-time freshman. Underrepresented students make up 45 percent of the enrollment and 53 percent of first-time freshman. Full-time students make up 67 percent of the enrolled students. For the years ended September 30, 2022, 2021, and 2020, net student tuition and fees revenue consisted of the following components:

	2022	2021	2020
Student tuition and fees, gross	\$ 334,484,698	\$ 335,202,452	\$ 330,385,766
Less: scholarship allowances	(95,706,620)	(91,726,065)	(85,456,029)
STUDENT TUITION AND FEES, NET	\$ 238,778,078	\$ 243,476,387	\$ 244,929,737

Tuition rates are reviewed annually by the University and presented to the Board for approval. Based upon the University's annual review of tuition the Board approved the management recommendation to hold all undergraduate/graduate rates for both resident and non-resident students consistent with the prior year for the 2021-2022 academic year. However, rate increases for First Professional programs were proposed and received Board approval in April 2021 as follows: School of Medicine, 1.0% residents only (no increase for non-residents); School of Dentistry, 1.0% for both residents and non-residents; and School of Optometry, 1.0% for residents only (no increase for non-residents). Additionally, the School of Dentistry received board approval to increase first year class size from 63 to 84 beginning in 2021-2022 academic year. Fall 2021 in-state enrollment decreased by 2.7% to 16,574 students and out-of-state enrollment increased by 3.4% to 5,715 students. The decline in in-state enrollment growth was offset by rate increases contributed to the decrease in gross tuition revenue of \$0.7 million. The increase in gross tuition and fees was offset by an increase of 4.3% or \$4.0 million in scholarship allowances. Net tuition and fees revenue decreased \$4.7 million, to \$238.8 million in 2022.

For the 2020-2021 academic year rate increases for First Professional programs were proposed and received Board approval in April 2020 as follows: School of Medicine, 2.5% residents only (no increase for non-residents); School of Dentistry, 3.2% for residents and 3.8% for non-residents; and School of Optometry, 2% for residents only (no increase for non-residents). Fall 2021 in-state enrollment increased by 1.4% to 17,034 students and out-of-state enrollment


increased by 4.7% to 5,529 students. The rate increases and enrollment growth contributed to the increase in gross tuition revenue of \$4.8 million. The increase in gross tuition and fees was offset by an increase of 7.3% or \$6.3 million in scholarship allowances. Net tuition and fees revenue decrease \$1.5 million, to \$243.5 million in 2021.

Grants and contracts revenue

The University receives revenues for sponsored programs from various government agencies and private sources, which normally provide for both direct and indirect costs to perform these sponsored projects, with a significant portion related to federal research.

During fiscal year 2022, UAB recognized \$634.4 million in sponsored grants and contracts revenues. Various federal agencies provided support for these projects, with the National Institutes of Health ("NIH") being the primary sponsor. Non-federal funding sources include state agencies, local governmental agencies, and a wide variety of private sponsors. Operating revenues from grants and contracts increased \$45.7 million in 2022, as compared to an increase of 8.8%, or \$42.8 million, to \$526.7 million in 2021. The increase in 2022 and 2021 was driven primarily by an increase in federally sponsored activity.

**Operating Grants and Contract Revenue
(in millions)**



Figures B and B1 below are illustrations of the breakout of the funding sources for grant and contract revenue for the years ended September 30, 2022 and 2021, respectively. These funds are used to further the mission of UAB: research, education, and public service.

Figure B: Grants and Contract Revenues 2022





Figure B1: Grants and Contract Revenues 2021



Sales and services revenue of hospital activities

University Hospital is a fund of UAB and a part of UAB Health System. For the fiscal year 2022, inpatient discharges decreased 2.7% and adjusted patient discharges increased 1.6%. Operating room cases increased 3.5% over fiscal year 2021. Also emergency room visits increased 5.4% during fiscal year 2022. University Hospital had a decrease in net position of \$272.0 million in fiscal year 2022. For the fiscal year 2021, inpatient discharges increased 8.8% and adjusted patient discharges increased 9.9%. Operating room cases increased 9.1% over fiscal year 2020. Also emergency room visits increased 8.3% during fiscal year 2021. The Hospital had an increase in net position of \$362.5 million in fiscal year 2021. Selected University Hospital operating statistics are outlined below:

	2022	2021	2020
Beds in service	1,172	1,172	1,126
Patient discharges	53,532	55,005	50,579
Adjusted patient discharges	92,004	90,594	82,418
Patient days	416,716	409,203	363,854
Adjusted patient days	716,197	673,966	592,899
Operating room cases	39,289	37,973	34,811
Emergency department visits	135,702	128,718	118,839
Patient origin:			
Jefferson County	46.3%	48.2%	47.2%
Other Alabama counties	47.8%	46.5%	47.2%
Out of state	5.9%	5.3%	5.6%

For the years ended September 30, 2022, 2021, and 2020, University Hospital revenues by source are summarized as follows:

	2022	2021	2020
Net patient service revenue	\$ 2,206,972,965	\$ 2,118,262,314	\$ 1,784,614,324
Other operating revenue	423,866,270	354,539,102	325,219,253
TOTAL UNIVERSITY HOSPITAL OPERATING REVENUE	\$ 2,630,839,235	\$ 2,472,801,416	\$ 2,109,833,577

Patient service revenue, net of allowances for contractual discounts, charity care and bad debt expense, was \$2.2 billion, an increase of \$88.7 million, or 4.2%, over fiscal year 2021. The increase was related to increased volume and contract improvements. The increase from 2020 to 2021 was \$333.6 million, or 18.7%. The increase was related to increased volume and contract improvements.

Other operating revenues primarily consists of pharmacy related sales. The increase in other operating revenues from September 30, 2022 to 2021 was \$69.6 million or 20% compared to \$29.1 million in 2020 or an 8.9% increase. Both 2022 and 2021 had increases related to increases in volumes associated with retail pharmacy.

Sales and services revenue of auxiliary enterprises

Auxiliary enterprise revenue primarily includes revenue from UAB's blended component unit, Triton Health Systems, L.L.C. Refer to Note 2 for additional information on blended component units. Net auxiliary sales and service revenue totaled \$822.2, \$782.4, and \$762.4 million, an increase of 5.1% and 2.6% from 2021 to 2022 and 2020 to 2021, respectively. These increases resulted from Triton's premium revenue growth.

Other sources

Other sources consist of sales and service educational activities and other operating revenues. Net educational sales and service revenue totaled \$66.6, \$67.7, and \$59.4 million, a decrease of 1.6% from 2021 to 2022 and an increase of 14.0% from 2020 to 2021, respectively. The current year decrease is due to miscellaneous external service revenue activity. Other operating revenue totaled \$27.3, \$40.6, and \$52.0 million, a decrease of 32.8% from 2021 to 2022 and a decrease of 21.9% from 2020 to 2021, respectively. The current year decrease is due to a decline in UAB Heersink School of Medicine Academic Enrichment Fund activity revenues.

Nonoperating revenues

Due to the required classification of key revenue sources such as State educational appropriations, financial aid grants, and private gifts as nonoperating revenues, UAB's operating expenses will typically exceed operating revenues, resulting in an operating loss. These nonoperating revenues are essential in offsetting the operating loss. For the years ended September 30, 2022, 2021, and 2020, UAB's nonoperating revenue is summarized as follows:

	<u>2022</u>	<u>2021</u>	<u>2020</u>
Economic relief funds	\$ 21,209,457	\$ 412,719	\$ 71,281,070
State educational appropriation	332,448,930	314,953,056	306,964,712
Grants and contracts	61,949,289	105,093,454	57,856,589
Gifts	37,066,668	61,112,310	18,705,016
Investment income	(521,865,832)	555,919,121	15,735,962
Capital gifts and grants	12,806,674	1,645,260	1,854,223
Endowment gifts	44,941,789	33,163,130	17,755,898
TOTAL UAB NONOPERATING (LOSSES) REVENUES	<u>\$ (11,443,025)</u>	<u>\$ 1,072,299,050</u>	<u>\$ 490,153,470</u>

In response to the impact of COVID-19, the federal government implemented the Coronavirus Aid, Relief and Economic Security ("CARES") Act. The CARES Act was signed into law in March 2020 in order to provide economic assistance for organizations and individuals that have been negatively impacted by the COVID-19 pandemic. During 2020, University Hospital received CARES Act payments primarily from the Provider Relief Fund. The Provider Relief Fund is administered through the U.S. Department of Health and Human Services and offers funding to hospitals and health care providers to offset expenses incurred or revenues lost associated due to the COVID-19 pandemic. Economic Relief Funds received and recognized by University Hospital totaled \$21.2 million and \$413 thousand in federal CARES Act provider relief funding through September 30, 2022 and 2021, respectively.

State Appropriations for UAB are made by the Alabama State Legislature based upon a process which involves requests from the Board of Trustees of The University of Alabama, and budget recommendations by the Alabama Commission on Higher Education and the Governor. State funds are appropriated annually from the Educational Trust Fund ("ETF") to UAB. In 2022, State educational appropriations from the ETF increased \$22.5 million from the prior year, reaching a total of \$328.3 million. In 2021, State educational appropriations from the ETF increased \$8.2 million over 2020 for a total received of \$305.9 million. State educational appropriations also include supplemental appropriations received from the Mental Health Trust Fund and Advancement and Technology Fund. In 2022, UAB received appropriations from Mental Health Trust Fund which totaled \$4.4 million. In 2021, UAB received appropriations from the Mental Health Trust Fund and Advancement and Technology Fund which totaled \$9.1 million. UAB also received Public School and College Authority funds and other state capital funds in 2022 and 2021 totaling \$26.4 million and \$3.6 million, respectively.

Nonoperating grants historically consist primarily of Federal Pell grant awards. This program provides financial assistance grants to qualifying undergraduate students to promote access to post-secondary education. During fiscal years 2022, 2021 and 2020, the University received COVID-19 emergency grant funding, primarily through Higher Education Emergency Relief Funds ("HEERF") I, II, and III, and the Coronavirus Relief Fund ("CRF"). Total HEERF funds of \$58.4 million and \$12.7 million were awarded in fiscal years 2021 and 2020, respectively, to be distributed as emergency financial aid grants directly to students, as well as to provide funding for areas of the University negatively impacted by the COVID-19 pandemic. CRF funds of \$49.6 million were received during fiscal 2020 to offset necessary expenses incurred due to the public health emergency with respect to COVID-19. These amounts were recorded in nonoperating grants revenue. As a result, nonoperating grant revenue increased to \$105.1 million from \$57.9 million in 2021, and then declined to \$61.9 million in 2022. UAB did not receive any additional HEERF in 2022 and did not receive any CRF funding during fiscal year 2022 and 2021. Further information on COVID-19 emergency grant funding can be found in note 1.

The University Hospital recognized \$172.4 thousand as nonoperating revenue from CARES funds allocated from the State of Alabama in 2021 and recognized no such revenue in 2022. Alabama State Cares funds were required to be expended by December 30, 2020 and used to cover expenses necessary to prevent, prepare for, and respond to COVID-19.

In addition, University Hospital received \$180.2 million during 2020 in advance payments from the Centers for Medicare and Medicaid Services (CMS) Accelerated and Advance Payments Program reported as due to third party payors and advances payable, net on the Statements of Net Position. The Medicare advance payment amount was classified as a current liability in 2020 based on guidance that existed as of September 30, 2020; however, guidance issued subsequent to September 30, 2020 provided for the advance payments to be repaid over a period extending beyond twelve months after the September 30, 2020 balance sheet date. Based on current guidance, however, the remaining Medicare advance payments are required to be paid by September 30, 2022 and were recorded as a current liability as of September 30, 2021. As of September 30, 2022, there are no funds outstanding to CMS.

Gift revenue consists of gifts, pledges, endowment gifts and capital gifts. UAB's gift revenue totaled \$94.8 million at September 30, 2022, which was a decrease of \$1.1 million from the prior year. The change in gift revenue is due to a decline in new pledges offset by an increase in endowment gifts during 2022. In 2021 UAB gift revenues increased \$57.6 million to \$95.9 million. The change in gift revenue is primarily due to the generous Heersink naming pledge made to the UAB School of Medicine in 2021.

Both investment and endowment income are combined as investment income on the SRECNP. Net investment income decreased \$1.08 billion from 2021 to 2022 and increased \$540.2 million from 2020 to 2021. The decrease in 2022 was largely the result of poor performance of the investments held in the UA Investment Pools, which eroded the fair value of investments at September 30, 2022. The increase in 2021 was the result of a much improved performance of the investments held in the UA Investment Pools, which strengthened the fair value of the investments at September 30, 2021.


Operating Expenses

A comparative summary of UAB's operating expenses by natural classification for the years ended September 30, 2022, 2021, and 2020, is as follows:

	2022	2021	2020
Salaries, wages, and benefits	\$ 2,028,850,498	\$ 1,963,628,897	\$ 1,766,044,825
Supplies and services	2,430,596,642	2,154,297,244	2,001,552,207
Depreciation	180,030,404	175,757,850	150,994,130
Scholarships and fellowships	33,114,448	55,053,095	35,285,313
TOTAL OPERATING EXPENSES	\$ 4,672,591,992	\$ 4,348,737,086	\$ 3,953,876,475

Graphic illustrations of UAB's operating expenses by natural classification for the year ended September 30, 2022 is presented as below:

2022 Operating Expenses by Natural Classification



UAB is one of the largest employers in the state with a total workforce of 24,259, 23,609, and 23,791 in 2022, 2021, and 2020, respectively. The workforce consisted of 17,723 full-time and 6,536 part-time employees, of which underrepresented employees making up approximately 42% in 2022. UAB employed 2,561 faculty of which 908 or 35% were tenured in 2022. UAB's salaries, wages, and benefits totaled \$2.03 billion, \$1.96 billion, \$1.77 billion and makes up 43.4%, 45.2%, and 44.7% of total operating expenses in 2022, 2021, and 2020, respectively. Salaries, wages, and benefits increased \$65.2 million or 3.3% to \$2.03 billion during 2022. Salaries, wages, and benefits increased

\$197.6 million or 11.2% to \$1.96 billion and \$17.0 million or 1.0% to \$1.77 billion during 2021 and 2020, respectively. The increases in both years are primarily due to the growth of UAB's salary base and rising benefit costs related to growth in salary base.

Supplies and services totaled \$2.43 billion, \$2.15 billion, and \$2.00 billion and makes up the largest portion of total operating expenses at 52.0%, 49.5%, and 50.6% in 2022, 2021, and 2020, respectively. During 2022, Supplies and services increased \$276.3 million to \$2.43 billion due to increases in patient volume and inflationary increases in supplies and service costs and an 3% increase in Triton's medical and hospital expenses per member. Supplies and services increased \$152.7 million or 7.6% to \$2.15 billion during 2021. This increase is due to increases in patient volume and inflationary increases in supplies and service costs and an 6% increase in Triton's medical and hospital expenses per member. Supplies and services increased \$155.3 million or 8.4% to \$2.00 billion during 2020. This increase is due to costs incurred to prevent, prepare for, and respond to the COVID-19 pandemic and inflationary increases in supplies and service costs.

Depreciation expense increased 2.4%, or \$4.3 million to \$180.0 million in 2022, as compared to an increase of 16.4%, or \$24.8 million, to \$175.8 million in 2021. This increase is due to the 4% or \$168.6 million growth in total assets in 2022. Capital assets placed in service during 2022 included phase two of the McCallum Building renovation and Physical Education Building renovation.


Scholarships and fellowships expense is reported net of scholarship allowances. The net expenses of \$33.1, \$55.1, and \$35.3 million for fiscal years 2022, 2021, and 2020, respectively, represent payments made directly to students after awards have been applied against tuition and fees and auxiliary housing charged to student accounts. Gross scholarship expenses, including allowances, totaled \$128.8, \$146.8, and \$120.7 million for the years ended September 30, 2022, 2021, and 2020, respectively. During fiscal year 2020 the University received CARES Act - HEERF funding to assist students negatively impacted by the COVID-19 pandemic. Student aid of \$23.9 million and \$6.1 million is included in scholarships and fellowships expense at September 30, 2021 and 2020, respectively.

In addition to natural classifications, operating expenses are reported by functional classifications as defined by the National Association of College and University Business Officers ("NACUBO"). It is informative to review operating expenses by functional classification. The functional classification of an operating expense (Instruction, Research, etc.) is assigned to a department based on the nature of the activity, which represents the material portion of the activity attributable to the department. This method reflects amounts expended in areas such as instruction, research, and operations and maintenance and is used most commonly for comparative reporting purposes among colleges and universities. The University's expenses by functional classification for the years ended September 30, 2022, 2021, and 2020, are summarized as follows:

	2022	2021	2020
Instruction	\$ 288,100,234	\$ 293,021,318	\$ 283,997,293
Research	335,222,646	338,353,105	294,178,648
Public service	191,887,121	182,472,393	167,182,949
Academic support	200,374,298	169,903,914	172,297,940
Student services	36,608,750	39,587,573	38,807,497
Institutional support	222,577,683	220,839,390	218,209,882
Operations and maintenance of plant	85,082,008	73,252,765	68,708,171
Scholarships and fellowships	33,114,448	55,053,095	35,285,313
University Hospital	2,315,809,037	2,060,650,890	1,800,120,115
Auxiliary	783,785,363	739,844,793	724,094,537
Depreciation	180,030,404	175,757,850	150,994,130
TOTAL OPERATING EXPENSES	<u>\$ 4,672,591,992</u>	<u>\$ 4,348,737,086</u>	<u>\$ 3,953,876,475</u>

Graphic illustrations of UAB's operating expenses by functional classification for the year ending September 30, 2022 is presented as follows:

2022 Operating Expenses by Functional Classification



The instruction category includes expenses for all activities that are part of UAB's instruction programs. Instruction expenses decreased \$4.9 million in 2022, and increased \$9.0 million in 2021. The research category includes all expenses for activities specifically organized to produce research, whether commissioned by an agency external to UAB or separately budgeted by an organizational unit within UAB. Research expenses decreased \$3.1 million in 2022, and increased \$44.2 million in 2021. The institutional support category includes expenses for central, executive-level activities concerned with management of UAB. Institutional expenses increased \$1.7 million in 2022, and increased \$2.6 million in 2021. University Hospital expenses increased 12.4%, or \$255.2 million, in 2022, and increased 14.5%, or \$260.5 million, in 2021, and reflect the impact of additional patient activity and capacity expansion. Increased compensation expense related to patient care includes annual salary adjustment and growth in staff levels. Increased medical supplies expense results from annual inflationary increases in supplied and services costs. The auxiliary enterprise category includes all expenses relating to the operation of auxiliary enterprises, and increased 5.9% or \$43.9 million in 2022, and increased 2.2% or \$15.8 million in 2021.

Economic Factors That Will Affect The Future

As a labor-intensive organization, UAB faces competitive pressures related to attracting and retaining faculty and staff.

The State of Alabama appropriates money each year to UAB for operating costs and nonoperating cash requirements, including capital expenditures. Because the State is mandated by its Constitution to operate with a balanced budget, the State occasionally has reduced its appropriations, through a process known as “proration,” when its annual revenues are not expected to meet budgeted appropriations. As the State could potentially implement proration in future years, UAB continues to implement cost-saving measures in order to minimize the impact of any future proration.

Private gifts are an important part of the fundamental support of UAB. Economic pressures affecting donors may also affect the future level of support UAB receives from corporate and individual giving. In 2021 the University received the single largest philanthropic commitment in university history from longtime UAB supporter Marnix E. Heersink, M.D. As a result, the school of medicine is now known as the UAB Marnix E. Heersink School of Medicine. In addition, UAB established the Marnix E. Heersink Institute of Biomedical Innovation and the Mary Heersink Institute for Global Health. The gift and related matching gifts provide support with both endowed and outright funds for key initiatives of the UAB Marnix E. Heersink School of Medicine.

During fiscal year 2022, 66.2% of UAB students received financial aid, including \$183.7 million of Federal Financial Aid. In recent years, financial aid reform and reauthorization of existing aid programs have been topics in legislative sessions. Management is monitoring proposed future legislation in order to respond in a manner to assist current and future students.

The University Hospital faces significant challenges in a dynamic healthcare sector and volatile economic environment. The demand for health care services and the cost of providing them are increasing significantly while the revenues to support these services are diminishing. In addition to cost increases such as rising salary and benefit costs, the University Hospital also faces additional costs associated with new technologies, the education and training of health care professionals and provision of care for a disproportionate share of the medically underserved in Alabama. In recent years, federal legislation has been enacted to slow future rate increases in Medicare and Medicaid and reduce medical education and disproportionate share funding. Management is committed to staying abreast of pertinent issues; implementing appropriate management actions and continuing to provide quality care for all patients.

In January 2020, the World Health Organization declared the novel Coronavirus (“COVID-19”) a Public Health Emergency of International Concern. The outbreak of COVID-19 caused domestic and global disruption in operations for institutions of higher education and healthcare organizations and impacted several areas of UAB and the University Hospital's financial statements as further discussed within Note 1.

These financial statements are prepared to provide a general overview of the University of Alabama at Birmingham and to demonstrate UAB's accountability. Questions concerning any information provided in this report or requests for additional information should be addressed to Office of the Senior Vice President for Finance and Administration, The University of Alabama at Birmingham, AB 1030, 1720 2ND AVE S, BIRMINGHAM AL 35294-0106.

The University of Alabama at Birmingham
Statements of Net Position
September 30, 2022 and 2021

	2022	2021
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 365,792,264	\$ 473,086,415
Short term investments	1,417,861,440	1,626,016,694
Accounts receivable, net	643,058,051	610,753,961
Loans receivable, current portion	1,624,939	1,824,938
Pledges receivable, current portion	9,587,255	8,610,396
Inventories	43,796,437	41,477,751
Prepaid expenses and unearned scholarships	93,153,155	81,226,121
Other current assets	13,501,311	13,569,435
Total current assets	2,588,374,852	2,856,565,711
Noncurrent Assets:		
Cash designated for capital activities	165,975,422	35,225,414
Restricted cash and cash equivalents	374,185	12,304,675
Investments for capital activities	746,525,202	1,079,385,621
Endowment and life income investments	673,323,752	711,622,472
Investment in Professional Liability Trust Fund	40,809,631	69,880,913
Other long-term investments	142,971,739	117,568,898
Loans receivable, net	7,076,686	8,555,102
Pledges receivable	43,311,474	34,104,960
Due from affiliates	52,206,128	52,206,128
Capital assets, net	1,918,644,336	1,896,543,024
Other noncurrent assets	15,728,198	16,696,636
Total noncurrent assets	3,806,946,753	4,034,093,843
Total Assets	6,395,321,605	6,890,659,554
DEFERRED OUTFLOWS OF RESOURCES		
Bond deferred refundings	15,092,272	12,081,090
Pension and OPEB related obligations	716,467,779	850,533,926
Total Deferred Outflows of Resources	731,560,051	862,615,016
Total Assets and Deferred Outflows of Resources	\$ 7,126,881,656	\$ 7,753,274,570

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Net Position (continued)
September 30, 2022 and 2021

	2022	2021
LIABILITIES		
Current Liabilities:		
Accounts payable and accrued liabilities	\$ 387,972,177	\$ 565,957,332
Deposits	19,553,960	17,439,588
Unearned revenue-grants	64,992,790	57,039,007
Unearned revenue-other	105,216,826	107,134,621
Long-term debt, current portion	56,667,288	54,585,413
Total current liabilities	634,403,041	802,155,961
Noncurrent Liabilities:		
Federal advances-loan funds	4,743,839	6,780,063
Long-term debt, noncurrent portion	1,292,453,575	1,157,183,123
Pension liability	1,048,949,000	1,413,306,000
OPEB liability	553,774,052	685,712,303
Other noncurrent liabilities	317,411	14,050,388
Total noncurrent liabilities	2,900,237,877	3,277,031,877
Total Liabilities	3,534,640,918	4,079,187,838
DEFERRED INFLOWS OF RESOURCES		
Leases	29,984,253	31,345,123
Pension and OPEB related obligations	846,514,810	525,445,555
Total Deferred Inflows Of Resources	876,499,063	556,790,678
NET POSITION		
Net investment in capital assets	785,417,963	786,585,310
Restricted		
Nonexpendable	435,778,701	390,793,182
Expendable	466,127,882	600,618,098
Unrestricted	1,028,417,129	1,339,299,464
Total Net Position	2,715,741,675	3,117,296,054
Total Liabilities, Deferred Inflows and Net Position	\$ 7,126,881,656	\$ 7,753,274,570

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Revenues, Expenses, and Changes in Net Position
Years Ended September 30, 2022 and 2021

	<u>2022</u>	<u>2021</u>
Operating Revenues		
Tuition and fees	\$ 334,484,698	\$ 335,202,452
Less: scholarship allowance	(95,706,620)	(91,726,065)
Tuition and fees, net	238,778,078	243,476,387
Grants and contracts:		
Federal	465,169,073	431,152,917
State	12,555,524	10,601,841
Local	2,610,062	2,733,401
Private	92,103,676	82,238,852
Sales and services:		
Educational activities	66,563,264	67,666,602
University Hospital, net of bad debt expense of \$204.9 million in 2022 and \$248.6 million in 2021	2,630,839,235	2,472,801,416
Other auxiliary enterprises, net of scholarship allowance of \$3.3 million in 2022 and \$1.8 million in 2021	822,174,964	782,355,857
Other operating revenues	27,307,442	40,614,568
Total operating revenues	4,358,101,318	4,133,641,841
Operating Expenses		
Salaries, wages and benefits	2,028,850,498	1,963,628,897
Supplies and services	2,430,596,642	2,154,297,244
Depreciation	180,030,404	175,757,850
Scholarships and fellowships	33,114,448	55,053,095
Total operating expenses	4,672,591,992	4,348,737,086
Operating loss	(314,490,674)	(215,095,245)
Nonoperating (Expenses) Revenues		
Economic Relief Funds	21,209,457	412,719
State educational appropriations	332,448,930	314,953,056
Grants and contracts	61,949,289	105,093,454
Gifts	37,066,668	61,112,310
Investment (loss) income	(521,865,832)	555,919,121
Interest expense	(41,794,231)	(38,235,066)
Loss on asset dispositions, net	(18,452,939)	(1,907,293)
Other nonoperating income, net	6,882,325	9,284,341
Net nonoperating (expenses) revenues	(122,556,333)	1,006,632,642
(Loss) income before other changes in net position	(437,047,007)	791,537,397
Other Changes in Net Position		
State capital funds	26,379,881	3,610,767
Capital gifts and grants	12,806,674	1,645,260
Endowment gifts	44,941,789	33,163,130
Intergovernmental transfers	(48,635,716)	—
Total other changes in net position	35,492,628	38,419,157
(Decrease) increase in net position	(401,554,379)	829,956,554
Net Position, beginning of year	3,117,296,054	2,287,339,500
Net Position, end of year	\$ 2,715,741,675	\$ 3,117,296,054

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Cash Flows
Years Ended September 30, 2022 and 2021

	<u>2022</u>	<u>2021</u>
Cash flows from operating activities		
Student tuition and fees	\$ 245,966,174	\$ 249,506,292
Grants and contracts:		
Federal	460,331,631	422,804,721
State	12,516,743	10,194,733
Local	1,246,452	4,307,528
Private	99,227,010	81,575,192
Receipts from sales and services of:		
Educational activities	66,820,688	66,724,028
Patient services	2,495,475,779	2,361,365,878
Auxiliary enterprises, net	52,651,080	46,375,753
Premium and administrative fees collected	763,992,459	750,236,493
Payment to employees and related benefits	(1,487,722,848)	(1,364,877,617)
Payment for contract labor	(641,738,750)	(536,408,405)
Payment to suppliers	(2,457,132,382)	(2,195,910,523)
Payment for scholarships and fellowships	(33,114,447)	(55,053,096)
Other receipts	26,752,341	34,006,204
Net cash used in operating activities	(394,728,070)	(125,152,819)
Cash flows from noncapital financing activities		
Economic relief funds	21,209,457	3,368,856
State educational appropriations	332,448,930	314,953,056
Private gifts	80,824,499	89,185,963
Student direct lending receipts	160,577,061	163,479,335
Student direct lending disbursements	(158,008,589)	(163,230,477)
Intragovernmental Transfers	(48,635,718)	—
Other deposits	55,499,781	141,166,406
Deposits from affiliates	(5,143,741)	(2,736,808)
Net cash provided by noncapital financing activities	438,771,680	546,186,331
Cash flows from investing activities		
Interest and dividends from investments, net	83,325,800	62,043,622
Proceeds from notes receivable	4,000	137,233
Proceeds from sales and maturities of investments	125,856,820	10,279,096
Purchases of investments	(148,651,671)	(418,466,261)
Net cash provided by (used in) investing activities	60,534,949	(346,006,310)
Cash flows from capital and related financing activities		
Proceeds from issuance of capital debt	179,231,494	758,968
State capital funds	26,379,881	3,610,767
Capital gifts, grants and contracts	3,807,185	4,433,541
Proceeds from sale of capital assets	2,689,301	4,985,095
Purchases of capital assets	(202,900,394)	(176,474,734)
Principal payments on capital debt	(56,740,231)	(55,961,723)
Interest payments on capital debt	(45,520,428)	(41,051,740)
Net cash used in capital and related financing activities	(93,053,192)	(259,699,826)
Net increase (decrease) in cash and cash equivalents	11,525,367	(184,672,624)
Cash and cash equivalents, beginning of year	520,616,504	705,289,128
Cash and cash equivalents, end of year	\$ 532,141,871	\$ 520,616,504

See accompanying notes to financial statements.

The University of Alabama at Birmingham
Statements of Cash Flows (continued)
Years Ended September 30, 2022 and 2021

	<u>2022</u>	<u>2021</u>
Reconciliation of cash and cash equivalents to the statements of net position		
Cash and cash equivalents	\$ 365,792,264	\$ 473,086,415
Cash designated for capital activities	165,975,422	35,225,414
Restricted cash and cash equivalents	374,185	12,304,675
Total cash and cash equivalents	<u>532,141,871</u>	<u>\$ 520,616,504</u>
Reconciliation of operating loss to net cash (used in) provided by operating activities		
Operating loss	\$ (314,490,674)	\$ (215,095,245)
Adjustments to reconcile operating loss to net cash (used in) provided by operating activities		
Depreciation expense	180,030,404	175,757,851
Pension expense	64,413,000	132,530,000
OPEB expense (benefit)	11,510,608	24,990,489
Changes in assets and liabilities:		
Accounts receivable, net	(130,324,594)	(121,792,055)
Prepaid expenses and other assets	(13,266,983)	(16,901,341)
Accounts payable and accrued liabilities	(81,218,562)	(2,428,892)
Pension obligations	(101,166,000)	(96,839,000)
OPEB obligations	(16,311,782)	(20,135,246)
Unearned Revenue	6,096,513	14,760,620
Net cash used in operating activities	<u>\$ (394,728,070)</u>	<u>\$ (125,152,819)</u>
Supplemental noncash activities information		
Capital assets acquired included in accounts payable	\$ 15,224,549	\$ 14,017,423
Capital assets acquired through all lease	11,773,467	42,106,867
Debt proceeds immediately transferred into escrow	150,772,683	—
Payment of outstanding bonds principal and interest via escrow	149,278,865	—

See accompanying notes to financial statements.

Southern Research Institute
(A Discretely Presented Component Unit)
Statements of Net Position
December 31, 2021 and January 1, 2021

	<u>2022</u>	<u>2021</u>
Current Assets:		
Cash and cash equivalents	\$ 2,218,692	\$ 15,846,028
Investments	51,179,367	26,287,986
Restricted cash and investments	13,308,476	12,226,041
Accounts receivable, net	20,639,167	17,227,864
Other receivables	514,425	577,048
Materials and supplies, net	920,111	974,676
Prepayments and other current assets	814,499	2,749,927
Total current assets	89,594,737	75,889,570
Noncurrent Assets:		
Net OPEB asset	2,053,566	1,565,283
Capital assets:		
Land and improvements	4,128,885	5,122,675
Buildings and major plant equipment	50,606,039	66,665,302
Laboratory equipment and fixtures	55,608,810	57,654,248
Office furniture and equipment	3,417,399	3,522,256
Intangible assets, net	2,103,141	1,906,909
	<u>115,864,274</u>	<u>134,871,390</u>
Less accumulated depreciation	(85,047,276)	(88,209,821)
	<u>30,816,998</u>	<u>46,661,569</u>
Construction-in-progress	1,630,206	1,341,134
Total capital assets, net	<u>32,447,204</u>	<u>48,002,703</u>
Total noncurrent assets	34,500,770	49,567,986
Total Assets	124,095,507	125,457,556
Deferred Outflows of Resources		
OPEB	174,529	280,742
Total Assets and Deferred Outflows of Resources	\$ 124,270,036	\$ 125,738,298
Current Liabilities:		
Accounts payable	\$ 2,228,778	\$ 3,841,344
Accrued liabilities	4,651,678	5,769,660
Unearned contract revenue	9,710,441	9,491,157
Current maturities of long-term debt and capital lease obligations	13,043,565	8,985,991
Total current liabilities	29,634,462	28,088,152
Noncurrent Liabilities:		
Long-term debt and capital lease obligations	585,318	13,634,937
Total noncurrent liabilities	585,318	13,634,937
Total Liabilities	30,219,780	41,723,089
Deferred Inflows of Resources		
OPEB	1,960,536	1,670,887
Net Position		
Net investment in capital assets	18,818,321	33,108,475
Restricted		
Expendable	12,481,131	12,401,179
Unrestricted	60,790,268	36,834,668
Total Net Position	92,089,720	82,344,322
Total Liabilities, Deferred Inflows Of Resources, and Net Position	\$ 124,270,036	\$ 125,738,298

See accompanying notes to financial statements.

Southern Research Institute
(A Discretely Presented Component Unit)
Statements of Revenues, Expenses, and Changes in Net Position
Years Ended December 31, 2021 and January 1, 2021

	<u>2022</u>	<u>2021</u>
Operating Revenues		
Contract revenues	\$ 78,975,963	\$ 80,481,381
Intellectual property revenues, net of direct expenses	1,882,898	1,669,020
Total operating revenues	80,858,861	82,150,401
Operating Expenses		
Salaries, wages and benefits	40,538,321	42,197,364
Supplies and services	30,542,548	31,769,278
Depreciation and amortization	5,643,278	6,170,775
Total operating expenses	76,724,147	80,137,417
Operating income	4,134,714	2,012,984
Nonoperating Revenues (Expenses)		
Contributions	155,458	270,253
Investment income	1,529,017	916,130
Interest expense	(327,828)	(457,436)
Gain on disposal of assets	4,254,037	9,329,832
Net nonoperating revenues	5,610,684	10,058,779
Change in net position	9,745,398	12,071,763
Net Position, beginning of year	82,344,322	70,272,559
Net Position, end of year	\$ 92,089,720	\$ 82,344,322

See accompanying notes to financial statements.

The University of Alabama at Birmingham

Notes to Financial Statements

Years Ended September 30, 2022 and 2021

(1) Organization and Summary of Significant Accounting Policies

The University of Alabama at Birmingham ("UAB") is one of three universities of The University of Alabama System ("the System"), which is a component unit of the State of Alabama ("the State"). The financial statements of UAB are intended to present the financial position, changes in financial position, and the cash flows of only that portion of the business-type activities of the financial reporting entity of the System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of the System, its changes in financial position or cash flows in accordance with accounting principles generally accepted in the United States of America. The System is recognized as an organization exempt from Federal income tax under Section 501(a) of the Internal Revenue Code as an organization described in Section 501(c)(3) of the Internal Revenue Code.

UAB, as a public institution, prepares its financial statements in accordance with accounting principles generally accepted in the United States of America, as prescribed by the Governmental Accounting Standards Board (GASB). UAB is not a separate legal entity from the System and therefore, management is not required to and has not performed a going concern analysis at the UAB level.

GASB Statement No. 35, *Basic Financial Statements and Management's Discussion and Analysis for Public Colleges and Universities*, establishes standards for external financial reporting for public colleges and universities and requires that resources be classified for accounting and reporting purposes into the following three net position categories:

- **Net Investment in Capital Assets:**

Capital assets, net of accumulated depreciation and outstanding principal balances of debt attributable to the acquisition, construction, or improvement of those assets.

- **Restricted:**

Nonexpendable: Net position subject to externally imposed stipulations that they be maintained permanently by UAB. Such assets include UAB's permanent endowment funds.

Expendable: Net position whose use by UAB is subject to externally imposed stipulations that can be fulfilled by actions of UAB pursuant to those stipulations or that expire by the passage of time.

- **Unrestricted:**

The net position that is not subject to externally imposed stipulations. Unrestricted net position may be designated for specific purposes by action of management. Substantially all of the unrestricted net position is designated for academic and research programs and initiatives and capital programs.

For financial reporting purposes, UAB is considered a special-purpose government engaged only in business-type activities as defined by GASB Statement No. 35. Business-type activities are those that are financed in whole or in part by fees charged to external parties for goods or services. Under the accrual basis, revenues are recognized when earned, and expenses are recorded when an obligation has been incurred.

UAB policy states that operating activities as reported by the statement of revenues, expenses, and changes in net position are those that generally result from exchange transactions such as payments received for providing services and payments made for services or goods received. Certain significant revenue streams relied upon for operations are recorded as nonoperating revenues, as defined by GASB Statement No. 35.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The estimates susceptible to significant changes include those used in determining the allowance for contractual adjustments and uncollectible accounts, valuation of investments, accruals related to compensated absences,

allowance for self-insurance, estimated amounts due to or from third-party payors, and reserves for general and professional liability claims. Although some variability is inherent in these estimates, management believes that the amounts provided are adequate.

Scope of Statements

UAB is principally comprised of a university ("the University") and the University of Alabama Hospital ("University Hospital") which are UAB's reportable segments as defined by GASB Statement No. 37, *Basic Financial Statements and Management's Discussion and Analysis-For State and Local Governments: Omnibus an Amendment of GASB Statements No. 21 and No. 34*. UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the University Hospital, and UAB's blended component units. Condensed financial information of UAB's reportable segments is presented at Note 15. Refer to Note 2 for information regarding UAB's component units.

UAB is affiliated with the UAB Educational Foundation ("UABEF"), the University of Alabama Health Services Foundation, P.C. ("HSF"), UAB Medicine Enterprise ("UABME"), formally known as UAB Health System ("UABHS"), Medical West, Cooper Green Mercy Health Services Authority, and the Valley Foundation ("VF"). UAB is not financially accountable for UABEF, HSF, UABME or VF; therefore, they do not constitute component units under the provisions of GASB Statement No. 14, *The Financial Reporting Entity*, as amended. These entities are not required to be presented as component units under GASB Statement No. 39, *Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No. 14* and No. 61, *The Financial Reporting Entity – an Amendment of GASB Statement No. 14 and 34*. More information regarding HSF, UABME and VF can be found at Note 16.

UABEF provides funds and certain facilities to UAB for its educational and scientific functions. UABEF has 11 board members, including seven outside members not affiliated with UAB. The UABEF Board approved to modify the fiscal year from June 30 to September 30 effective as of September 30, 2021. The fiscal year 2021 amounts reflected below is for the fifteen months ended September 30, 2021. UABEF leases certain facilities to UAB, with lease payments of approximately \$2.7 million for the year ended September 30, 2022 and \$3.3 million for the fifteen months ended September 30, 2021. UABEF made contributions to UAB which totaled approximately \$3.5 million for the year ended September 30, 2022 and approximately \$3.0 million for the year ended June 30, 2021.

Implementation of new standards: During fiscal year 2022, UAB adopted GASB Statement No. 87, *Leases*, which establishes a single model for lease accounting based on the principle that leases serve to finance the right to use an underlying asset. The statement requires lessees to recognize right-to-use assets and related liabilities, and lessors to recognize receivables and corresponding deferred inflows of resources, for leases that were previously classified as operating and recognized as inflows or outflows of resources. UAB's discretely presented component Southern Research Institute ("SRI") and blended component Triton Health Systems, L.L.C. ("Triton") have not yet adopted GASB 87 due to both entities have different fiscal year ends preceding the GASB Statement No. 87 effective date. The adoption of GASB Statement No. 87 has been reflected on a retrospective basis at the beginning of the earliest period presented in the financial statements, or October 1, 2020. The effects of adopting GASB 87 in the UAB's financial statements for the year ended September 30, 2021 are as follows:

	As Previously Reported	Effect of Adoption of GASB 87	As Restated
Statement of Net Position			
Current Assets			
Account receivable, net	\$ 608,413,710	\$ 2,340,252	\$ 610,753,962
Total current assets	\$ 2,854,225,459	\$ 2,340,252	\$ 2,856,565,711
Noncurrent Assets			
Capital assets, net	\$ 1,788,161,516	\$ 108,381,508	\$ 1,896,543,024
Other noncurrent assets	125,061	16,571,575	16,696,636
Total noncurrent assets	\$ 3,909,140,760	\$ 124,953,083	\$ 4,034,093,843
Total assets	\$ 6,763,366,219	\$ 127,293,335	\$ 6,890,659,554

	As Previously Reported	Effect of Adoption of GASB 87	As Restated
Current Liabilities			
Accounts payable and accrued expenses	\$ 565,985,667	\$ (28,335)	\$ 565,957,332
Long-term debt, current	\$ 37,443,982	\$ 17,141,431	\$ 54,585,413
Total current liabilities	\$ 785,042,866	\$ 17,113,096	\$ 802,155,961
Noncurrent Liabilities			
Long-term debt, noncurrent	\$ 1,063,644,857	\$ 93,538,266	\$ 1,157,183,123
Other noncurrent liabilities	\$ 26,655,309	\$ (12,604,921)	\$ 14,050,388
Total noncurrent liabilities	\$ 3,196,098,532	\$ 80,933,345	\$ 3,277,031,877
Total Liabilities	\$ 3,981,141,397	\$ 98,046,441	\$ 4,079,187,838
Deferred Inflow Of Resources			
Deferred inflows of resources - leases	\$ —	\$ 31,345,123	\$ 31,345,123
Total deferred inflow of resources	\$ —	\$ 31,345,123	\$ 31,345,123
Net Position			
Net Position - Unrestricted	\$ 1,341,397,693	\$ (2,098,229)	\$ 1,339,299,464
Total net position	\$ 3,119,394,283	\$ (2,098,229)	\$ 3,117,296,054
	As Previously Reported	Effect of Adoption of GASB 87	As Restated
Statement of Revenues, Expenses and Changes in Net Position			
Operating Revenues			
Other operating revenue	\$ 40,280,076	\$ 334,492	\$ 40,614,568
Total operating revenues	\$ 4,133,307,349	\$ 334,492	\$ 4,133,641,841
Operating Expenses			
Supplies and services	\$ 2,174,043,204	\$ (19,745,960)	\$ 2,154,297,244
Depreciation	156,533,614	19,224,236	175,757,850
Total operating expenses	\$ 4,349,258,810	\$ (521,724)	\$ 4,348,737,086
Operating loss	\$ (215,951,461)	\$ 856,216	\$ (215,095,245)
Nonoperating Revenues (Expenses)			
Interest expense	\$ (35,280,621)	\$ (2,954,445)	\$ (38,235,066)
Total nonoperating revenues	\$ 1,009,587,087	\$ (2,954,445)	\$ 1,006,632,642
Income before other changes in net position	\$ 793,635,626	\$ (2,098,229)	\$ 791,537,397
Increase in net position	\$ 832,054,783	\$ (2,098,229)	\$ 829,956,554

	As Previously Reported	Effect of Adoption of GASB 87	As Restated
Statements of Cash Flows			
Cash flows from operating activities			
Other receipts	\$ 33,633,580	\$ 372,624	\$ 34,006,204
Payment to suppliers	(2,215,523,953)	19,613,430	(2,195,910,523)
Net cash used in operating activities	\$ (145,138,873)	\$ 19,986,054	\$ (125,152,819)
Cash from capital and related financing activities			
Principal payments on capital debt	\$ (38,935,420)	\$ (17,026,303)	\$ (55,961,723)
Interest payments on capital debt	(38,097,294)	(2,954,446)	(41,051,740)
Net cash used in capital and related financing activities	\$ (239,719,077)	\$ (19,980,749)	\$ (259,699,826)
Reconciliation of operating loss to net cash used in operating activities			
Operating loss	\$ (215,984,292)	\$ 889,047	\$ (215,095,245)
Depreciation	\$ 156,533,614	\$ 19,224,237	\$ 175,757,851
Accounts payable and accrued liabilities	\$ (2,296,355)	\$ (132,537)	\$ (2,428,892)
Net cash used in operating activities	\$ (145,138,873)	\$ 19,986,054	\$ (125,152,819)
Supplemental noncash activities information			
Capital assets acquired through lease	\$ —	\$ 11,773,467	\$ 11,773,467

Certain notes to the financial statements for the period ended September 30, 2021 have been restated due to the adoption of GASB Statement No 87, Leases.

Cash and Cash Equivalents: For purposes of the statement of cash flows, UAB considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents representing assets of UAB's endowment, life income, and other long-term investments are included in noncurrent assets.

Investments: UAB's investments are reported at fair value. The majority of UAB's investment portfolio is invested in separate investment pools sponsored by the System. Fair value for the investment pools is provided by the System, based on the fair value of the underlying investment securities held by each investment pool. Fair value of the underlying securities held in each investment pool is based on quoted market prices or dealer quotes, where available, or determined using net asset values provided by underlying investment partnerships or companies. Fair value for equity securities, debt securities, mutual funds and U.S. government and agency obligations held by UAB is determined from quoted market prices or market prices of similar instruments. Real estate held as investments is reported at fair value based upon appraisals, acquisition value at the date of donation, and other valuations typically based on management assumptions or expectations. Investments received by gift are reported at fair value at date of receipt. Net investment income, including realized and unrealized gains and losses, is reported as nonoperating revenues (expenses) in the statements of revenues, expenses, and changes in net position.

Investments are reported in four categories in the statement of net position. Investments recorded as endowment and life income investments are those invested funds that cannot be used to fund current operations and thus are included in noncurrent assets. Investments for capital activities represent the investment of cash to fund future capital projects and are included in noncurrent assets. Other long-term investments are those invested funds with maturities greater than one year or are considered by management to be of a long duration that are not an investment of the endowment and life income fund or the plant fund. Short-term investments represent investments available for current operations.

Inventories: Inventories are carried at the lower of cost or market. Inventories consist primarily of medical supplies and pharmaceuticals.

Accounts Receivable: Accounts receivable consist primarily of patient receivables, tuition charged to students and amounts due from federal, state, and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

Capital Assets: All capital assets are carried at cost on date of acquisition (or in the case of gifts, at fair value on the date of donation, and in the case of right of use assets for leased property and equipment, an amount equal to the lease liability at lease inception), less accumulated depreciation. UAB computes depreciation for buildings and building improvements (15-40 years) and for fixed equipment systems (3-20 years) using a component method. Depreciation of land improvements (40 years), library collection (10 years), inventoried equipment (3-20 years), and right of use assets (3-40 years) is computed on a straight-line basis. The University Hospital uses guidelines established by the American Hospital Association to assign useful lives to inventoried equipment.

Right of use assets acquired are amortized over the shorter of the lives of the respective leases or the estimated useful lives of the underlying assets. Capital assets acquired through federal grants and contracts in which the Federal government retains a reversionary interest are capitalized and depreciated.

Computer software capitalization, which is included as inventoried equipment, includes the costs of software and implementation. Implementation costs include consulting expenses and allocation of internal salaries and fringes for the core implementation team.

Pledges: UAB receives gift pledges and bequests of financial support. Revenue is recognized when a pledge representing an unconditional promise to give is received and all eligibility requirements, including time requirements, have been met. In the absence of such a promise, revenue is recognized when the gift is received. Pledges are recorded at their gross, undiscounted amount. Endowment pledges do not meet eligibility requirements and are not recorded as assets until the related gift is received in accordance with the requirements of GASB Statement No. 33, *Accounting and Financial Reporting for Nonexchange Transactions*. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

Endowment Spending: The State Legislature adopted the Alabama Uniform Prudent Management of Institutional Funds Act ("UPMIFA"), effective January 1, 2009, which permits the Board of Trustees of the University of Alabama (the "Board") to appropriate an amount of realized and unrealized endowment appreciation as the Board determines to be prudent. UPMIFA prescribes guidelines for the expenditure of donor-restricted endowment funds in the absence of overriding, explicit donor stipulations. UPMIFA focuses on the entirety of a donor-restricted endowment fund, that is, both the original gift amount(s) and net appreciation. UPMIFA eliminates UMIFA's historic-dollar-value threshold, an amount below which an organization could not spend from the fund, in favor of a more robust set of guidelines about what constitutes prudent spending, explicitly requiring consideration of the duration and preservation of the fund.

UAB's policy is to retain the endowment realized and unrealized appreciation within an endowment after the spending rate distributions in a manner consistent with the standards of prudence prescribed by UPMIFA. The Board approved a spending rate for fiscal years September 30, 2022 and 2021 of 4.5%, based on a moving five-year average of the market (unit) value.

Prepaid Expenses and Unearned Scholarships: Prepaid expenses are composed of future expenses that have been paid in advance and include prepaid postage, travel, and other miscellaneous expenses. Unearned scholarship expense results from the Fall academic term spanning across the fiscal year-end. UAB prorates scholarship expense to recognize only the amounts incurred in each fiscal year.

Unearned Revenue: Unearned revenue consists primarily of student tuition and fees related predominantly to future fiscal years and amounts received from grant and contract sponsors that have not yet been earned under the terms of the agreements and, therefore, have not yet been included in the net position.

Federal Refundable Loans: Certain loans to students are administered by UAB with funding primarily supported by the federal government. UAB's statements of net position include both the notes receivable and the related federal refundable loan liability representing federal capital contributions and related activity owed upon termination of the program. The Federal Perkins Loan Program expired June 30, 2018. The University will continue operating the program and remit any excess cash annually for the pro rata federal and institutional capital contributions. As of September 30, 2022 and 2021, there was \$1.0 million and \$1.3 million, respectively, payable to the Department of Education for its portion of the excess cash available at June 30, 2022.

Compensated Absences: UAB accrues annual leave for employees at rates based upon length of service and job classification. UAB accrues compensatory time based upon job classification and hours worked. These amounts are included in accounts payable and accrued liabilities.

Deferred Outflows of Resources: Deferred outflows of resources consist of bond deferred refunding amounts, pension obligations, and OPEB obligations (Trust and UAB Plan). Pension obligations include employer contributions to the Teachers' Retirement System subsequent to the Plan's measurement date, differences between expected and actual

experience, and changes in actuarial and other assumptions. The Trust's obligations include employer contributions to the Alabama Retired Education Employees' Health Care Trust subsequent to the Trust's measurement date, differences between expected and actual experience, and changes in proportion and differences between employer contributions and proportionate share of contributions. The UAB Plan's obligations include employer contributions to the UAB Health Care Plan subsequent to the Plan's measurement date for eligible disabled retirees.

Deferred Inflows of Resources: Deferred inflows of resources are composed of pension obligations, OPEB obligations (Trust and UAB Plan), and leases. Pension obligations include differences between expected and actual experience, changes in proportion and differences between employer contributions and proportionate share of contributions, and net difference between projected and actual earnings on pension plan investments. The Trust's obligations include changes in actuarial and other assumptions and net difference between projected and actual earnings on OPEB plan investments. The UAB Plan's obligations include differences between expected and actual experience and changes in actuarial and other assumptions. Deferred inflows for leases relate to those arrangements where UAB is the lessor.

Student Tuition and Fees and Scholarship Allowances and Student Aid: Student tuition and fees are presented net of scholarships and fellowships applied to student accounts, while stipends and other payments made directly to students are presented as scholarships and fellowships expense.

Grant and Contract Revenue: UAB receives grant and contract revenue from governmental and private sources. UAB recognizes revenue associated with the sponsored programs in accordance with GASB Statement No. 33, based on the terms of the individual grant or contract.

University Hospital Revenue: Net patient service revenue is reported at the University Hospital's estimated net realizable amounts from patients, third-party payors, and others for services rendered, including estimated retroactive revenue adjustments due to revenue audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered.

The University Hospital provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its estimated rates. Because the University Hospital does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

Auxiliary Enterprise Revenue: Auxiliary enterprise revenues primarily represent revenues generated by intercollegiate athletics and parking as well as subscriber premiums for Triton Health Systems, L.L.C.

Other Revenue: Other revenue represents primarily revenues generated by UAB for activities such as intellectual property income and the University of Alabama Health Services Foundation, P.C. ("HSF") transfers.

Equity Investments: Investments in affiliated companies where UAB can exercise significant influence and for which UAB's ownership interest is 50% or less are accounted for using the equity method. The investment in the Professional Liability Trust Fund ("PLTF") also is accounted for using the equity method. See Notes 4 and 8.

Nonoperating Revenues (Expenses): Nonoperating revenues and expenses include State educational appropriations, federal appropriations, Federal Pell grants, private gifts for other than capital purposes, investment income, net unrealized appreciation or depreciation in the fair value of investments, interest expense, loss on asset dispositions, and CARES Act funds for fiscal years 2022 and 2021.

COVID-19 Pandemic: In January 2020, the World Health Organization declared the novel Coronavirus ("COVID-19") a Public Health Emergency of International Concern. The outbreak of COVID-19 caused domestic and global disruption in operations for institutions of higher education. The outbreak also negatively impacted both the global financial markets and the University's investments, including the investments held within the System Pools, and may continue to do so.

COVID-19 Emergency Grants for Higher Education: The CARES Act was signed into law in March 2020 to provide economic assistance for businesses and individuals that have been negatively impacted by the COVID-19 pandemic. The Higher Education Emergency Relief Fund ("HEERF I") and the Coronavirus Relief Fund ("CRF") are authorized by the CARES Act.

The Higher Education Emergency Relief Fund II ("HEERF II") is authorized by the Coronavirus Response and Relief Supplemental Appropriations Act ("CRRSAA"), which was signed into law in December 2020. The CRRSAA funds support education in addition to the HEERF I CARES Act funding.

The Higher Education Emergency Relief Fund III ("HEERF III") is authorized by the American Rescue Plan ("ARP"), which was signed into law in March 2021 to provide support to institutions of higher education to serve students and ensure learning continues during the COVID-19 pandemic. ARP funds are in addition to funds authorized by the CRRSAA and CARES Act.

The HEERF funds are administered through the U.S. Department of Education and are designed to facilitate the distribution of emergency financial aid grants directly to students, as well as to provide funding for institutions negatively impacted by the COVID-19 pandemic. Under the terms of the student portion of this program, revenue is recognized once eligible expenditures associated with the distribution of aid to students have been incurred. For the institutional portions of this program, revenue is recognized as the University identifies eligible expenditures or lost revenues which qualify for reimbursement.

The Coronavirus Relief Fund is administered through the State of Alabama Department of Finance. The purpose of the Coronavirus Relief Fund appropriation is for the funds to be used to prevent, prepare for, and respond to coronavirus only. The CRF covers only those costs that are necessary expenditures incurred due to the public health emergency with respect to COVID-19. Eligibility to receive payment from the State's portion of funds from the CRF is contingent upon certifying that the University will: (1) use the funds in a lawful manner consistent with Section 601(d) of the Coronavirus Relief Fund and (2) will comply with any and all policies and directives issued by the Alabama Department of Finance related to the Coronavirus Relief Funds.

The Provider Relief Fund ("PRF") is administered through the U.S. Department of Health and Human Services ("HHS"). PRF payments may be used to cover lost revenue attributable to COVID-19 or health-related expenses purchased to prevent, prepare for, and respond to COVID-19. Providers are required to report the use of funds expended through June 30, 2021 by September 30, 2021 and funds expended through December 31, 2021 by March 31, 2022. Based on the most recent guidance, providers may be reimbursed for healthcare-related expenses attributable to coronavirus that another source has not reimbursed, as well as lost revenues as measured by one of three options, which include a) calculating based on the negative change in calendar year 2020 and 2021 patient care revenues compared to calendar year 2019 patient care revenues, b) calculating based on the negative change in calendar year 2020 and 2021 patient revenue compared to budgeted 2020 and 2021 patient care revenues, respectively, provided the budget had been established and approved prior to March 27, 2020, and c) calculating by another reasonable method of estimating revenues.

All COVID-19 emergency grants received are included in nonoperating grants in the accompanying statements of revenues, expenses, and changes in net position.

(2) Component Unit(s)

GASB Statement No. 14, *The Financial Reporting Entity*, as amended by GASB Statement No. 39, *Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No. 14*, No. 61, *The Financial Reporting Entity – an Amendment of GASB Statement No. 14 and 34* and No. 80, *Blending Requirements for Certain Component Units – an amendment of GASB Statement No. 14*, requires governmental entities to include in their financial statements as a component unit, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable. The primary objective of these statements is to determine whether all entities associated with a primary government are potential component units and should be evaluated for inclusion in the financial reporting entity. The statements as amended provide additional guidance to determine whether certain organizations for which the primary government is not financially accountable should be reported as component units based on the nature and significance of their relationship with the primary government.

Southern Research Institute ("SRI") is a legally separate entity but its financial relationship with UAB is such that excluding SRI from the UAB financial report would be misleading. Management has therefore determined that SRI is a discretely presented component unit of UAB under GASB Statements No. 14 and No. 61. SRI reports financial results under principles prescribed under the GASB. SRI offers research and technology services to support industry and federal government agencies primarily in the areas of drug design and evaluation, environmental controls, materials engineering, and chemical and biological defense. The activities of SRI are maintained using a fiscal calendar year-end that ends prior to UAB's fiscal year-end of September 30. The financial results of SRI are discretely presented in these financial statements.

UAB includes four blended component units, as follows: UAB Research Foundation ("UABRF"), UAB Athletics Foundation ("UABAF"), UAB Hospital Management, L.L.C. ("LLC") and Triton Health Systems, L.L.C. ("Triton"). The by-laws and corporate charters of UABRF allow UAB to appoint a majority of the board of directors and allow UAB to impose its will on the entity. UABRF operates for the exclusive benefit of UAB. UABAF was organized to support the UAB Athletics Department in its quest for excellence in all programs. UABAF operates as an extension of the UAB Athletics Department and it almost exclusively benefits the University. Additionally, LLC and Triton have governing bodies that are substantively the same as the governing body of UAB and there is a financial benefit or burden

relationship between UAB and these entities. Therefore, management has determined that UABRF, UABAF, LLC and Triton (the Blended Component Units) constitute blended component units of UAB under GASB Statements No. 14 and No. 61. The Blended Component Units report financial results under principles prescribed under the GASB.

UABRF was organized exclusively for charitable, scientific, and educational purposes in order to benefit UAB. UABAF was formed in November 2015 as a nonprofit corporation organized to build loyalty and philanthropic support for the UAB athletic program and support the staff in coordinating, developing and improving a superior inter-collegiate athletics program. UABAF encourages alumni and friends to generously support the Athletics Department and contribute to scholarship funding for UAB's student athletes. The LLC was organized for the exclusive purpose of supporting UAB in connection with the management, administration, and operation of the University Hospital, including, without limitation, providing management, administrative, and staffing services to the University Hospital. Triton was formed to advance the educational and research mission of UAB and to educate and train physicians and other health care professionals. Triton is owned 99% by UAB and 1% by The UABEF.

UABRF and LLC maintain a September 30 year-end. UABAF maintains a June 30 year-end. The activities of Triton are maintained using a fiscal calendar year-end that ends prior to UAB's fiscal year-end of September 30. However, interfund cash transactions during the period from January 1 through September 30 have been eliminated. Since Triton qualifies as a major component unit under GASB Statement No. 61, financial information for the years ended December 31, 2021 and 2020 is presented below.

TRITON HEALTH SYSTEMS, L.L.C.
CONDENSED STATEMENT OF NET POSITION

	2022	2021
Current assets	\$ 230,034,809	\$ 264,795,048
Capital assets, net	1,993,300	2,727,482
Other assets	142,499,054	117,099,812
TOTAL ASSETS	\$ 374,527,163	\$ 384,622,342
Current liabilities	95,330,642	97,434,894
Other noncurrent liabilities	317,411	633,846
TOTAL LIABILITIES	95,648,053	98,068,740
Net investment in capital assets	1,993,300	2,727,482
Restricted nonexpendable net position	100,000	100,000
Unrestricted net position	276,785,810	283,726,120
TOTAL NET POSITION	278,879,110	286,553,602
TOTAL LIABILITIES AND NET POSITION	\$ 374,527,163	\$ 384,622,342

CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION

Operating revenues	\$ 864,396,954	\$ 845,745,980
Operating expenses	(830,085,277)	(799,945,073)
Depreciation and amortization expense	(1,230,269)	(1,282,471)
OPERATING INCOME	33,081,408	44,518,436
Investment income	(1,865,876)	7,737,096
Interest expense	20	—
Income tax expense	(612,693)	(2,266,772)
INCOME BEFORE OTHER CHANGES IN NET POSITION	30,602,859	49,988,760
Distributions to members	(38,277,351)	(35,272,264)
(DECREASE) INCREASE IN NET POSITION	(7,674,492)	14,716,496
Net position, beginning of year	286,553,602	271,837,106
NET POSITION, END OF YEAR	\$ 278,879,110	\$ 286,553,602

CONDENSED STATEMENT OF CASH FLOWS

Net cash provided by (used in):		
Operating activities	\$ 13,140,146	\$ 37,114,595
Noncapital financing activities	(38,277,351)	(35,272,264)
Capital and related financing activities	(496,086)	(63,402)
Investing activities	(15,709,069)	(1,540,132)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(41,342,360)	238,797
Cash and cash equivalents, beginning of year	144,582,084	144,343,287
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 103,239,724	\$ 144,582,084

(3) Cash and Cash Equivalents

The Board approves, by resolution, all banks or other financial institutions utilized as depositories for UAB funds. Prior to approval, each proposed depository must provide evidence of its designation by the Alabama state treasurer as a qualified public depository under the Security for Alabama Funds Enhancement Act (SAFE). From time to time, the Board may request that the depository provide evidence of its continuing designation as a qualified public depository. In the past, the bank pledged collateral directly to each individual public entity. Under the mandatory SAFE program, each qualified public depository (QPD) is required to hold collateral for all its public deposits on a pooled basis in a custody account established for the State Treasurer as SAFE administrator. In the unlikely event a public entity should suffer a deposit loss due to QPD insolvency or default, a claim form would be filed with the state treasurer, who would use the SAFE pool collateral or other means to reimburse the loss. As of September 30, 2022 and 2021, respectively, UAB had cash and cash equivalents totaling \$532.1 million and \$520.6 million.

(4) Investments

The Board has the responsibility for the establishment of the investment policy and the oversight of the investments for the System and related entities. In order to facilitate System-wide investment objectives and achieve economies of scale, the Board has established two distinct investment pools based primarily on the projected investment time-horizons for System funds: the Pooled Endowment Fund (“PEF”) and the Liquidity and Capital Reserve Pool Fund (“LCRP”); collectively, the “System Pools.” Pursuant to Board investment policies, each System or related entity may include all or a portion of their investments within the System-sponsored investment pools. These investment funds are considered “internal” investment pools under GASB Statement No. 31, *Accounting and Financial Reporting for Certain Investments and for External Investment Pools, with the assets pooled on a market value basis*. Separately managed funds that reside with each entity are to be invested consistent with the asset mix of the corresponding System investment pool.

The following disclosures relate to both the System Pools, which include the investments of other System entities and other affiliated entities, and the UAB-specific investment portfolio.

Pooled Endowment Fund

The purpose of the PEF is to pool endowment and similar funds to support the System universities, University Hospital and related entities in carrying out their respective missions over a perpetual time frame. Accordingly, the primary investment objectives of the PEF are to preserve the purchasing power of the principal and provide a stable source of perpetual financial support to the endowment beneficiaries. To satisfy the long-term rate of return objective, the PEF relies on a total return strategy in which investment returns are achieved through both capital appreciation and natural income. Asset allocation targets are established to meet return objectives while providing adequate diversification in order to minimize investment volatility.

Liquidity and Capital Reserve Pool

The LCRP serves as an investment vehicle to manage operating reserves of the System universities, University Hospital, and related entities with an investment strategy that matches the duration of reserves to their projected needs. The goals of the pool are to preserve and grow capital, maximize returns without undue exposure to risk, and maintain sufficient liquidity for credit ratings. The pool is invested in a diversified asset mix of liquid, semi-liquid, and illiquid securities. The pool can invest no more than 15% in illiquid assets and must invest no less than 60% in liquid assets as defined by Board Rule 404.

Fair Value Measurements

GASB 72 sets forth the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under GASB 72 are described as follows:

- Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that UAB has the ability to access.

-
- Level 2 – Inputs to the valuation methodology include:
 - Quoted prices for similar assets or liabilities in active markets;
 - Quoted prices for identical or similar assets or liabilities in inactive markets;
 - Inputs other than quoted prices that are observable for the assets or liabilities;
 - Inputs that are derived principally from or corroborated by observable market data by correlation or other means.
 - Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect UAB's own assumptions about the inputs market participants would use in pricing the asset or liability (including assumptions about risk). Unobservable inputs are developed based on the best information available in the circumstances and may include UAB's own data.

GASB 72 allows for the use of net asset value ("NAV") as a practical expedient for valuation purposes for investments that do not have readily determinable fair value and meet certain other criteria. Investments that use NAV in determining fair value are disclosed separately from the valuation hierarchy as presented herein.

The level within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The determination of what constitutes observable requires judgment by UAB's management. UAB management considers observable data to be that market data which is readily available, regularly distributed or updated, reliable, and verifiable, not proprietary, and provided by multiple independent sources that are actively involved in the relevant market.

The categorization of an investment within the hierarchy is based upon the relative observability of the inputs to its fair value measurement and does not necessarily correspond to UAB management's perceived risk of that investment.

The following is a description of the valuation methods and assumptions used by UAB to estimate the fair value of its investments. There have been no changes in the methods and assumptions used at September 30, 2022. The methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. UAB management believes its valuation methods are appropriate and consistent with other market participants. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

When available, quoted prices are used to determine fair value. When quoted prices in active markets are available, investments are classified within Level 1 of the fair value hierarchy. UAB's Level 1 investments primarily consist of investments in mutual funds, exchange traded funds, and both domestic and foreign equity funds.

UAB's Level 2 investments consist of mutual funds that are priced or traded at the end of the day.

UAB's Level 3 investments primarily consist of very illiquid securities. The inputs or methodologies used for valuing securities are not necessarily an indication of the risks associated with investing in those securities. Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. Valuation techniques utilized by UAB are appraisals, entry price at the date of donation, and other valuations typically based on management assumptions or expectations.

At September 30, 2022 and 2021, the fair value of UAB's investments based on the inputs used to value them is summarized as follows:

	2022				
	Level 1	Level 2	Level 3	NAV	Total
Cash and equivalents:					
Commercial paper	\$ 100,000	\$ —	\$ —	\$ —	\$ 100,000
Equities:					
Common Stock	420,806	—	—	—	420,806
Fixed Income Securities:					
Corporate bonds	—	162,525,395	—	—	162,525,395
Commingled Funds:					
U.S. equity funds	—	1,022,600	—	—	1,022,600
Non-U.S. equity funds	—	251,427	—	—	251,427
Real Estate	—	—	159,600	—	159,600
	\$ 520,806	\$ 163,799,422	\$ 159,600	\$ —	\$ 164,479,828

Equity investments in partnerships	40,809,631
UAB Portion of System Pool Investments:	
Pooled Endowment Fund	674,860,514
Liquidity and Capital Reserve Pool Fund	2,141,341,791
Total Net Asset Value with System Pooled Investments	\$ 3,021,491,764

	2021				
	Level 1	Level 2	Level 3	NAV	Total
Cash and equivalents:					
Commercial paper	\$ 100,000	\$ —	\$ —	\$ —	\$ 100,000
Equities:					
Common Stock	420,806	—	—	—	420,806
Fixed Income Securities:					
Corporate bonds	—	148,895,846	—	—	148,895,846
Commingled Funds:					
U.S. equity funds	—	1,057,467	—	—	1,057,467
Non-U.S. equity funds	—	411,206	—	—	411,206
Real Estate	—	—	159,600	—	159,600
	\$ 520,806	\$ 150,364,519	\$ 159,600	\$ —	\$ 151,044,925

Equity investments in partnerships	69,880,913
UAB Portion of System Pool Investments:	
Pooled Endowment Fund	712,833,170
Liquidity and Capital Reserve Pool Fund	2,670,715,589
Total Net Asset Value with System Pooled Investments	\$ 3,604,474,598

At September 30, 2022 and 2021, the fair value of investments for the System Pools based on the inputs used to value them is summarized as follows:

POOLED ENDOWMENT FUND					
	2022				
	Level 1	Level 2	Level 3	NAV	Total
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 745,691
Total Receivables	—	—	—	—	745,691
Cash Equivalents:					
Money Market Funds	45,006,743	—	—	—	45,006,743
Total Cash Equivalents	45,006,743	—	—	—	45,006,743
Equities:					
U.S. Common Stock	140,307,712	—	—	—	140,307,712
Foreign Stock	30,583,042	—	—	—	30,583,042
Total Equities	170,890,754	—	—	—	170,890,754
Fixed Income Securities:					
U.S. Government Obligations	—	10,282,592	—	—	10,282,592
Mortgage Backed Securities	—	12,621,581	—	—	12,621,581
Corporate Bonds	—	21,255,552	—	—	21,255,552
Non-U.S. Bonds	—	4,370,866	—	—	4,370,866
Total Fixed Income Securities	—	48,530,591	—	—	48,530,591
Commingled Funds:					
U.S. Equity Funds	—	37,059,134	—	—	37,059,134
Non-U.S. Equity Funds	—	96,076,595	—	—	96,076,595
Hedge Funds	—	—	—	654,582,348	654,582,348
Private Equity Funds	—	—	2,043,040	444,027,507	446,070,547
Real Estate Funds	—	—	4,652,000	345,261,463	349,913,463
Total Commingled Funds	—	133,135,729	6,695,040	1,443,871,318	1,583,702,087
Total Fund Investments	215,897,497	181,666,320	6,695,040	1,443,871,318	1,848,130,175
Total Fund Assets	\$ 215,897,497	\$ 181,666,320	\$ 6,695,040	\$ 1,443,871,318	\$ 1,848,875,866
Total Fund Liabilities					(468,780)
Affiliated Entity Investments					(276,714,171)
Total Net Asset Value					\$ 1,571,692,915

POOLED ENDOWMENT FUND

	2021				Total
	Level 1	Level 2	Level 3	NAV	
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 515,924
Total Receivables	—	—	—	—	515,924
Cash Equivalents:					
Money Market Funds	45,941,864	—	—	—	45,941,864
Total Cash Equivalents	45,941,864	—	—	—	45,941,864
Equities:					
U.S. Common Stock	175,095,293	—	—	—	175,095,293
Foreign Stock	52,258,192	—	—	—	52,258,192
Total Equities	227,353,485	—	—	—	227,353,485
Fixed Income Securities:					
U.S. Government Obligations	—	13,246,381	—	—	13,246,381
Mortgage Backed Securities	—	14,281,482	—	—	14,281,482
Corporate Bonds	—	33,019,460	—	—	33,019,460
Non-U.S. Bonds	—	6,034,696	—	—	6,034,696
Total Fixed Income Securities	—	66,582,019	—	—	66,582,019
Commingled Funds:					
Non-U.S. Equity Funds	—	134,788,898	—	—	134,788,898
Hedge Funds	—	—	—	785,762,770	785,762,770
Private Equity Funds	—	—	3,673,786	415,061,514	418,735,300
Real Estate Funds	—	—	7,610,408	314,943,245	322,553,653
Total Commingled Funds	—	134,788,898	11,284,194	1,515,767,529	1,661,840,621
Total Fund Investments	273,295,349	201,370,917	11,284,194	1,515,767,529	2,001,717,989
Total Fund Assets	\$ 273,295,349	\$ 201,370,917	\$ 11,284,194	\$ 1,515,767,529	\$ 2,002,233,913
Total Fund Liabilities					(463,514)
Affiliated Entity Investments					(313,952,384)
Total Net Asset Value					\$ 1,687,818,015

LIQUIDITY AND CAPITAL RESERVE POOL FUND

	2022				Total
	Level 1	Level 2	Level 3	NAV	
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 5,962,851
Total Receivables	—	—	—	—	5,962,851
Cash Equivalents:					
Money Market Funds	44,987,405	—	—	—	44,987,405
Total Cash Equivalents	44,987,405	—	—	—	44,987,405
Equities:					
U.S. Common Stock	385,970,310	—	—	—	385,970,310
Foreign Stock	60,037,640	—	—	—	60,037,640
Total Equities	446,007,950	—	—	—	446,007,950
Fixed Income Securities:					
U.S. Government Obligations	—	227,749,680	—	—	227,749,680
Mortgage Backed Securities	—	207,578,465	—	—	207,578,465
Collateralized Mortgage Obligations	—	18,211,357	—	—	18,211,357
Corporate Bonds	—	201,087,489	—	—	201,087,489
Non-U.S. Bonds	—	94,105,656	—	—	94,105,656
Other Fixed Income Assets	—	6,877,721	—	—	6,877,721
Total Fixed Income Securities	—	755,610,368	—	—	755,610,368
Commingled Funds:					
U.S. Equity Funds	—	118,141,348	—	—	118,141,348
Non-U.S. Equity Funds	—	171,024,233	—	—	171,024,233
U.S. Bond Funds	—	372,671,133	—	—	372,671,133
Hedge Funds	—	—	—	1,121,752,329	1,121,752,329
Real Asset Funds	—	—	—	228,743,023	228,743,023
Total Commingled Funds	—	661,836,714	—	1,350,495,352	2,012,332,066
Total Fund Investments	490,995,355	1,417,447,082	—	1,350,495,352	3,258,937,789
Total Fund Assets	\$ 490,995,355	\$ 1,417,447,082	\$ —	\$ 1,350,495,352	\$ 3,264,900,640
Total Fund Liabilities					(1,094,294)
Affiliated Entity Investments					(230,500,974)
Total Net Asset Value					\$ 3,033,305,372

LIQUIDITY AND CAPITAL RESERVE POOL

	2021				
	Level 1	Level 2	Level 3	NAV	Total
Receivables:					
Accrued Income Receivables	\$ —	\$ —	\$ —	\$ —	\$ 3,879,956
LOC - Crimson Tide Foundation	—	—	—	—	13,464,676
Total Receivables	—	—	—	—	17,344,632
Cash Equivalents:					
Money Market Funds	101,990,000	—	—	—	101,990,000
Total Cash Equivalents	101,990,000	—	—	—	101,990,000
Equities:					
U.S. Common Stock	470,698,065	—	—	—	470,698,065
Foreign Stock	116,375,236	—	—	—	116,375,236
Total Equities	587,073,301	—	—	—	587,073,301
Fixed Income Securities:					
U.S. Government Obligations	—	250,565,337	—	—	250,565,337
Mortgage Backed Securities	—	239,316,613	—	—	239,316,613
Collateralized Mortgage Obligations	—	21,324,002	—	—	21,324,002
Corporate Bonds	—	204,635,474	—	—	204,635,474
Non-U.S. Bonds	—	91,866,955	—	—	91,866,955
Other Fixed Income Assets	—	10,780,861	—	—	10,780,861
Total Fixed Income Securities	—	818,489,242	—	—	818,489,242
Commingled Funds:					
U.S. Equity Funds	—	165,108,021	—	—	165,108,021
Non-U.S. Equity Funds	—	334,327,898	—	—	334,327,898
U.S. Bond Funds	—	495,084,539	—	—	495,084,539
Hedge Funds	—	—	—	1,253,780,387	1,253,780,387
Real Asset Funds	—	—	—	253,017,907	253,017,907
Total Commingled Funds	—	994,520,458	—	1,506,798,294	2,501,318,752
Total Fund Investments	689,063,301	1,813,009,700	—	1,506,798,294	4,008,871,295
Total Fund Assets	\$ 689,063,301	\$ 1,813,009,700	\$ —	\$ 1,506,798,294	\$ 4,026,215,927
Total Fund Liabilities					(3,334,581)
Affiliated Entity Investments					(259,048,937)
Total Net Asset Value					\$ 3,763,832,409

Additional information on fair values, unfunded commitments, remaining life, and redemption for investments measured at the NAV for the System Pools at September 30, 2022 and 2021 is as follows:

POOLED ENDOWMENT FUND

	2022				
	Fair Value	Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 654,582,348	\$ 36,000,000	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Private equity - private credit, buyouts, venture, secondary	444,027,507	210,125,649	1-15 years	Partnerships ineligible for redemption	Not redeemable
Real assets - public real estate, natural resources, and infrastructure	57,784,904	—	No limit	Monthly and Quarterly	None
Real assets - private real estate, natural resources, and infrastructure	287,476,559	102,280,510	1-15 years	Partnerships ineligible for redemption	Not redeemable
	\$ 1,443,871,318	\$ 348,406,159			

POOLED ENDOWMENT FUND

	2021				
	Fair Value	Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 785,762,770	\$ —	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Private equity - private credit, buyouts, venture, secondary	415,061,514	174,482,041	1-10 years	Partnerships ineligible for redemption	Not redeemable
Real assets - public real estate, natural resources, and infrastructure	86,098,351	—	No limit	Monthly and Quarterly	None
Real assets - private real estate, natural resources, and infrastructure	228,844,894	131,972,561	1-15 years	Partnerships ineligible for redemption	Not redeemable
	<u>\$ 1,515,767,529</u>	<u>\$ 306,454,602</u>			

LIQUIDITY AND CAPITAL RESERVE FUND

	2022				
	Fair Value	Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 1,121,752,329	\$ 67,500,000	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Real assets - public real estate, natural resources, and infrastructure	228,743,023	—	No limit	Monthly and Quarterly	None
	<u>\$ 1,350,495,352</u>	<u>\$ 67,500,000</u>			

LIQUIDITY AND CAPITAL RESERVE FUND

	2021				
	Fair Value	Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 1,253,780,387	\$ —	No limit	Monthly, Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Real assets - public real estate, natural resources, and infrastructure	253,017,907	—	No limit	Monthly and Quarterly	None
	<u>\$ 1,506,798,294</u>	<u>\$ —</u>			

Investment Risk Factors

There are many factors that can affect the value of investments. Some, such as custodial credit risk, concentration of credit risk and foreign currency risk, may affect both equity and fixed income securities. Equity securities respond to such factors as economic conditions, individual company earnings performance and market liquidity, while fixed income securities are particularly sensitive to credit risks and changes in interest rates.

Credit Risk

Fixed income securities are subject to credit risk, which is the chance that a bond issuer will fail to pay interest or principal in a timely manner, or that negative perceptions of the issuer's ability to make these payments will cause security prices to decline. These circumstances may arise due to a variety of factors such as financial weakness, bankruptcy, litigation, and/or adverse political developments. Certain fixed income securities, primarily obligations of the U.S. government or those explicitly guaranteed by the U.S. government, are not considered to have significant credit risk.

The investment policy recognizes that credit risk is appropriate in balanced investment pools such as the PEF and LCRP, and the credit quality of underlying fund investments is monitored on an ongoing basis. Fixed income investments within the PEF and LCRP include corporate, mortgage backed, asset backed, collateralized mortgage and U.S. treasury and/or agency bonds. In addition, approximately \$180.3 million and \$208.9 million in the PEF and LCRP, collectively, at September 30, 2022 and 2021, respectively, is invested in unrated fixed income securities, excluding fixed income commingled funds. Fixed income commingled funds and money market funds were approximately \$462.7 million and \$643.0 million in the PEF and LCRP, collectively, at September 30, 2022 and 2021, respectively.

The credit risk for fixed and variable income securities, for the System Pools, at September 30, 2022 and 2021 is as follows:

	POOLED ENDOWMENT FUND		LCRP FUND	
	2022	2021	2022	2021
Fixed or Variable Income Securities				
U.S. Government Obligations	\$ 10,282,592	\$ 13,246,381	\$ 227,749,680	\$ 250,565,337
Other U.S. Denominated:				
AAA	1,111,407	751,743	28,847,345	33,536,982
AA	777,166	1,691,717	42,527,588	49,370,980
A	8,524,786	12,042,928	143,652,806	135,358,729
BBB	12,054,784	18,930,562	124,110,357	128,995,396
BB	3,940,529	5,670,545	6,363,702	7,716,916
B	—	242,759	9,672,564	12,510,612
C and < C	—	—	4,226,053	5,566,724
Unrated	11,839,327	14,005,384	168,460,273	194,867,566
Commingled Funds:				
U.S. Bond Funds: Unrated	—	—	372,671,133	495,084,539
Non-U.S. Bond Funds: Unrated	—	—	—	—
Money Market Funds: Unrated	45,006,743	45,941,864	44,987,405	101,990,000
TOTAL	\$ 93,537,334	\$ 112,523,883	\$ 1,173,268,906	\$ 1,415,563,781

In accordance with the Board policy disclosed previously, credit risk for UAB's fixed and variable income securities held outside of the System Pools is managed by diversifying across issuers and limiting the amount of portfolio assets that are invested in non- investment grade securities.

The credit risk for fixed and variable income securities of UAB's separately held investments at September 30, 2022 and 2021 is as follows:

	2022	2021
Fixed or Variable Income Securities		
U.S. Government Guaranteed	\$ —	\$ —
Other U.S. and Non U.S. Denominated:		
AAA	162,525,395	148,895,846
AA	—	—
A	—	—
BBB	—	—
BB	—	—
B	—	—
CCC	—	—
CC	—	—
Unrated	—	—
Commingled Funds:		
U.S. Bond Funds: Unrated	—	—
Non-U.S. Bond Funds: Unrated	—	—
Money Market Funds: Unrated	—	—
Commercial Paper: Unrated	100,000	100,000
TOTAL	\$ 162,625,395	\$ 148,995,846

Custodial Credit Risk

Custodial credit risk is the risk that in the event of the corporate failure of the custodian, the investment securities may not be returned.

Investment securities in the System Pools and UAB's separately held investments are registered in the Board's name by the custodial bank as an agent for the System. Other types of investments (e.g. open-ended mutual funds, money market funds) represent ownership interests that do not exist in physical or book-entry form. As a result, custodial credit risk is remote.

Concentration of Credit Risk

Concentration of credit risk is the risk associated with a lack of diversification, such as having substantial investments in a few individual issuers, thereby exposing the organization to greater risks resulting from adverse economic, political, regulatory, geographic, or credit developments.

As previously mentioned, credit risk in each investment pool and UAB's separately held portfolio is managed primarily by diversifying across issuers and limiting the amount of portfolio assets that can be invested in non-investment grade securities.

As of September 30, 2022 and 2021, there was no investment in a single issuer that represents 5% or more of total investments held by any single investment manager of the System Pools or UAB's separately held investment portfolio except for investments issued by the U.S. government and money market fund investments.

Interest Rate Risk

Interest rate risk is the risk that the value of fixed income securities will decline because of changing interest rates. The prices of fixed income securities with a longer time to maturity, measured by effective duration, tend to be more sensitive to changes in interest rates and, therefore, more volatile than those with shorter durations. Effective duration is the approximate change in price of a security resulting from a 100 basis point (1 percentage point) change in the level of interest rates. It is not a measure of time.

The Board does not have a specific policy relative to interest rate risk. As such, there are no restrictions on weighted average maturity for each investment pool as they are managed relative to the investment objectives and liquidity demands of the investors.

The effective durations in years for fixed or variable income securities, for the System Pools at September 30, 2022 and 2021 are as follows:

	POOLED ENDOWMENT FUND		LCRP FUND	
	2022	2021	2022	2021
U.S. Government Obligations	10.2	9.8	3.8	3.2
Corporate Bonds	5.0	6.1	2.4	2.5
Non-US Bonds	5.0	6.1	2.4	2.5
Commingled Bond Funds	—	—	2.8	2.5
Other Fixed Income	—	—	—	1.9

The effective durations for fixed or variable income securities for UAB's separately held investments at September 30, 2022 and 2021 are as follows:

	SEPARATELY HELD	
	2022	2021
Commingled Bond Funds	2.7	3.4

Investments may also include mortgage pass through securities and collateralized mortgage obligations that may be considered to be highly sensitive to changes in interest rates due to the existence of prepayment or conversion features. At September 30, 2022 and 2021, the fair market values of these investments in the System Pools are as follows:

	POOLED ENDOWMENT FUND		LCRP FUND	
	2022	2021	2022	2021
Mortgage Backed Securities	\$ 12,621,581	\$ 14,281,482	\$ 207,578,465	\$ 239,316,613
Collateralized Mortgage Obligations	—	—	18,211,357	21,324,002
TOTAL FIXED	\$ 12,621,581	\$ 14,281,482	\$ 225,789,822	\$ 260,640,615

Mortgage Backed Securities. These securities are issued by the Federal National Mortgage Association ("Fannie Mae"), Government National Mortgage Association ("Ginnie Mae") and Federal Home Loan Mortgage Association ("Freddie Mac") and include short embedded prepayment options. Unanticipated prepayments by the obligees of the underlying asset reduce the total expected rate of return.

Collateralized Mortgage Obligations. Collateralized mortgage obligations ("CMOs") generate a return based upon either the payment of interest or principal on mortgages in an underlying pool. The relationship between interest rates and prepayments makes the fair value highly sensitive to changes in interest rates. In falling interest rate environments, the underlying mortgages are subject to a higher propensity of prepayments. In a rising interest rate environment, the opposite is true.

At September 30, 2022 and 2021, the effective durations for these securities held in the System Pools are as follows:

	POOLED ENDOWMENT FUND		LCRP FUND	
	2022	2021	2022	2021
Mortgage Backed Securities	6.6	3.6	3.3	2.6
Collateralized Mortgage Obligations	—	—	4.3	6.6

There are no mortgage backed securities or CMOs in UAB's separately held investments at September 30, 2022 and 2021.

Foreign Currency Risk

The strategic asset allocation policy for the PEF, the LCRP, and UAB's separately held investments includes an allocation to non-United States equity and fixed income securities. Currency hedging of foreign bonds and stocks is allowed under System policy. As of September 30, 2022 and 2021, all foreign investments in the System Pools and UAB's separately held investments are denominated in U.S. dollars and are in international commingled funds, which in turn invest in equity securities and bonds of foreign issuers except for foreign stock and non-U.S. bond funds denominated in U.S. dollars and held by each of the two pools as disclosed in previous tables.

Securities Lending

The System permits security lending as a mechanism to augment income. Loans of the securities are required to be collateralized by cash, letters of credit or securities issued or guaranteed by the U.S. Government or its agencies. The collateral must equal at least 102% of the current market value of the loaned securities. Securities lending contracts must state acceptable collateral for securities loaned, duties of the borrower, delivery of loaned securities and acceptable investment of the collateral. At September 30, 2022 and 2021, there were no securities on loan from the investment pools.

Joint Ventures

UAB accounts for its ownership of the PLTF as a joint venture, using the equity method in the amount of approximately \$40.8 million and \$69.9 million at September 30, 2022 and 2021, respectively. See Note 8 for further discussion of the PLTF.

(5) Receivables

Account receivable:

Accounts receivable consist of patient receivables, tuition charged to students and amounts due from federal, state and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

The composition of accounts receivable at September 30, 2022 and 2021 is summarized as follows:

	2022	2021
Patient care	\$ 536,007,761	\$ 579,841,693
Receivables from sponsoring agencies	114,513,548	93,499,257
Student accounts	49,607,347	47,080,570
Other	129,216,472	94,578,147
Total accounts receivable	\$ 829,345,128	\$ 814,999,667
Less: Allowances for doubtful accounts from patient care	176,530,020	199,997,424
Less: Allowances for doubtful accounts from student accounts	6,591,447	1,157,044
Less: Allowances for doubtful accounts, other	3,165,610	3,091,238
ACCOUNTS RECEIVABLE, NET	\$ 643,058,051	\$ 610,753,961

Loans receivable:

Loans receivable represent all amounts owed on promissory notes from debtors, including student loans made under the Federal Perkins Loan Program and other loan programs. The principal repayment and interest rate terms of federal and university loans vary considerably. The allowance for doubtful accounts only applies to University-funded notes and the University portion of federal student loans, since the University is not obligated to fund the federal portion of uncollected student loans. Federal loan programs are funded principally with federal advances to UAB under the Perkins and various health professions loan programs.

The composition of loans receivable at September 30, 2022 and 2021 is summarized in the table as follows:

	<u>2022</u>	<u>2021</u>
Federal loan program	\$ 10,022,381	\$ 11,172,570
University loan funds	2,298,824	2,338,606
Other	45,153	116,794
Total loans receivable	<u>\$ 12,366,358</u>	<u>\$ 13,627,970</u>
Less allowance for doubtful accounts	3,664,733	3,247,930
Total loans receivable, net	<u>\$ 8,701,625</u>	<u>\$ 10,380,040</u>
Less: current portion	1,624,939	1,824,938
TOTAL LOANS RECEIVABLE OUTSTANDING, NONCURRENT	<u><u>\$ 7,076,686</u></u>	<u><u>\$ 8,555,102</u></u>

Pledges receivable:

Pledges receivable represent unconditional promises to give from third party donors. Pledges for permanent endowments do not meet eligibility requirements, as defined by GASB Statement No. 33, until the related gift is received. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

The composition of pledges receivable at September 30, 2022 and 2021 is summarized in the following table.

	<u>2022</u>	<u>2021</u>
Operations	\$ 36,420,624	\$ 35,236,666
Capital	16,478,105	7,478,690
Total gift pledges	<u>\$ 52,898,729</u>	<u>\$ 42,715,356</u>
Less: current portion	9,587,255	8,610,396
TOTAL GIFT PLEDGES, NONCURRENT	<u><u>\$ 43,311,474</u></u>	<u><u>\$ 34,104,960</u></u>

(6) Capital Assets

Capital assets as of September 30, 2022 and 2021 are summarized as follows:

	BEGINNING BALANCE	ADDITIONS	SALES/ RETIREMENTS/ TRANSFERS	ENDING BALANCE
	October 1, 2021			September 30, 2022
UNIVERSITY AND BLENDED COMPONENT UNITS				
Capital assets not being depreciated				
Land	\$ 87,061,419	\$ —	\$ (505,611)	\$ 86,555,808
Construction in progress	28,844,822	62,812,125	(9,338,905)	82,318,042
	115,906,241	62,812,125	(9,844,516)	168,873,850
Capital assets being depreciated				
Land Improvements	62,660,947	560,531	—	63,221,478
Buildings	1,841,750,043	40,841,664	(28,152,322)	1,854,439,385
Fixed Equipment Systems	89,926,623	827,980	—	90,754,603
Equipment	414,215,557	28,121,591	(8,066,975)	434,270,173
Library Materials	142,395,957	10,770,391	—	153,166,348
Right Of Use Assets	61,778,267	12,465,088	(90,144)	74,153,211
	2,612,727,394	93,587,245	(36,309,441)	2,670,005,198
Total Capital Assets	2,728,633,635	156,399,370	(46,153,957)	2,838,879,048
Less: Accumulated Depreciation	1,501,950,370	92,335,071	(15,869,713)	1,578,415,728
Total Net Capital Assets	\$ 1,226,683,265	\$ 64,064,299	\$ (30,284,244)	\$ 1,260,463,320
UNIVERSITY HOSPITAL				
Capital assets not being depreciated				
Land	\$ 20,813,545	\$ —	\$ —	\$ 20,813,545
Construction in progress	17,834,349	21,192,596	(4,661,044)	34,365,901
	38,647,894	21,192,596	(4,661,044)	55,179,446
Capital assets being depreciated				
Land Improvements	705,439	1,487,257	—	2,192,696
Buildings	993,041,519	14,065,474	—	1,007,106,993
Fixed Equipment Systems	10,217,842	—	—	10,217,842
Equipment	629,036,807	37,427,798	(17,905,118)	648,559,487
Right Of Use Assets	65,827,477	6,743,390	—	72,570,867
	1,698,829,084	59,723,919	(17,905,118)	1,740,647,885
Total Capital Assets	1,737,476,978	80,916,515	(22,566,162)	1,795,827,331
Less: Accumulated Depreciation	1,067,617,219	87,695,333	(17,666,237)	1,137,646,315
Total Net Capital Assets	\$ 669,859,759	\$ (6,778,818)	\$ (4,899,925)	\$ 658,181,016
TOTAL UAB				
Capital assets not being depreciated				
Land	\$ 107,874,964	\$ —	\$ (505,611)	\$ 107,369,353
Construction in progress	46,679,171	84,004,721	(13,999,949)	116,683,943
	154,554,135	84,004,721	(14,505,560)	224,053,296
Capital assets being depreciated				
Land Improvements	63,366,386	2,047,788	—	65,414,174
Buildings	2,834,791,562	54,907,138	(28,152,322)	2,861,546,378
Fixed Equipment Systems	100,144,465	827,980	—	100,972,445
Equipment	1,043,252,364	65,549,389	(25,972,093)	1,082,829,660
Library Materials	142,395,957	10,770,391	—	153,166,348
Right Of Use Assets	127,605,744	19,208,478	(90,144)	146,724,078
	4,311,556,478	153,311,164	(54,214,559)	4,410,653,083
Total Capital Assets	4,466,110,613	237,315,885	(68,720,119)	4,634,706,379
Less: Accumulated Depreciation	2,569,567,589	180,030,404	(33,535,950)	2,716,062,043
TOTAL NET CAPITAL ASSETS	\$ 1,896,543,024	\$ 57,285,481	\$ (35,184,169)	\$ 1,918,644,336

	BEGINNING BALANCE	ADDITIONS	SALES/ RETIREMENTS/ TRANSFERS	ENDING BALANCE
	October 1, 2020			September 30, 2021
UNIVERSITY AND BLENDED COMPONENT UNITS				
Capital assets not being depreciated				
Land	\$ 87,075,169	\$ —	\$ (13,750)	\$ 87,061,419
Construction in progress	30,327,101	21,054,258	(22,536,537)	28,844,822
	117,402,270	21,054,258	(22,550,287)	115,906,241
Capital assets being depreciated				
Land Improvements	61,582,590	1,078,357	—	62,660,947
Buildings	1,802,926,979	49,165,597	(10,342,533)	1,841,750,043
Fixed Equipment Systems	89,398,978	527,645	—	89,926,623
Equipment	393,974,360	26,710,865	(6,469,668)	414,215,557
Library Materials	133,503,852	8,892,105	—	142,395,957
Right Of Use Assets	28,952,879	32,825,388	—	61,778,267
	2,510,339,638	119,199,957	(16,812,201)	2,612,727,394
Total Capital Assets	2,627,741,908	140,254,215	(39,362,488)	2,728,633,635
Less: Accumulated Depreciation	1,425,716,711	90,274,715	(14,041,056)	1,501,950,370
Total Net Capital Assets	\$ 1,202,025,197	\$ 49,979,500	\$ (25,321,432)	\$ 1,226,683,265
UNIVERSITY HOSPITAL				
Capital assets not being depreciated				
Land	\$ 20,813,545	\$ —	\$ —	\$ 20,813,545
Construction in progress	14,170,963	11,883,702	(8,220,316)	17,834,349
	34,984,508	11,883,702	(8,220,316)	38,647,894
Capital assets being depreciated				
Land Improvements	656,874	48,565	—	705,439
Buildings	982,792,320	14,314,104	(4,064,905)	993,041,519
Fixed Equipment Systems	10,217,842	—	—	10,217,842
Equipment	576,012,153	65,143,192	(12,118,538)	629,036,807
Right Of Use Assets	56,057,742	9,769,735	—	65,827,477
	1,625,736,931	89,275,596	(16,183,443)	1,698,829,084
Total Capital Assets	1,660,721,439	101,159,298	(24,403,759)	1,737,476,978
Less: Accumulated Depreciation	993,505,604	85,483,135	(11,371,520)	1,067,617,219
Total Net Capital Assets	\$ 667,215,835	\$ 15,676,163	\$ (13,032,239)	\$ 669,859,759
TOTAL UAB				
Capital assets not being depreciated				
Land	\$ 107,888,714	\$ —	\$ (13,750)	\$ 107,874,964
Construction in progress	44,498,064	32,937,960	(30,756,853)	46,679,171
	152,386,778	32,937,960	(30,770,603)	154,554,135
Capital assets being depreciated				
Land Improvements	62,239,464	1,126,922	—	63,366,386
Buildings	2,785,719,299	63,479,701	(14,407,438)	2,834,791,562
Fixed Equipment Systems	99,616,820	527,645	—	100,144,465
Equipment	969,986,513	91,854,057	(18,588,206)	1,043,252,364
Library Materials	133,503,852	8,892,105	—	142,395,957
Right Of Use Assets	85,010,621	42,595,123	—	127,605,744
	4,136,076,569	208,475,553	(32,995,644)	4,311,556,478
Total Capital Assets	4,288,463,347	241,413,513	(63,766,247)	4,466,110,613
Less: Accumulated Depreciation	2,419,222,315	175,757,850	(25,412,576)	2,569,567,589
TOTAL NET CAPITAL ASSETS	\$ 1,869,241,032	\$ 65,655,663	\$ (38,353,671)	\$ 1,896,543,024

A summary of right of use asset by major classes as of September 30, 2022 and 2021, is as follows:

	July 14, 1905	July 13, 1905
Land	\$ 593,302	\$ 714,883
Building	94,814,426	96,281,792
Equipment	10,676,869	11,383,723
Vehicle	9,508	1,111
	<u>106,094,105</u>	<u>108,381,509</u>

(7) Long-Term Debt

Long-term debt activity for the years ended September 30, 2022 and 2021 is summarized as follows:

	BEGINNING BALANCE	NEW DEBT	PRINCIPAL REPAYMENT	ENDING BALANCE	CURRENT PORTION
	October 1, 2021			September 30, 2022	
UNIVERSITY					
Direct Borrowings and Direct Placement Other					
Leases Payable, 0.38% to 5.39% due monthly through 2045	\$ 52,916,757	\$ 12,763,869	\$ 10,213,401	\$ 55,467,225	\$ 8,441,040
Note Payable, 2.7% due annually from 2023 through 2044	\$ —	\$ 80,250,000	\$ —	\$ 80,250,000	\$ 1,495,000
General Receipts Bonds					
Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2025	8,185,000	—	8,185,000	—	—
Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2025	5,505,000	—	5,505,000	—	—
Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044	72,595,000	—	61,700,000	10,895,000	3,480,000
Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2030	24,040,000	—	3,270,000	20,770,000	3,325,000
Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2024	7,130,000	—	2,330,000	4,800,000	2,375,000
Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044	78,325,000	—	75,855,000	2,470,000	—
Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028	18,890,000	—	3,005,000	15,885,000	3,160,000
Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027	21,195,000	—	3,365,000	17,830,000	3,430,000
Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044	95,585,000	—	—	95,585,000	—
Birmingham General Revenue Bonds Series 2019A, 4.0% to 5.0% due annually from 2022 through 2030	24,775,000	—	1,135,000	23,640,000	1,330,000
Birmingham General Revenue Bonds Series 2019B, 3.0% to 5.0% due annually from 2031 through 2049	145,940,000	—	—	145,940,000	—
Birmingham General Revenue Bonds Series 2019C, 3.0% to 5.0% due annually from 2021 through 2041	38,495,000	—	1,410,000	37,085,000	1,500,000
Birmingham General Revenue Bonds Series 2019D, 2.15% to 4.0% due annually from 2021 through 2041	35,530,000	—	205,000	35,325,000	210,000
Birmingham General Revenue Bonds Series 2022A, 3.0% to 5.0% due annually from 2023 through 2052	—	162,700,000	—	162,700,000	1,480,000
Birmingham General Revenue Bonds Series 2022B, 5.0% due annually from 2023 through 2025	—	9,585,000	—	9,585,000	3,560,000
Birmingham General Revenue Bonds Series 2022C, 2.15% due annually 2023 through 2044	—	58,960,000	—	58,960,000	—
	<u>\$ 629,106,757</u>	<u>\$ 324,258,869</u>	<u>\$ 176,178,401</u>	<u>\$ 777,187,225</u>	<u>\$ 33,786,040</u>
Less (Plus): unamortized bond discount (premium)				(31,816,458)	—
TOTAL UNIVERSITY DEBT				<u>\$ 809,003,683</u>	<u>\$ 33,786,040</u>

	Balance October 1, 2021	New Debt	Principal Repayment	Balance September 30, 2022	Current Portion
UNIVERSITY HOSPITAL					
Direct Borrowings and Direct Placement Other					
Lease Payable, 2.25% to 4.0% due monthly through 2046	\$ 59,498,764	\$ 6,743,390	\$ 10,595,305	\$ 55,646,849	\$ 11,143,684
Note payable UAB Medical Enterprise, 3.0% to 5.0% due annually through 2048	91,995,143	—	1,464,525	\$ 90,530,618	1,461,564
General Receipts Bonds					
Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027	9,226,000	—	1,437,000	\$ 7,789,000	1,476,000
UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually through 2022	11,340,000	—	11,340,000	\$ —	—
UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due annually from 2023 through 2041	302,530,000	—	—	\$ 302,530,000	8,800,000
UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027	18,385,000	—	—	\$ 18,385,000	—
UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042	44,810,000	—	—	\$ 44,810,000	—
	\$ 537,784,907	\$ 6,743,390	\$ 24,836,830	\$ 519,691,467	\$ 22,881,248
Less (Plus): unamortized bond discount (premium)				(20,425,713)	—
TOTAL UNIVERSITY HOSPITAL DEBT				\$ 540,117,180	\$ 22,881,248
TOTAL UAB	\$1,166,891,664	\$ 331,002,259	\$ 201,015,231	\$1,296,878,692	\$ 56,667,288
Less (Plus): unamortized bond discount (premium)				(52,242,171)	—
TOTAL UAB DEBT				\$1,349,120,863	\$ 56,667,288

	BEGINNING BALANCE	NEW DEBT	PRINCIPAL REPAYMENT	ENDING BALANCE	CURRENT PORTION
	October 1, 2020			September 30, 2021	
UNIVERSITY					
Direct Borrowings and Direct Placement Other					
Leases Payable, 0.38% to 5.39% due monthly through 2045	\$ 29,247,212	\$ 32,925,644	\$ 9,256,099	\$ 52,916,757	\$ 9,074,464
General Receipts Bonds					
Birmingham General Revenue Bonds Series 2005A, 3.0% to 5.0% due annually through 2021	3,390,000	—	3,390,000	—	—
Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2025	10,080,000	—	1,895,000	8,185,000	1,950,000
Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2025	7,150,000	—	1,645,000	5,505,000	1,700,000
Birmingham General Revenue Bonds Series 2013A-1, 1.1% due annually through 2021	3,280,000	—	3,280,000	—	—
Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044	72,595,000	—	—	72,595,000	3,320,000
Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2030	27,245,000	—	3,205,000	24,040,000	3,270,000
Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2024	9,415,000	—	2,285,000	7,130,000	2,330,000
Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044	78,325,000	—	—	78,325,000	—
Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028	21,755,000	—	2,865,000	18,890,000	3,005,000
Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027	24,495,000	—	3,300,000	21,195,000	3,365,000
Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044	95,585,000	—	—	95,585,000	—
Birmingham General Revenue Bonds Series 2019A, 4.0% to 5.0% due annually from 2022 through 2030	24,775,000	—	—	24,775,000	1,135,000
Birmingham General Revenue Bonds Series 2019B, 3.0% to 5.0% due annually from 2031 through 2049	145,940,000	—	—	145,940,000	—
Birmingham General Revenue Bonds Series 2019C, 3.0% to 5.0% due annually from 2021 through 2041	39,820,000	—	1,325,000	38,495,000	1,410,000
Birmingham General Revenue Bonds Series 2019D, 2.15% to 4.0% due annually from 2021 through 2041	\$ 35,725,000	—	195,000	35,530,000	205,000
	\$ 628,822,212	\$ 32,925,644	\$ 32,641,099	\$ 629,106,757	\$ 30,764,464
Less (Plus): unamortized bond discount (premium)				(23,014,875)	—
TOTAL UNIVERSITY DEBT				\$ 652,121,632	\$ 30,764,464

	Balance October 1, 2020	New Debt	Principal Repayment	Balance September 30, 2021	Current Portion
UNIVERSITY HOSPITAL					
Direct Borrowings and Direct Placement Other					
Lease Payable, 2.25% to 4.0% due monthly through 2046	\$ 59,031,376	\$ 9,769,735	\$ 9,302,347	59,498,764	\$ 9,579,424
Note payable UAB Medicine Enterprise, 3.0% to 5.0% due annually through 2048	75,754,420	17,654,000	1,413,277	91,995,143	1,464,525
General Receipts Bonds					
Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027	10,626,000	—	1,400,000	9,226,000	1,437,000
UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually through 2022	22,545,000	—	11,205,000	11,340,000	11,340,000
UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due annually from 2023 through 2041	302,530,000	—	—	302,530,000	—
UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027	18,385,000	—	—	18,385,000	—
UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042	44,810,000	—	—	44,810,000	—
	\$ 533,681,796	\$ 27,423,735	\$ 23,320,624	\$ 537,784,907	\$ 23,820,949
Less (Plus): unamortized bond discount (premium)				(21,861,997)	—
TOTAL UNIVERSITY HOSPITAL DEBT				\$ 559,646,904	\$ 23,820,949
TOTAL UAB	\$ 1,162,504,008	\$ 60,349,379	\$ 55,961,723	\$ 1,166,891,664	\$ 54,585,413
Less (Plus): unamortized bond discount (premium)				(44,876,872)	—
TOTAL UAB DEBT				\$ 1,211,768,536	\$ 54,585,413

Maturities and interest on Direct Borrowings and Direct Placement Other and General Receipts Bonds for the next five years and in subsequent five-year incremental periods are presented in the table below:

Direct Borrowings and Direct Placement Other

Year	UNIVERSITY			UNIVERSITY HOSPITAL			TOTAL		
	Principal	Interest	Total	Principal	Interest	Total	Principal	Interest	Total
2023	\$ 9,872,179	\$ 3,907,419	\$ 13,779,598	\$ 12,605,252	\$ 4,326,877	\$ 16,932,129	\$ 22,477,431	\$ 8,234,296	\$ 30,711,727
2024	6,955,386	3,114,743	10,070,129	11,469,199	3,990,599	15,459,798	18,424,585	7,105,342	25,529,927
2025	5,785,585	2,804,573	8,590,158	10,791,996	3,669,558	14,461,554	16,577,581	6,474,131	23,051,712
2026	8,101,432	2,599,507	10,700,939	10,267,880	3,376,525	13,644,405	18,369,312	5,976,032	24,345,344
2027	7,229,276	2,382,474	9,611,750	9,937,726	3,098,213	13,035,939	17,167,002	5,480,687	22,647,689
2028-2032	25,156,990	9,985,808	35,142,798	24,592,903	12,760,643	37,353,546	49,749,893	22,746,451	72,496,344
2033-2037	26,480,690	7,060,153	33,540,843	17,301,210	10,254,367	27,555,577	43,781,900	17,314,520	61,096,420
2038-2042	30,533,591	3,749,571	34,283,162	19,956,418	7,230,200	27,186,618	50,490,009	10,979,771	61,469,780
2043-2047	15,602,096	480,098	16,082,194	23,707,940	3,466,334	27,174,274	39,310,036	3,946,432	43,256,468
2048-2052	—	—	—	5,546,943	172,550	5,719,493	5,546,943	172,550	5,719,493
TOTAL	\$ 135,717,225	\$ 36,084,346	\$ 171,801,571	\$ 146,177,467	\$ 52,345,866	\$ 198,523,333	\$ 281,894,692	\$ 88,430,212	\$ 370,324,904

General Receipts Bonds

Year	UNIVERSITY			UNIVERSITY HOSPITAL			TOTAL		
	Principal	Interest	Total	Principal	Interest	Total	Principal	Interest	Total
2023	\$ 23,850,000	\$ 22,338,154	\$ 46,188,154	\$ 10,276,000	\$ 15,623,290	\$ 25,899,290	\$ 34,126,000	\$ 37,961,444	\$ 72,087,444
2024	25,210,000	21,599,998	46,809,998	10,711,000	15,145,280	25,856,280	35,921,000	36,745,278	72,666,278
2025	26,500,000	20,674,384	47,174,384	11,347,000	14,636,516	25,983,516	37,847,000	35,310,900	73,157,900
2026	24,125,000	19,800,525	43,925,525	13,739,000	14,250,402	27,989,402	37,864,000	34,050,927	71,914,927
2027	24,655,000	19,015,382	43,670,382	14,781,000	13,801,196	28,582,196	39,436,000	32,816,578	72,252,578
2028-2032	114,420,000	82,079,648	196,499,648	83,495,000	59,274,325	142,769,325	197,915,000	141,353,973	339,268,973
2033-2037	116,120,000	58,961,244	175,081,244	108,310,000	39,260,263	147,570,263	224,430,000	98,221,507	322,651,507
2038-2042	122,085,000	37,340,413	159,425,413	120,855,000	14,193,138	135,048,138	242,940,000	51,533,551	294,473,551
2043-2047	100,560,000	17,795,393	118,355,393	—	—	—	100,560,000	17,795,393	118,355,393
2048-2052	63,945,000	3,830,250	67,775,250	—	—	—	63,945,000	3,830,250	67,775,250
TOTAL	\$ 641,470,000	\$ 303,435,391	\$ 944,905,391	\$ 373,514,000	\$ 186,184,410	\$ 559,698,410	\$ 1,014,984,000	\$ 489,619,801	\$ 1,504,603,801

Pledged revenues for 2022 and 2021, as defined by the Series 2012A Hospital Revenue Trust Indenture, are as follows:

UNIVERSITY HOSPITAL BONDS	2022	2021
Total pledged revenues	\$ 2,670,517,272	\$ 2,490,817,657

Pledged revenues for 2022 and 2021, as defined by the Series 2005A, 2010A, 2010B, 2010C, 2013A, 2013B, 2013C, 2013D, 2015A, 2016A, 2016B, 2019A, 2019B, 2022A and 2022B, General Revenue Trust Indentures, are as follows:

UNIVERSITY BONDS	2022	2021
Tuition fees	\$ 337,336,681	\$ 336,412,781
Indirect cost recovery	130,043,971	112,448,434
Sales and service of educational activities	66,563,264	67,666,602
Auxiliary sales and service	57,796,141	36,611,584
Endowment and investment income	45,279,211	33,944,327
Other sources	20,772,484	35,235,066
TOTAL PLEDGED REVENUES	\$ 657,791,752	\$ 622,318,794

The University defeased certain indebtedness during fiscal year 2022 with the 2022 Series B, C and D bond issuance. For this defeasance, funds were deposited in escrow trust accounts sufficient to provide for the subsequent payment of principal and interest on the defeased indebtedness. Under the trust agreements, funds deposited in the trust accounts were invested in obligations of the U.S. Government. The University estimates that the amounts on deposit will be sufficient to satisfy the debt service requirements on the defeased indebtedness and that the defeasance will result in lower overall debt service payments to the University. Should the amounts on deposit not be sufficient to retire the defeased indebtedness upon maturity, the University would be responsible to satisfy the shortfall. The University remains legally obligated for the repayment of the defeased indebtedness. Neither the assets of the trust accounts nor

the defeased indebtedness are included in the accompanying statements of net position. The principal outstanding on the 2022 defeased indebtedness at September 30, 2022 was approximately \$148.8 million.

In February 2022, the University issued \$80.3 million in Series 2022D General Revenue Bonds. The Bond is being issued to evidence a taxable loan made to the Board by Regions Commercial Equipment Finance, LLC, as lender and the holder of the bond. The bond pay interest rate of 2.70%, with principal due annually through October 1, 2043. As part of the Series 2022D bond agreement, the University has the option to redeem the Series 20 22D bonds in whole during a period beginning July 3, 2023 and ending on October 1, 2023. The redemption of the Series 2022D bonds would be accomplished through an exchange of the Series 2022D bonds for a forward delivery bond with an initial principal amount equal to the principal amount of the Series 2022D bonds being redeemed plus payment of any accrued interest on those same bonds. The proceeds of this offering is being used for the purposes of advance refunding Series 2013D2 General Revenue Bonds; and paying costs and expenses associated with this issue.

In March 2022, the University issued \$162.7 million and \$9.6 million in Series 2022A and Series 2022B General Revenue Bonds, respectively. The Series 2022A bonds consisted of \$101.2 million in serial bonds and \$61.5 million in term bonds. The bonds pay interest at varying rates of 3.0% to 5.0%, respectively. The Serial bonds have principal due annually through October 1, 2043. The term bonds principal due October 1, 2047 and October 1, 2051. The proceeds of these offering are being used to finance the cost of certain capital improvements to the facilities of UAB, for the purposes of advance refunding Series 2010A and 2010C General Revenue Bonds; and paying costs and expenses associated with this issue. These bonds were issued at a premium of \$11.7 million and \$0.5 million resulting in total proceeds of \$174.4 million and \$10.2 million respectively.

In July 2022, the University issued \$58.9 million in Series 2022C General Revenue Bonds. The bonds pay taxable interest rate of 2.76% or tax-exempt interest rate of 2.15%, with principal due annually through October 1, 2043. The proceeds of these offering are being used for the purposes of advance refunding Series 2013A2 General Revenue Bonds; and paying costs and expenses associated with this issue. The bonds were issued at a par resulting in total proceeds of \$58.9 million.

The undiscounted cash flows required to service principal and interest under the old bonds as of September 30, 2022, would have been \$213.4 million compared to undiscounted cash flow requirements of \$184.3 million under the new bonds. The economic gain to the University of the bond refinancing in fiscal year 2022 was calculated to be approximately \$21.6 million using an effective interest rate of approximately 2.2% applied to the old and new bond cash flow requirements.

The University defeased certain indebtedness during fiscal year 2020 with the 2019 Series C and D bond issuance. For this defeasance, funds were deposited in escrow trust accounts sufficient to provide for the subsequent payment of principal and interest on the defeased indebtedness. Under the trust agreements, funds deposited in the trust accounts were invested in obligations of the U.S. Government. The University estimates that the amounts on deposit will be sufficient to satisfy the debt service requirements on the defeased indebtedness and that the defeasance will result in lower overall debt service payments to the University. Should the amounts on deposit not be sufficient to retire the defeased indebtedness upon maturity, the University would be responsible to satisfy the shortfall. The University remains legally obligated for the repayment of the defeased indebtedness. Neither the assets of the trust accounts nor the defeased indebtedness are included in the accompanying statements of net position. There was no principal outstanding on the 2019 defeased indebtedness at September 30, 2021.

In November 2019, the University issued \$39.8 million and \$35.7 million in Series 2019C and Series 2019D General Revenue Bonds, respectively. The bonds pay interest at varying rates of 3.0% to 5.0% and 2.15% to 4.0%, respectively, with principal due annually through October 1, 2041. The proceeds of these offering are being used for the purposes of advance refunding Series 2010A, 2010B, and 2010C General Revenue Bonds; and paying costs and expenses associated with this issue. These bonds were issued at a premium of \$5.8 million resulting in total proceeds of \$81.4 million.

In June 2019, the University issued \$24.8 million in Series 2019A General Revenue Bonds. The bonds pay interest at a rate of 4.00% with principal due annually through October 1, 2029. In June 2019, the University issued \$145.9 million in Series 2019B General Revenue Bonds, \$75.1 million of which was in the form of Serial Bonds and \$71.9 million of which was in the form of Term Bonds. The bonds pay interest at varying rates of 3.0% to 5.0% with principal due annually through October 1, 2041 and October 1, 2048, respectively. The proceeds of both the Series 2019A and 2019B bonds will be used for the purposes of financing a portion of the cost of certain capital improvements to the UAB campus, as well as paying costs and expenses associated with this issue. These bonds were issued at a premium of \$16.4 million resulting in total cash received of \$187.1 million.

In June 2019, the UAB Medicine Finance Authority issued \$8.1 million in Series 2019A Revenue Bonds and \$103.3 million in Series 2019B Revenue Bonds, the proceeds of which were loaned to UAB Medicine Enterprise pursuant to Series 2019A and Series 2019B loan agreements. Concurrently, University Hospital entered into a loan agreement with UAB Medicine Enterprise for \$77 million of the 2019A and 2019B bond proceeds for the purpose of financing capital improvement projects. In January 2021, University Hospital borrowed an additional \$17.7 million of the 2019A and 2019B bond proceeds from UAB Medicine Enterprise. Of the total amount borrowed, \$42.5 million was distributed to University Hospital as of September 30, 2020 and September 30, 2021. As University Hospital is legally obligated to repay \$94.7 million and is currently paying principal and interest on this full amount, University Hospital has reflected the full \$94.7 million on its statement of net position as long-term debt and \$52.2 million as Due from affiliate on the statement of net position. University Hospital pays interest to UAB Medicine Enterprise on the entire amount, regardless of the amount outstanding. There are no financial covenants related to the loan between University Hospital and UAB Medicine Enterprise.

The UAB general revenue bonds and the Hospital Revenue Trust Indentures are subject to certain covenants with the most restrictive being those on the Hospital's 2012A series issuance. These covenants, among other things, require the University Hospital to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. UAB and the University Hospital are in compliance with all financial covenants as of September 30, 2022.

The UAB Medicine Financing Authority's Revenue Trust Indentures are also subject to certain covenants. These covenants require the obligated group to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. The obligated group is in compliance with all financial covenants as of September 30, 2022.

UAB has leases for land, buildings, vehicles, and equipment under agreements that extend through 2046. Some leases include one or more options to renew. Leases may also include options to terminate the leases. UAB measures the lease liability at the present value of payments expected to be made during the lease term. If the interest rate implicit in the lease cannot be readily determined, UAB uses an incremental borrowing rate to discount the lease payments, which is an estimate of the interest rate that would be charged for borrowing the lease payment amounts during the lease term.

(8) Self-Insurance

UAB manages risks related to medical malpractice, general liability, and employee health care through a combination of self-insurance, risk pooling arrangements, and commercial insurance coverage.

UAB's medical malpractice liability is managed by PLTF, a professional liability trust fund. PLTF functions as a risk-sharing vehicle for UAB and more than ten nongovernmental organizations. PLTF covers liabilities of the covered parties, including UAB, arising from reported claims, claims that are incurred but not reported, and future costs of handling these claims. The liabilities are generally based on present value actuarial valuations discounted at a rate of 2% in 2022 and 2021. The associated risks of claims are subject to aggregate limits, with excess liability coverage provided by independent insurers to protect participants against losses should a claim arise that exceeds PLTF coverage limits. Although UAB is the sponsor of PLTF, it is not the predominant participant in the fund.

The PLTF's policy committee establishes the premium rate of participants based on recommendations from consulting actuaries and considering the assumption of risk from the PLTF's date of inception. Premiums paid to the PLTF are provided by UAB, HSF, and other participants. In addition, certain legal and administrative services are provided to the PLTF by the University of Alabama System.

The PLTF agreement requires a flat \$15 million of all PLTF assets to be held in liquid assets. At September 30, 2022 and 2021, the liquid assets of the PLTF, as defined by the agreement, were in compliance with the agreement.

As discussed in Note 4, UAB accounts for its ownership of the PLTF under the equity method of accounting and it is not included in the table below.

General liability is subject to various claims and aggregate limits, with excess liability coverage provided by an independent insurer. General liability and employee health care claims and expenses are reported when it is probable that a loss has occurred and the amount of the loss can be reasonably estimated. Those losses include an estimate of claims that have been incurred but not reported and the future costs of handling claims. The liabilities are based on actuarial valuations and are reported at present value. The discount rate used for the general liability was 2% in both 2022 and 2021. Changes in the total self-insured liabilities for the years ended September 30, 2022 and 2021 are presented as follows for UAB:

SELF INSURED LIABILITIES

	<u>2022</u>	<u>2021</u>
Balance, beginning of year	\$ 3,548,183	\$ 7,765,760
Claims incurred and changes in estimates	\$ 96,302,841	\$ 78,523,589
Claim payments	\$ (92,907,360)	\$ (82,741,166)
BALANCE, END OF YEAR	\$ 6,943,664	\$ 3,548,183

(9) Employee Benefits

Eligible employees of the University and University Hospital participate in the mandatory Teachers' Retirement System of Alabama ("TRS"), a cost sharing, multiple-employer public retirement system designated as a defined benefit plan. In addition, eligible employees may elect to participate in a voluntary 403(b) defined contribution retirement plan. Teachers Insurance and Annuity Association ("TIAA") serves as the single recordkeeper and sole vendor for the plan.

Defined Benefit Plan - TRS

Plan Description. The TRS, a cost-sharing multiple-employer public employee retirement plan, was established as of September 15, 1939, pursuant to the Code of Alabama 1975, Title 16, Chapter 25 (Act 419 of the Legislature of 1939) for the purpose of providing retirement allowances and other specified benefits for qualified persons employed by State-supported educational institutions. The responsibility for the general administration and operation of the TRS is vested in its Board of Control which consists of 15 trustees. The plan is administered by the Retirement Systems of Alabama ("RSA"). The Code of Alabama 1975, Title 16, Chapter 25 grants the authority to establish and amend the benefit terms to the TRS Board of Control. The Plan issues a publicly available financial report that can be obtained at www.rsa-al.gov.

Benefits provided. State law establishes retirement benefits as well as death and disability benefits and any ad hoc increase in postretirement benefits for the TRS. Members of TRS are classified as either Tier 1 or Tier 2 plan members, contingent upon if their eligible service began prior to January 1, 2013.

Tier 1 members who retire after age 60 with 10 years or more of creditable service or with 25 years of service (regardless of age) are entitled to an annual retirement benefit, payable monthly for life unless there is a return to full-time employment with a TRS or Employees' Retirement System ("ERS") agency, or to temporary employment in excess of specified limits. Service and disability retirement benefits are based on a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under the formula method, Tier 1 members of the TRS are allowed 2.0125% of their average final compensation (highest 3 of the last 10 years) for each year of service.

Act 377 of the Legislature of 2012 established a new tier of benefits (Tier 2) for members hired on or after January 1, 2013. Tier 2 TRS members are eligible for retirement after age 62 with 10 years or more of creditable service and are entitled to an annual retirement benefit, payable monthly for life unless there is a return to full-time employment with a TRS or ERS agency, or to temporary employment in excess of specified limits. Service and disability retirement benefits are based on a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under the formula method, Tier 2 members of the TRS are allowed 1.65% of their average final compensation (highest 5 of the last 10 years) for each year of service up to 80% of their average final compensation. Members are eligible for disability retirement if they have 10 years of creditable service, are currently in-service, and determined by the RSA Medical Board to be permanently incapacitated from further performance of duty. Preretirement death benefits equal to the annual earnable compensation of the member as reported to the Plan for the preceding year ending June 30 are paid to a qualified beneficiary.

Contributions. Covered Tier 1 members of the TRS contributed 5% of earnable compensation to the TRS as required by statute until September 30, 2011. From October 1, 2011 to September 30, 2012, covered members of the TRS were required by statute to contribute 7.25% of earnable compensation. Effective October 1, 2012, covered members of the TRS are required by statute to contribute 7.50% of earnable compensation. Effective October 1, 2021, the covered Tier 2 members' contribution rate increased from 6% to 6.2% of earnable compensation to the TRS as required by statute. All regular employees of the University are members of the TRS with the exception of temporary employees. Contributions for covered employees are mandatory for both employee and employer.

Tier 2 covered members of the TRS contribute 6% of earnable compensation to the TRS as required by statute. Tier 2 certified law enforcement, correctional officers, and firefighters of the TRS are required by statute to contribute 7% of earnable compensation.

UAB's contractually required contribution rate for the year ended September 30, 2022 was 12.43% of annual pay for Tier 1 members and 11.32% of annual pay for Tier 2 members. UAB's contractually required contribution rate for the year ended September 30, 2021 was 12.36% of annual pay for Tier 1 members and 11.22% of annual pay for Tier 2 members.

These required contribution rates are a percent of annual payroll, actuarially determined as an amount that, when combined with member contributions, is expected to finance the costs of benefits earned by members during the year, with an additional amount to finance any unfunded accrued liability. The total contribution requirement for fiscal years 2022, 2021 and 2020 is as follows:

	2022	2021	2020
Employer Contributions	\$ 101,166,000	\$ 96,839,000	\$ 98,485,000
Employee Contributions	59,625,000	57,052,000	57,688,000
TOTAL CONTRIBUTIONS	\$ 160,791,000	\$ 153,891,000	\$ 156,173,000

Pensionable salaries and wages for covered employees participating in TRS were approximately \$1.02 billion during fiscal year 2022 and \$947.5 million during fiscal year 2021.

Pension Liabilities, Pension Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to Pensions. At September 30, 2022 and September 30, 2021, the financial statements of UAB reflected a liability of \$1.05 billion and \$1.41 billion, respectively, for its proportionate share of the collective net pension liability, as prescribed by GASB Standard No. 68, *Accounting and Financial Reporting for Pensions - An Amendment of GASB No. 27*. The collective net pension liability was measured as of September 30, 2021 and the total pension liability used to calculate the net pension liability was determined by an actuarial valuation as of September 30, 2020. UAB's proportion of the collective net pension liability was based on the employers' shares of contributions to the pension plan relative to the total employer contributions of all participating TRS employers. At September 30, 2021, UAB's proportion was 11.13%, which was a decrease of 0.29% from its proportion measured as of September 30, 2020. At September 30, 2020, UAB's proportion was 11.43%, which was an increase of 0.16% from its proportion measured as of September 30, 2019.

For the years ended September 30, 2022 and September 30, 2021, UAB recognized pension expense of \$64.4 million and \$132.5 million, respectively. At September 30, 2022 and 2021, UAB reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

2022	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 48,566,000	\$ 61,114,000
Changes of assumptions	110,107,000	—
Net difference between projected and actual earnings on pension plan investments	—	247,602,000
Changes in proportion and differences between Employer contributions and proportionate share of contributions	10,425,000	47,545,000
Employer contributions subsequent to the measurement date	101,166,000	—
TOTAL	\$ 270,264,000	\$ 356,261,000

2021	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 69,947,000	\$ 24,511,000
Changes of assumptions	14,700,000	—
Net difference between projected and actual earnings on pension plan investments	104,961,000	—
Changes in proportion and differences between Employer contributions and proportionate share of contributions	13,898,000	34,807,000
Employer contributions subsequent to the measurement date	96,839,000	—
TOTAL	\$ 300,345,000	\$ 59,318,000

\$101.2 million reported as deferred outflows of resources related to pensions resulting from UAB contributions subsequent to the measurement date will be recognized as a reduction of the net pension liability in the year ending September 30, 2023. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to pensions will be recognized in pension expense as follows:

Years ending September 30:		
2023	\$	(32,733,000)
2024		(29,273,000)
2025		(47,626,000)
2026		(77,531,000)
2027		—
Thereafter		—

Actuarial assumptions. The total pension liability as of September 30, 2021 was determined by an actuarial valuation as of September 30, 2020 using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.50%
Projected salary increases	3.25% - 5.00%
Investment rate of return*	7.45%
*Net of pension plan investment expense	

The actuarial assumptions used in the actuarial valuation as of September 30, 2020, were based on the results of an investigation of the economic and demographic experience for the TRS based upon participant data as of September 30, 2020. The Board of Control accepted and approved these changes in September 2021 which became effective the beginning of fiscal year 2021.

Mortality rates were based on the Pub-2010 teacher tables with the following adjustments, projected generationally using scale MP-2020 adjusted by 66-2/3% beginning with year 2019:

Group	Membership Table	Set Forward (+) / Set Back (1)	Adjustment to Rates
Service Retirees	Teacher Retiree - Below Median	Male: +2 Female: +2	Male: 108% ages < 63, 96% ages > 67, Phasing down 63-67 Female: 112% ages < 69, 98% ages > 74, Phasing down 69-74
Beneficiaries	Contingent Survivor - Below Median	Male: +2 Female: None	None
Disabled Retirees	Teacher Disability	Male: +8 Female: +3	None

The long-term expected rate of return on pension plan investments was determined using a log-normal distribution analysis in which best-estimate ranges of expected future real rates of return (expected returns, net of pension plan investment expense and inflation) are developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target asset allocation and best estimates of geometric real rates of return for each major asset class are as follows:

	Target Allocation	Long-Term Expected Rate of Return*
Fixed Income	15.00 %	2.80 %
U.S. Large Stocks	32.00 %	8.00 %
U.S. Mid Stocks	9.00 %	10.00 %
U.S. Small Stocks	4.00 %	11.00 %
International Developed Market Stocks	12.00 %	9.50 %
International Emerging Market Stocks	3.00 %	11.00 %
Alternatives	10.00 %	9.00 %
Real Estate	10.00 %	6.50 %
Cash	5.00 %	2.50 %
TOTAL	100.00 %	

*Includes assumed rate of inflation of 2.00%

Discount rate. The discount rate used to measure the total pension liability was 7.45%. The discount rate used to measure the total pension liability at the prior measurement date was 7.70%. The projection of cash flows used to determine the discount rate assumed that plan member contributions will be made at the current contribution rate and that the employer contributions will be made at rates equal to the difference between actuarially determined contribution rates and the member rate. Based on those assumptions, components of the pension plan's fiduciary net position were projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on pension plan investments was applied to all periods of projected benefit payments to determine the total pension liability.

Sensitivity of UAB's proportionate share of the net pension liability to changes in the discount rate. The following table reflects UAB's proportionate share of the net pension liability, as prescribed by GASB 68, calculated using the discount rate of 7.45%, as well as what UAB's proportionate share of the net pension liability would be if it were calculated using a discount rate that is 1-percentage-point lower (6.45%) or 1-percentage-point higher (8.45%) than the current rate:

	1% Decrease	Current Rate	1% Increase
UAB's proportionate share of collective net pension liability	\$ 1,543,953,000	\$ 1,048,949,000	\$ 632,029,000

Pension plan fiduciary net position. Detailed information about the pension plan's fiduciary net position is available in the separately issued RSA Comprehensive Annual Report for the fiscal year ended September 30, 2021. The supporting actuarial information is included in the GASB Statement No. 67 Report for the TRS prepared as of September 30, 2021. The auditor's report on the Schedule of Employer Allocation and Pension Amounts by Employer and accompanying note detail by employer and in aggregate information needed to comply with GASB 68. The additional financial and actuarial information is available at <http://www.rsa-al.gov/index.php/employers/financial-reports/gasb-68-reports/>

Defined Contribution Plans

As previously noted, some employees also participate in a voluntary UA System 403(b) defined contribution plan. In defined contribution plans, benefits depend solely on amounts contributed plus investment earnings. All full-time regular monthly employees are eligible to participate from the date of employment. UAB contributes a matching amount of up to 5% of total salaries for participating employees. UAB's contribution is funded as it accrues and, along with that of the employee, is immediately and fully vested. The contributions for fiscal years 2022 and 2021, excluding employee amounts not eligible for matching, were approximately \$77.4 million and \$68.9 million, respectively. This includes employee contributions eligible for matching of \$38.7 million and \$34.5 million, and UAB contributions of \$38.7 million and \$34.5 million, in 2022 and 2021, respectively.

The LLC sponsors a voluntary 403(b) retirement plan for eligible employees. The 403(b) plan is a voluntary, defined-contribution, tax-deferred as well as Roth after tax plan governed by Internal Revenue Code 403(b). TIAA is the administrator for the voluntary retirement program. Employees are vested after 3 years of employment. Eligibility for matching is for all full-time and part-time regular, twelve-hour shift, and weekend staff employees.

The University, the University Hospital, LLC and UABRF total salaries and wages for fiscal years 2022 and 2021 were approximately \$1.55 billion and \$1.40 billion, respectively. Total salaries and wages during fiscal years 2022 and 2021 for covered employees participating in TRS were approximately \$862.1 million and \$815.5 million, respectively. Total

salaries and wages during fiscal years 2022 and 2021 for covered employees participating in the 403(b) Plan were approximately \$869.9 million and \$760.7 million, respectively.

Triton sponsors a 401(k) plan covering substantially all employees who have completed at least six months of service. Information regarding this benefit is presented in Triton's annual report.

Compensated Absences

Certain UAB employees accumulate vacation and sick leave at varying rates depending upon their years of continuous service and their payroll classification, subject to maximum limitations. Upon termination of employment, employees are paid unused accrued vacation at their regular rate of pay up to a designated maximum number of days.

In accordance with GASB Statement No. 16, *Accounting for Compensated Absences*, the financial statements include accruals of approximately \$85 million and \$84 million as of September 30, 2022 and 2021, respectively, for accrued vacation pay and salary-related payments associated with vacation pay. There is no such accrual recognized for sick leave benefits because there is no terminal cash benefit available to employees for accumulated sick leave.

(10) Post-Employment Benefits

Post-employment health care benefits ("OPEB") are offered to all employees who officially retire from UAB through the Alabama Retired Education Employees Health Care Trust Plan with TRS or certain retired employees may elect to continue to participate in UAB's group health plan until they are eligible for Medicare by paying the full cost of the plan premium. TRS offers health care benefits through a cost-sharing multiple-employer defined benefit health care plan administered by the Public Education Employee Health Insurance Plan ("PEEHIP"). Retired employees age sixty-five or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB's health care plan becomes the secondary insurer. Despite the availability of the UAB plan, most retirees elect to participate in the PEEHIP with TRS, in which case the retirees pay a portion of the PEEHIP premium, with UAB paying an allocation towards the cost of retiree coverage.

Certain retirees may also elect to continue their basic term life insurance coverage and accidental death and dismemberment insurance up to certain maximum amounts. The retirees pay the full amount of the premiums in such cases. Retirees are not eligible for tuition assistance benefits themselves. However, their unmarried dependent children may qualify in some cases.

PEEHIP

Plan description. The Alabama Retired Education Employees' Health Care Trust (the "Trust") is a cost-sharing multiple-employer defined benefit post-employment healthcare plan that administers healthcare benefits to the retirees of participating state and local educational institutions. The Trust was established under the Alabama Retiree Health Care Funding Act of 2007 which authorized and directed the Public Education Employees' Health Insurance Board ("PEEHI Board") to create an irrevocable trust to fund post-employment healthcare benefits to retirees participating in PEEHIP. Active and retiree health insurance benefits are paid through the PEEHIP. In accordance with GASB, the Trust is considered a component unit of the State of Alabama (the "State") and is included in the State's Annual Financial Report.

The PEEHIP was established in 1983 pursuant to the provisions of the *Code of Alabama 1975, Title 16, Chapter 25A (Act 83-455)* to provide a uniform plan of health insurance for active and retired employees of state and local educational institutions which provide instruction at any combination of grades K-14 (collectively, eligible employees), and to provide a method for funding the benefits related to the plan. The four-year universities participate in the plan with respect to their retired employees, and are eligible and may elect to participate in the plan with respect to their active employees. Responsibility for the establishment of the health insurance plan and its general administration and operations is vested in the PEEHI Board. The PEEHI Board is a corporate body for purposes of management of the health insurance plan. The *Code of Alabama 1975, Section 16-25A-4* provides the PEEHI Board with the authority to amend the benefit provisions in order to provide reasonable assurance of stability in future years for the plan. All assets of the PEEHIP are held in trust for the payment of health insurance benefits. The Teachers' Retirement System of Alabama ("TRS") has been appointed as the administrator of the PEEHIP and, consequently, serves as the administrator of the Trust.

Benefits provided. PEEHIP offers a basic hospital medical plan to active members and non-Medicare eligible retirees. Benefits include inpatient hospitalization for a maximum of 365 days without a dollar limit, inpatient rehabilitation, outpatient care, physician services, and prescription drugs.

Active employees and non-Medicare eligible retirees who do not have Medicare eligible dependents can enroll in a health maintenance organization (HMO) in lieu of the basic hospital medical plan. The HMO includes hospital medical benefits, dental benefits, vision benefits, and an extensive formulary. However, participants in the HMO are required to receive care from a participating physician in the HMO plan.

The PEEHIP offers four optional plans (Hospital Indemnity, Cancer, Dental, and Vision) that may be selected in addition to or in lieu of the basic hospital medical plan or HMO. The Hospital Indemnity Plan provides a per-day benefit for hospital confinement, maternity, intensive care, cancer, and convalescent care. The Cancer Plan covers cancer disease only and benefits are provided regardless of other insurance. Coverage includes a per-day benefit for each hospital confinement related to cancer. The Dental Plan covers diagnostic and preventative services, as well as basic and major dental services. Diagnostic and preventative services include oral examinations, teeth cleaning, x-rays, and emergency office visits. Basic and major services include fillings, general aesthetics, oral surgery not covered under a Group Medical Program, periodontics, endodontics, dentures, bridgework, and crowns. Dental services are subject to a maximum of \$1,250 per year for individual coverage and \$1,000 per person per year for family coverage. The Vision Plan covers annual eye examinations, eye glasses, and contact lens prescriptions.

PEEHIP members may opt to elect the PEEHIP Supplemental Plan as their hospital medical coverage in lieu of the PEEHIP Hospital Medical Plan. The PEEHIP Supplemental Plan provides secondary benefits to the member's primary plan provided by another employer. Only active and non-Medicare retiree members and dependents are eligible for the PEEHIP Supplemental Plan. There is no premium required for this plan, and the plan covers most out-of-pocket expenses not covered by the primary plan. The plan cannot be used as a supplement to Medicare, the PEEHIP Hospital Medical Plan, or the State or Local Governmental Plans administered by the State Employees' Insurance Board (the "SEIB").

Effective January 1, 2020, Medicare eligible members and Medicare eligible dependents who are covered on a retiree contract were enrolled in the Humana Group Medicare Advantage plan for PEEHIP. The plan is fully insured, and members are able to have all of their Medicare Part A (hospital insurance), Part B (medical insurance), and Part D (prescription drug coverage) in one convenient plan. Retirees can continue to see their same providers with no interruption and see any doctor who accepts Medicare on a national basis. Members have the same benefits in and out-of-network and there is no additional retiree cost share if a retiree uses an out-of-network provider and no balance billing from the provider.

Contributions. The *Code of Alabama 1975, Section 16-25A-8* and the *Code of Alabama 1975, Section, 16-25A-8.1* provide the Board with the authority to set the contribution requirements for plan members and the authority to set the employer contribution requirements for each required class, respectively. Additionally, the Board is required to certify to the Governor and the Legislature, the amount, as a monthly premium per active employee, necessary to fund the coverage of active and retired member benefits for the following fiscal year. The Legislature then sets the premium rate in the annual appropriation bill.

For employees who retired after September 30, 2005, but before January 1, 2012, the employer contribution of the health insurance premium set forth by the Board for each retiree class is reduced by 2% for each year of service less than 25 and increased by 2% percent for each year of service over 25 subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree.

For employees who retired after December 31, 2011, the employer contribution to the health insurance premium set forth by the Board for each retiree class is reduced by 4% for each year of service less than 25 and increased by 2% for each year over 25, subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree. For employees who retired after December 31, 2011, who are not covered by Medicare, regardless of years of service, the employer contribution to the health insurance premium set forth by the Board for each retiree class is reduced by a percentage equal to 1% multiplied by the difference between the Medicare entitlement age and the age of the employee at the time of retirement as determined by the Board. This reduction in the employer contribution ceases upon notification to the Board of the attainment of Medicare coverage.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2022 and 2021, the financial statements of UAB reflected a liability of \$546.6 million and \$680.4 million, respectively for its proportionate share of the net OPEB liability, as prescribed by GASB Statement No. 75, *Accounting and Financial Reporting for Postemployment Benefits Other Than Pensions*. The net OPEB liability was measured as of September 30, 2021 and the total OPEB liability used to calculate the net OPEB liability was determined by an actuarial valuation as of September 30, 2020. UAB's proportion of the net OPEB liability was based on a projection of UAB's share of contributions to the OPEB plan relative to the projected contributions of all participating

PEEHIP employers, actuarially determined. At September 30, 2021, UAB's proportion was 10.58%, which was an increase of 0.09% from its proportion measured as of September 30, 2020.

For the years ended September 30, 2022 and 2021, UAB recognized an OPEB expense of \$12.5 million and \$26.2 million, respectively with no special funding situations. At September 30, 2022 and 2021, UAB reported deferred outflows of resources and deferred inflows of resources related to the PEEHIP plan from the following sources:

2022	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 12,931,778	\$ 190,151,498
Changes of assumptions	194,654,383	211,853,862
Net difference between projected and actual earnings on OPEB plan investments	—	17,049,322
Changes in proportion and differences between Employer contributions and proportionate share of contributions	219,964,781	62,471,151
Employer contributions subsequent to the measurement date	15,600,447	—
TOTAL	\$ 443,151,389	\$ 481,525,833

2021	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 17,255,266	\$ 244,631,528
Changes of assumptions	237,669,500	126,349,962
Net difference between projected and actual earnings on OPEB plan investments	—	28,691
Changes in proportion and differences between Employer contributions and proportionate share of contributions	275,052,969	84,816,231
Employer contributions subsequent to the measurement date	18,240,187	—
TOTAL	\$ 548,217,922	\$ 455,826,412

\$15.6 million reported as deferred outflows of resources related to OPEB resulting from UAB's contributions subsequent to the measurement date will be recognized as a reduction of the net OPEB liability in the year ending September 30, 2023. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

Years ending September 30:		
2023	\$	(33,395,742)
2024		(35,950,132)
2025		(37,172,738)
2026		42,342,366
2027		25,315,788
Thereafter		(15,114,433)

Actuarial assumptions. The total OPEB liability for the PEEHIP was determined by an actuarial valuation as of September 30, 2020, using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.50%
Projected Salary Increase ¹	3.25%-5.00%
Long-Term Investment Rate of Return ²	7.00%
Municipal Bond Index Rate at the Measurement	2.29%
Municipal Bond Index Rate at the Prior	2.25%
Projected Year for Fiduciary Net Position (FNP) to be	2051
Single Equivalent Interest Rate the Measurement	3.97%
Single Equivalent Interest Rate the Prior	3.05%
Healthcare Cost Trend Rate	
Pre-Medicare Eligible	6.50%
Medicare Eligible	**
Ultimate Trend Rate	
Pre-Medicare Eligible	4.50% in 2028
Medicare Eligible	4.75% in 2025

¹Includes 3.00% wage inflation.

²Compounded annually, net of investment expense, and includes inflation.

**Initial Medicare claims are set based on scheduled increases through plan year 2022.

The rates of mortality are based on the Pub-2010 Public Mortality Plans Mortality Tables, adjusted generationally based on scale MP-2020, with an adjustment of 66-2/3% to the table beginning in year 2019. The mortality rates are adjusted forward and/or back depending on the plan and group covered, as shown in the table below:

Group	Membership Table	Set Forward (+) / Set Back (f)	Adjustment to Rates
Active Members	Teacher Employee Below Median	None	65%
Service Retirees	Teacher Below Median	Male: +2 Female: +2	Male: 108% ages < 63, 96% ages > 67, Phasing down 63-67 Female: 112% ages < 69, 98% ages > 74, Phasing down 69-74
Disabled Retirees	Teacher Disability	Male: +8 Female: +3	None
Beneficiaries	Teacher Contingent Survivor Below Median	Male: +2 Female: None	None

The decremental assumptions used in the valuation were selected based on the actuarial experience study prepared as of September 30, 2020, submitted to and adopted by the Teachers' Retirement System of Alabama Board on September 13, 2021.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) were based on the September 30, 2020 valuation.

The long-term expected return on plan assets is to be reviewed as part of regular experience studies prepared every five years, in conjunction with similar analysis for the Teachers' Retirement System of Alabama. Several factors should be considered in evaluating the long-term rate of return assumption, including long-term historical data, estimates inherent in current market data, and a log-normal distribution analysis in which best-estimate ranges of expected future real rates of return (expected return, net of investment expense and inflation), as developed for each major asset class. These ranges should be combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and then adding expected inflation. The assumption is intended to be a long-term assumption and is not expected to change absent a significant change in the asset allocation, a change in the inflation assumption, or a fundamental change in the market that alters expected returns in future years.

The long-term expected rate of return on the OPEB plan investments is determined based on the allocation of assets by asset class and by the mean and variance of real returns. The target asset allocation and best estimates of expected geometric real rates of return for each major asset class is summarized below:

	Target Allocation	Long-Term Expected Real Rate of Return*
Fixed Income	30.00 %	4.40 %
U.S. Large Stocks	38.00 %	8.00 %
U.S. Mid Stocks	8.00 %	10.00 %
U.S. Small Stocks	4.00 %	11.00 %
International Developed Market Stocks	15.00 %	9.50 %
Cash	5.00 %	1.50 %
TOTAL	100.00 %	

* Geometric mean, includes 2.5% inflation

Discount Rate. The discount rate (also known as the Single Equivalent Interest Rate (SEIR), as described by GASB 74) used to measure the PEEHIP total OPEB liability at September 30, 2021 was 3.97%. The discount rate used to measure the total OPEB liability at the prior measurement date was 3.05%. Premiums paid to the PEEHI Board for active employees shall include an amount to partially fund the cost of coverage for retired employees. The projection of cash flows used to determine the discount rate assumed that plan contributions will be made at the current contribution rates. Each year, the State specifies the monthly employer rate that participating school systems must contribute for each active employee. Currently, the monthly employer rate is \$800 per non-university active member. Approximately, 12.990% of the employer contributions were used to assist in funding retiree benefit payments in 2021 and it is assumed that the 12.990% will increase at the same rate as expected benefit payments for the closed group until reaching an employer rate of 20.000%. It is assumed the \$800 rate will increase with inflation at 2.50% starting in 2024. Retiree benefit payments for UAB members are paid by the UAB and are not included in the cash flow projections. The discount rate determination will use a municipal bond rate to the extent the trust is projected to run out of money before all benefits are paid. Therefore, the projected future benefit payments for all current plan members were projected through 2119. The long-term rate of return is used until the assets are expected to be depleted in 2051, after which the municipal bond rate is used.

Sensitivity of the UAB's proportionate share of the net OPEB liability to changes in the healthcare cost trend rates.

The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the current healthcare trend rate, as well as what the net OPEB liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate. A 1-percent-point decrease would change the current healthcare trend rate from 6.50% to 5.50%, the pre-Medicare from 4.50% to 3.50%, the Known Medicare eligible from 4.50% to 3.50%. A 1-percent-point increase would change the current healthcare trend rate from 6.50% to 7.50%, the pre-Medicare from 4.50% to 5.50%, the Known Medicare eligible from 4.50% to 5.50%.

	1% Decrease	Current Healthcare Trend Rate	1% Increase
UAB's proportionate share of the collective net OPEB liability	\$ 428,875,789	\$ 546,566,499	\$ 698,199,578

The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the discount rate of 3.97%, as well as what the net OPEB liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate:

	2.97%	3.97%	4.97%
UAB's proportionate share of the collective net OPEB liability	\$ 672,300,965	\$ 546,566,499	\$ 445,713,574

OPEB plan fiduciary net position. Detailed information about the OPEB plan's fiduciary net position is located in the Trust's financial statements for the fiscal year ended September 30, 2021. The supporting actuarial information is included in the GASB Statement No. 74 Report for PEEHIP prepared as of September 30, 2021. Additional financial and actuarial information is available at www.rsa-al.gov.

UAB Plan

Plan description. The UAB plan is considered a single-employer plan which is administered by University of Alabama at Birmingham ("UAB"). The UAB Plan offers its members hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit. The health care benefits cover medical and hospitalization costs for retirees and their dependents. The portion of the UAB plan related to health care

may be amended by the approval of the President of UAB upon recommendation from the Benefits Committee. The portion of the UAB plan related to the life insurance may be amended by the System.

Benefits provided. UAB employees can participate in the UAB plan as a retiree if the following conditions are met; retiree has 25 years of creditable service, regardless of age (Tier I only), or retiree has 10 years of service and is 60 years old (62 years old for Tier II), or retiree has 10 years of service and is determined disabled by the Social Security Administration or the Teachers' Retirement System of Alabama's Medical Board. These retired UAB employees may elect to continue to participate in UAB Plan until they are eligible for Medicare by paying the full cost of the plan premium. Retired employees age 65 or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB Plan becomes the secondary insurer. Despite the availability of the UAB Plan, most retirees elect to participate in the PEEHIP with TRS. The UAB Plan consists of hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit.

Employees included in the actuarial valuation include active employees, retirees and disabled employees enrolled in the medical plan and retirees not enrolled in the medical plan with retiree life insurance. The following table summarizes the membership of the UAB Plan as of September 30, 2021, the Valuation Date.

Membership:	2022
Inactive Employees or Beneficiaries Currently Receiving Benefits	202
Inactive Members Entitled To But Not Yet Receiving Benefits	—
Active Employees	10,317
TOTAL MEMBERSHIP	10,519

Contributions. UAB retired employees make contributions to the plan by making premium payments associated with their selected health plan option. Eligible disabled retirees are responsible for only the employee portion of those premiums and UAB is responsible for the employer portion. All other UAB retirees are responsible for the full premium cost of the plan and in no case does the employer contribute to the plan.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2022 and 2021, UAB reported a total OPEB liability ("TOL") of \$7.2 million and \$5.3 million, respectively. The TOL is based upon an Entry Age Normal ("EAN") actuarial funding method as of the valuation date, September 30, 2020. Since the valuation date at which the TOL is determined is before the measurement date, the TOL must be rolled forward to the measurement date.

For the years ended September 30, 2022 and 2021, UAB recognized an OPEB benefit of \$1.0 million and \$1.2 million, respectively with no special funding situations. At September 30, 2022 and 2021, UAB reported deferred outflows of resources and deferred inflows of resources related to the UAB plan from the following sources:

2022	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ 678,374	\$ 4,823,778
Changes of assumptions	1,662,683	3,904,199
Employer contributions subsequent to the measurement period	711,333	—
TOTAL	\$ 3,052,390	\$ 8,727,977

2021	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ —	\$ 5,668,729
Changes of assumptions	75,946	4,632,413
Employer contributions subsequent to the measurement period	1,895,059	—
TOTAL	\$ 1,971,005	\$ 10,301,142

\$0.7 million reported as deferred outflows of resources related to OPEB resulting from University Hospital's contributions subsequent to the measurement date will be recognized as a reduction of the net OPEB liability in the year ending September 30, 2023. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

Year ended September 30:

2023	\$	(1,302,468)
2024		(1,302,468)
2025		(1,302,468)
2026		(1,289,471)
2027		(1,173,168)
Thereafter		(16,877)

Actuarial assumptions. The total OPEB liability for the UAB Plan was determined by an actuarial valuation as of September 30, 2020, using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.50 %
Real Wage Growth	0.25 %
Projected Salary Increases ¹	3.25% - 5.00%
Wage inflation.	2.75 %
Municipal Bond Index Rate at the Measurement Date	2.29 %
Municipal Bond Index Rate at the Prior Measurement Date	2.25 %
Healthcare Cost Trend Rate	
Pre-Medicare Medical and Prescription Drug (decreasing to an ultimate rate of 4.50% by 2029)	6.50 %

¹Includes 3.00% wage inflation.

The rates of mortality are based on the Pub-2010 Public Mortality Plans Mortality Tables, adjusted generationally based on scale MP-2020, with an adjustment of 66-2/3% to the table beginning in year 2019. The mortality rates are adjusted forward and/or back depending on the plan and group covered, as shown in the table below:

Group	Membership Table	Set Forward (+) / Set Back (1)	Adjustment to Rates
Active Members	Teacher Employee Below Median	None	65%
Service Retirees	Teacher Below Median	Male: +2 Female: +2	Male: 108% ages < 63, 96% ages > 67, Phasing down 63-67 Female: 112% ages < 69, 98% ages > 74, Phasing down 69-74
Disabled Retirees	Teacher Disability	Male: +8 Female: +3	None
Beneficiaries	Teacher Contingent Survivor Below Median	Male: +2 Female: None	None

The demographic actuarial assumptions for retirement, disability incidence, withdrawal, and salary increases used in the September 30, 2021 valuation were based on the actuarial experience study prepared as of September 30, 2015, submitted to and adopted by the Teachers' Retirement System of Alabama Board on September 13, 2021.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) used in the September 30, 2021 valuation were based on a review of recent plan experience performed concurrently with the September 30, 2021 valuation.

The UAB Plan does not hold any plan assets, as such, there are no long-term expected rate of return or target allocation presented.

Discount Rate. The discount rate, as defined by Paragraph 155 of GASB 75 is to be a 20-year tax-exempt municipal bond (rating AA/Aa or higher) rate (Municipal Bond Index Rate) The Municipal Bond Index Rate used for this purpose is the average of the Bond Buyer General Obligation 20-year Municipal Bond Index, the Fidelity General Obligation AA 20-year Municipal Bond Index, and the S&P High Grade 20-year Municipal Bond Index. The rates as of September 30, 2020 were 2.21%, 2.41%, and 2.14% for the Bond Buyer, Fidelity, and S&P Municipal Bond Indices respectively. These three rates resulted in an averaged Municipal Bond Index Rate of 2.25%. This is a change from the Municipal Bond

Index Rate of 2.29% as of the Prior Measurement Date, which used a single source from the Bond Buyer (www.bondbuyer.com).

Sensitivity of the UAB Plan's net OPEB liability to changes in the healthcare cost trend rates. The following table presents the total OPEB Liability of the UAB Plan, calculated using the current healthcare trend rate, as well as what the total OPEB Liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate. A 1-percentage-point decrease would change the current healthcare trend rate from 6.50% to 5.50% and pre-Medicare from 4.50% to 3.50%. A 1-percentage-point increase would change the current healthcare trend rate from 6.50% to 7.50% and the pre-Medicare from 4.50% to 5.50%.

	<u>1% Decrease</u>	<u>Current Healthcare Trend Rate</u>	<u>1% Increase</u>
UAB's total OPEB liability	\$ 6,967,652	\$ 7,207,553	\$ 7,467,200

The following table presents the total OPEB Liability of the UAB Plan, calculated using the discount rate of 2.29%, as well as what the total OPEB liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate:

	<u>1.29%</u>	<u>2.29%</u>	<u>3.29%</u>
UAB's total OPEB liability	\$ 7,586,915	\$ 7,207,553	\$ 6,861,866

Changes in the Total OPEB Liability. Since the UAB Plan does not meet the definition within paragraph 4 of GASB Statement No 75, UAB is disclosing a schedule of changes in the total OPEB liability below:

	<u>2022</u>
Total OPEB Liability as of September 30, 2021	\$ 5,280,513
Changes for the year:	
Service cost	176,656
Interest on TOL and cash flows	108,805
Changes in benefit terms	250
Difference between expected and actual experience	756,169
Changes of assumptions or other inputs	1,779,639
Benefit payments	(894,479)
Net changes	<u>\$ 1,927,040</u>
Total OPEB Liability as of September 30, 2022	<u>\$ 7,207,553</u>

*The service cost include interest for the year.

(11) Federal Direct Student Loan Program

The Federal Direct Student Loan Program ("FDSLPL") was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSLPL enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through the university rather than through private lenders. UAB began participation in the FDSLPL on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan process, including funds management, as well as promissory note functions. UAB is not responsible for collection of these loans. During the years ended September 30, 2022 and 2021, UAB disbursed approximately \$158.0 million and \$163.2 million, respectively, under the FDSLPL.

(12) Grants and Contracts

At September 30, 2022 and 2021, UAB had been awarded approximately \$950.1 million and \$907.5 million, respectively, in grants and contracts which have not been expended. These awards, which represent commitments of sponsors to provide funds for specific research, training, and service projects, have not been reflected in the financial statements.

(13) Operating Expenses by Function

Total operating expenses by functional classification for the years ended September 30, 2022 and 2021 are as follows for UAB:

2022 Operating Expenses

(by functional classification)

	Salaries, Wages, and Benefits	Supplies and Services	Depreciation and Amortization	Scholarships and Fellowships	Total
Instruction	\$ 254,093,368	\$ 34,006,866	\$ —	\$ —	\$ 288,100,234
Research	204,583,844	130,638,802	—	—	335,222,646
Public service	110,208,683	81,678,438	—	—	191,887,121
Academic support	172,405,795	27,968,503	—	—	200,374,298
Student services	28,266,610	8,342,140	—	—	36,608,750
Institutional support	119,432,872	103,144,811	—	—	222,577,683
Operations and maintenance of plant	42,976,230	42,105,778	—	—	85,082,008
Scholarships and fellowships	—	—	—	33,114,448	33,114,448
University Hospital	1,020,673,576	1,295,135,461	—	—	2,315,809,037
Auxiliary	76,209,520	707,575,843	—	—	783,785,363
Depreciation	—	—	180,030,404	—	180,030,404
TOTAL OPERATING EXPENSES	\$ 2,028,850,498	\$ 2,430,596,642	\$ 180,030,404	\$ 33,114,448	\$ 4,672,591,992

2021 Operating Expenses

(by functional classification)

	Salaries, Wages, and Benefits	Supplies and Services	Depreciation and Amortization	Scholarships and Fellowships	Total
Instruction	\$ 259,960,374	\$ 33,060,944	\$ —	\$ —	\$ 293,021,318
Research	206,051,685	132,301,420	—	—	338,353,105
Public service	113,748,440	68,723,953	—	—	182,472,393
Academic support	161,076,915	8,826,999	—	—	169,903,914
Student services	29,096,394	10,491,179	—	—	39,587,573
Institutional support	129,108,352	91,731,038	—	—	220,839,390
Operations and maintenance of plant	41,346,247	31,906,518	—	—	73,252,765
Scholarships and fellowships	—	—	—	55,053,095	55,053,095
University Hospital	951,567,782	1,109,083,108	—	—	2,060,650,890
Auxiliary	71,672,708	668,172,085	—	—	739,844,793
Depreciation	—	—	175,757,850	—	175,757,850
TOTAL OPERATING EXPENSES	\$ 1,963,628,897	\$ 2,154,297,244	\$ 175,757,850	\$ 55,053,095	\$ 4,348,737,086

(14) Contingencies and Commitments

UAB has sovereign immunity and is, therefore, in the opinion of UAB counsel, immune to ordinary tort actions including those based on medical malpractice or general injury to patients. Consequently, while UAB is sometimes named as defendant in malpractice actions and other actions for injuries arising in the University Hospital, it has consistently been dismissed from those lawsuits on the basis of the sovereign immunity doctrine. That doctrine also protects UAB from vicarious liability arising from the negligence of its employees. To the extent that UAB employees are sued in their individual capacity for actions related to their official duties within the line and scope of their employment, UAB has defended those actions and paid for any resulting costs through its self-insured trust fund. While UAB is not aware of any impending threat to this doctrine, UAB is a named insured under the terms of the PLTF and excess insurance purchased from commercial companies (Note 8). There are some exceptions to the sovereign immunity doctrine, most notably federal court cases arising under the federal constitution or federal statutes.

UAB is engaged in various legal actions in the ordinary course of business. Management does not believe the ultimate outcome of these actions will have a material adverse effect on the financial statements. However, the settlement of legal actions is subject to inherent uncertainties and it is possible that such outcomes could differ materially from management's current expectations.

Amounts received or receivable from grantor agencies are subject to audit and adjustments by such agencies, principally the United States Government. Any disallowed claims, including amounts already collected, may constitute a liability of UAB. The amount, if any, of expenditures that may be disallowed by the grantor cannot be determined at this time, although UAB expects any such amounts to be immaterial.

UAB has contracted for the construction and renovation of several facilities. At September 30, 2022 and 2021, the estimated remaining cost to complete the construction and renovation of these facilities was approximately \$468 million and \$293 million, respectively, which is expected to be financed from private gifts, grants, bond proceeds, and UAB reserves.

(15) Segment Reporting

As discussed in Note 1, UAB's two significant identifiable activities that have bonds outstanding where revenue is pledged in support of the bonds are the University and the University Hospital. Condensed financial statement information related to the University and University Hospital as of and for the years ended September 30, 2022 and 2021 is as follows:

UNIVERSITY	2022	2021
CONDENSED STATEMENTS OF NET POSITION		
Current assets	\$ 905,310,840	\$ 988,756,461
Capital assets, net	1,258,377,988	1,223,358,141
Other assets	1,207,170,848	1,153,604,330
TOTAL ASSETS	\$ 3,370,859,676	\$ 3,365,718,932
DEFERRED OUTFLOW OF RESOURCES	\$ 484,468,683	\$ 562,409,447
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 3,855,328,359	\$ 3,928,128,379
Current liabilities	339,189,442	334,151,703
Long-term debt	775,217,646	621,357,170
Other noncurrent liabilities	1,019,965,334	1,373,463,572
TOTAL LIABILITIES	\$ 2,134,372,422	\$ 2,328,972,445
DEFERRED INFLOW OF RESOURCES	\$ 567,293,559	\$ 334,290,774
Net investment in capital assets	605,982,389	608,224,952
Restricted nonexpendable	435,550,602	390,565,083
Restricted expendable	416,868,445	548,697,797
Unrestricted	(304,739,058)	(282,622,672)
TOTAL NET POSITION	\$ 1,153,662,378	\$ 1,264,865,160
TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION	\$ 3,855,328,359	\$ 3,928,128,379

UNIVERSITY

	2022	2021
CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION		
Tuition and fees, net	\$ 238,778,078	\$ 243,476,387
Grant and contract revenue	572,438,336	526,727,010
Sales and services, educational	66,563,264	67,666,602
Other operating revenues	78,568,625	72,219,276
Salaries, wages, and benefits	(947,380,434)	(955,714,291)
Supplies and services	(458,464,190)	(406,825,370)
Depreciation	(91,104,802)	(88,992,244)
Scholarships and fellowships	(33,099,152)	(55,047,847)
OPERATING LOSS	(573,700,275)	(596,490,477)
State appropriations	292,027,354	276,997,252
Investment income	(239,084,640)	307,137,486
Interest expense	(22,017,589)	(18,327,490)
Gifts	31,620,373	57,336,704
Other nonoperating revenues	51,230,247	115,065,144
(LOSS) INCOME BEFORE OTHER CHANGES IN NET POSITION	(459,924,530)	141,718,619
Capital gifts and grants	12,806,599	1,645,260
State capital funds	26,379,881	3,610,767
Endowment gifts	44,941,789	33,163,130
Intergovernmental transfers	264,593,479	255,710,660
(DECREASE) INCREASE IN NET POSITION	(111,202,782)	435,848,436
Net position, beginning of year	1,264,865,160	829,016,724
NET POSITION, END OF YEAR	\$ 1,153,662,378	\$ 1,264,865,160

UNIVERSITY

	2022	2021
CONDENSED STATEMENTS OF CASH FLOWS		
Net cash provided by (used in):		
Operating activities	\$ (524,256,332)	\$ (498,196,337)
Noncapital financing activities	683,388,794	737,375,181
Investing activities	(60,104,419)	(55,038,798)
Capital and related financing activities	21,931,212	(133,606,799)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	120,959,255	50,533,247
Cash and cash equivalents, beginning of year	215,490,306	164,957,059
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 336,449,561	\$ 215,490,306

UNIVERSITY HOSPITAL**CONDENSED STATEMENTS OF NET POSITION**

	2022	2021
Current assets	\$ 1,392,058,470	\$ 1,521,544,493
Capital assets, net	658,181,017	669,859,761
Other assets	532,814,383	860,118,237
TOTAL ASSETS	\$ 2,583,053,870	\$ 3,051,522,491
DEFERRED OUTFLOW OF RESOURCES	\$ 247,091,368	\$ 300,205,570
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 2,830,145,238	\$ 3,351,728,061
Current liabilities	236,651,954	400,401,897
Long-term debt	517,235,928	535,825,954
Other noncurrent liabilities	587,501,559	741,468,850
TOTAL LIABILITIES	\$ 1,341,389,441	\$ 1,677,696,701
DEFERRED INFLOW OF RESOURCES	\$ 309,205,504	\$ 222,499,903
Net investment in capital assets	177,350,244	175,035,236
Restricted nonexpendable	128,099	128,099
Restricted expendable	38,034,426	40,600,146
Unrestricted	964,037,524	1,235,767,976
TOTAL NET POSITION	\$ 1,179,550,293	\$ 1,451,531,457
TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION	\$ 2,830,145,238	\$ 3,351,728,061

UNIVERSITY HOSPITAL**CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION**

	2022	2021
Operating revenues	\$ 2,630,862,366	\$ 2,472,592,069
Operating expenses	(2,317,714,012)	(2,051,279,108)
Depreciation expense	(87,695,333)	(85,483,135)
OPERATING INCOME	225,453,021	335,829,826
Economic relief funds	21,209,457	412,719
State appropriations	40,421,576	37,955,804
Investment income	(280,918,844)	241,041,041
Interest expense	(19,776,642)	(19,907,574)
Gifts	121,661	104,779
Other nonoperating expenses	(238,881)	(327,872)
(LOSS) INCOME BEFORE OTHER CHANGES IN NET POSITION	(239,181,673)	259,278,897
Capital gifts and grants	75	—
Intergovernmental transfers	(258,252,587)	(232,565,085)
(DECREASE) INCREASE IN NET POSITION	(271,981,164)	362,543,638
Net position, beginning of year	1,451,531,457	1,088,987,819
NET POSITION, END OF YEAR	\$ 1,179,550,293	\$ 1,451,531,457

CONDENSED STATEMENTS OF CASH FLOWS

Net cash provided by (used in):		
Operating activities	126,823,107	353,382,547
Noncapital financing activities	(196,499,893)	(190,862,468)
Investing activities	136,344,929	(289,430,883)
Capital and related financing activities	(114,993,929)	(126,029,622)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(48,325,786)	(252,940,426)
Cash and cash equivalents, beginning of year	81,233,509	334,173,935
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 32,907,723	\$ 81,233,509

(16) Health Care Services

Net Patient Service Revenue

The University Hospital has agreements with governmental and other third-party payors that provide for reimbursement to the University Hospital at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the difference between the University Hospital's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

Medicare. Substantially all acute-care services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to the patient classification systems that are based on clinical, diagnostic, and other factors. Additionally, the University Hospital is reimbursed for both its direct and indirect medical education costs (as defined), principally based on per-resident prospective payment amounts and certain adjustments to prospective rate-per-discharge operating reimbursement payments. The University Hospital generally is reimbursed for certain retroactively settled items at tentative rates, with final settlement determined after submission of annual cost reports by the University Hospital and audits by the Medicare fiscal intermediary. The University Hospital's cost reports have been audited and settled for all fiscal years through 2012. Revenue from the Medicare program accounted for approximately 17% and 18% of the University Hospital's net patient service revenue for the years ended September 30, 2022 and 2021, respectively.

Section 302 of the Tax Relief and Health Care Act of 2006 authorized a permanent program involving the use of third-party recovery audit contractors (RACs) to identify Medicare overpayments and underpayments made to providers. As of September 30, 2022, the University Hospital reported claims in various stages of review based on the requests received by the RACs during the fiscal year. Payment recoveries resulting from RAC reviews are appealable through administrative and judicial processes, and the University Hospital intends to pursue the reversal of adverse determinations, where appropriate. The University Hospital cannot predict with certainty the impact of the Medicare RAC program on our future results of operations or cash flows.

Blue Cross. Inpatient services rendered to Blue Cross subscribers are paid at a prospectively determined per diem rate. Outpatient services are reimbursed at a prospectively determined rate. The method of reimbursement is determined by the procedures that are performed. Revenue from the Blue Cross program accounted for approximately 36% and 35% of the University Hospital's net patient service revenue for the years ended September 30, 2022 and 2021, respectively.

Medicaid. Inpatient services rendered to Medicaid program beneficiaries are reimbursed at all-inclusive prospectively determined per diem rates. Outpatient services are reimbursed based on an established fee schedule. The University Hospital is designated as a Disproportionate Share Hospital (DSH) and receives payments under the Medicaid DSH program. In addition, as a participant in the Alabama Medicaid Plan, the University Hospital also receives supplemental payments based on formulas established by the Alabama Medicaid Agency. The net benefit associated with the University Hospital's participation in these programs, totaling approximately \$154.1 million and \$168.2 million in 2022 and 2021, respectively, is included in net patient service revenue in the accompanying statement of revenues, expenses and changes in net position. There can be no assurance that the University Hospital will continue to qualify for future participation in these programs or that the programs will not ultimately be discontinued or materially modified. Revenue from the Medicaid program accounted for approximately 15% and 16% of the University Hospital's net patient service revenue for the years ended September 30, 2022 and 2021, respectively.

Other. The University Hospital has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payments to the University Hospital under these agreements includes discounts from established charges and prospectively determined daily and case rates.

The composition of University Hospital operating revenue follows:

	<u>2022</u>	<u>2021</u>
Gross Patient Service Revenue	\$ 10,318,705,328	\$ 9,562,939,692
Less Provision for Contractual and Other Adjustments	(7,906,817,837)	(7,196,037,301)
Less Provision for Uncollectible Accounts	<u>(204,914,523)</u>	<u>(248,640,077)</u>
Net Patient Service Revenue	\$ 2,206,972,968	\$ 2,118,262,314
Capitation Revenue	80,335,191	79,939,250
Other Operating Revenue	<u>524,715,538</u>	<u>435,683,905</u>
TOTAL UNIVERSITY HOSPITAL SALES REVENUE	<u>\$ 2,812,023,697</u>	<u>\$ 2,633,885,469</u>

Charity Care

The University Hospital maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for services and supplies furnished under its charity care policy, the estimated costs of those services, and supplies and equivalent service statistics. The estimated cost of charity care provided during the years ended September 30, 2022 and 2021 was approximately \$42.4 million and \$36.6 million, respectively, calculated based on the ratio of total direct and indirect costs to establish charges applied to the charges foregone under the charity care policy.

	<u>2022</u>	<u>2021</u>
Approximate charges foregone, based on established rates	\$ 155,552,620	\$ 137,442,012
Percentage of charity charges to total charges	1.5%	1.4%

Credit Risk

The University Hospital grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors at September 30, 2022 and 2021 follows:

	<u>2022</u>	<u>2021</u>
Blue Cross	40%	40%
Medicare	10%	11%
Medicaid	6%	6%
Other	<u>44%</u>	<u>43%</u>
	<u>100%</u>	<u>100%</u>

Related Parties

The University Hospital and the other divisions of UAB provide a variety of support services to each other. The cost of these services is allocated to the end user on bases which vary according to the service being furnished. These services are paid for by transfers of funds which reduce operating expenses of the unit providing the service and are included in the operating costs of the unit receiving the service. Administrative and purchased services provided by UAB and allocated to and reimbursed by the University Hospital during the years ended September 30, 2022 and 2021 were approximately \$38.1 million and \$36.1 million, respectively. In addition, during the years ended September 30, 2022 and 2021, the University Hospital transferred approximately \$209.6 million and \$232.6 million, respectively, to UAB to support UAB's academic and medical programs.

As noted in footnote 7, in June 2019, the UAB Medicine Finance Authority issued \$8.1 million in Series 2019A Revenue Bonds and \$103.4 million in Series 2019B Revenue Bonds, the proceeds of which were loaned to UAB Medicine Enterprise, formally known as UAB Health System pursuant to Series 2019A and Series 2019B loan agreements. Concurrently, University Hospital entered into a loan agreement with UAB Medicine Enterprise for \$77.0 million of the 2019A and 2019B bond proceeds for the purpose of financing capital improvement projects. In January 2021, University Hospital borrowed an additional \$17.7 million of the 2019A and 2019B bond proceeds from UAB Medicine Enterprise. Of the total amount borrowed, \$42.5 million was distributed to University Hospital as of September 30, 2022 and September 30, 2021. As University Hospital is legally obligated to repay \$94.7 million and is currently paying principal and interest on this full amount, University Hospital has reflected the full \$94.7 million on its statement of net position as long-term debt and \$52.2 million as Due from affiliate on the statement of net position. University Hospital pays interest to UAB Medicine Enterprise on the entire amount, regardless of the amount outstanding. There are no financial covenants related to the loan between University Hospital and UAB Medicine Enterprise.

During 2008, the University Hospital entered into an operating agreement with the Health Services Foundation ("HSF") whereby HSF would lease two floors of the Women and Infants Center ("WIC"). HSF reimbursed the University Hospital for construction costs of this space as they were incurred on a square-footage basis. Total reimbursements are being amortized as rent revenue on a straight-line basis over a period equal to the 90 year total lease term, commencing on February 22, 2010, the date the building was placed into service. The University Hospital had received reimbursements from HSF totaling approximately \$14.7 million in 2022 and 2021, of which approximately \$12.4 million and \$12.6 million respectively, is included in the accompanying statement of net position as lease related deferred inflows for the years ended September 30, 2022 and 2021, respectively.

In the normal course of business, HSF purchases various services from University Hospital, which aggregated to approximately \$50.3 million and \$45.3 million for the years ended September 30, 2022 and 2021, respectively, and University Hospital purchased various services from HSF, which aggregated to approximately \$81.6 million and \$76.5 million for the years ended September 30, 2022 and 2021, respectively. University Hospital had a net receivable from HSF of approximately \$16.5 million at September 30, 2022, and a net payable to HSF of \$2.0 million at September 30, 2021, which is included in accounts receivable and accrued expenses in the accompanying statements of net position, respectively.

The Board and HSF entered into an agreement dated October 7, 1996, amended April 6, 2017, to establish the UAB Medicine Enterprise and to provide common management for both existing and future healthcare delivery operations. In connection with its agreement with UAB Medicine Enterprise, University Hospital partially funded the operations of UAB Medicine Enterprise and its corporate office, charging approximately \$18.3 million and \$17.4 million to other operating expense in fiscal year 2022 and 2021, respectively. University Hospital made equity transfers of approximately \$76.0 million and \$86.9 million to UAB Medicine Enterprise during fiscal year 2022 and 2021, respectively. In addition, UAB Medicine Enterprise periodically makes payments on behalf of University Hospital for which it is reimbursed. University Hospital had a net payable to UAB Medicine Enterprise of approximately \$6.7 million and \$6.9 million at September 30, 2022 and 2021, respectively.

In March 2014, the University Hospital assumed operations of the outpatient clinics in The Kirklin Clinic and entered into an agreement with HSF to lease the land and the building known as The Kirklin Clinic. The initial term of the lease, which is cancellable by either party upon proper written notice and without penalty, is five years, with automatic one-year renewals thereafter. The expenses related to this agreement for year ending September 30, 2022 and 2021 is \$9.4 million and \$9.3 million, respectively.

VF's primary purpose is to provide a group medical practice for physicians who are faculty members in the UAB School of Medicine Huntsville. It is governed by a 17-member board of directors, consisting of three nonvoting members and 14 voting members, of whom seven are affiliated with UAB.

During the years ended September 30, 2022 and 2021, University Hospital received approximately \$80.3 million and \$79.9 million, respectively, in capitation fees from Triton Health Systems, LLC ("Triton"), a Health Insurance Plan sponsored by UAB.

During October 2021, University Hospital transferred \$48.6 million via an equity transfer to the UAB Health System Authority. These funds were subsequently transferred by the UAB Health System Authority to UAB Medicine Enterprise for the purpose of purchasing the Medical West Hospital Authority main hospital facility located in Bessemer, Alabama.

Effective July 1, 2012, all new hires of University Hospital are employed by UAB Hospital Management, LLC ("LLC"), the single member of which is UAB. The LLC offers the employees a voluntary 403(b) retirement plan for eligible employees. The 403(b) is a voluntary, defined-contribution, tax-deferred plan as well as Roth after-tax plan governed by Internal Revenue Code 403(b). Eligible employees can choose between both TIAA and VALIC (Variable Annuity Life Insurance Company) for investments. The LLC matches the individual's contributions up to 5% of gross monthly pay not to exceed \$245,000 annual LLC salary. The salary cap only applies to employees hired on or after July 1, 1996. Employees are vested in LLC contributions after 3 years of employment with the LLC. Eligibility for matching is for all full-time and part-time regular, twelve-hour shift, and weekend staff employees. Upon the LLC formation, University Hospital employees were given the option to become employees of the LLC. Those University Hospital employees who chose not to transfer to the LLC effective July 2012 may choose to transfer to the LLC at any time in the future. Once employees transfer to the LLC, they may not transfer employment back to University Hospital. For the years ended September 30, 2022 and 2021, respectively, University Hospital purchased \$617.5 million and \$549.8 million in contract labor from the LLC. There were approximately 8,950 employees of the LLC at September 30, 2022 and approximately 8,207 employees at September 30, 2021. In addition to the LLC contract labor, for the years ended September 30, 2022 and 2021, respectively, the University Hospital purchased \$25.6 million and \$26.6 million of contract labor from HSF related to provider based clinics.

(17) Recently Issued Pronouncements

The GASB issued Statement No. 91, *Conduit Debt Obligations*, in May 2019. The objectives of this Statement are to provide a single method of reporting conduit debt obligations by issuers and eliminate diversity in practice associated with (1) commitments extended by issuers, (2) arrangements associated with conduit debt obligations, and (3) related note disclosures. This statement is effective for reporting periods beginning after December 15, 2021. UAB has determined there will be no material impact from its adoption of GASB 91.

The GASB issued Statement No. 92, *Omnibus 2020, in January 2020*. The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing practice issues that have been identified during implementation and application of certain GASB Statements. The statement is effective for reporting periods beginning after June 15, 2021. UAB has determined there was no material impact from its adoption of GASB 92

The GASB issued Statement No. 93, *Replacement of Interbank Offered Rates*, in March 2020. The objective of this Statement is to address those and other accounting and financial reporting implications that result from the replacement of the IBOR. The requirements of this Statement, except for paragraphs 11b, 13, and 14 are effective for reporting periods beginning after June 15, 2020. The requirement in paragraph 11b is effective for reporting periods ending after December 31, 2021. The requirements in paragraphs 13 and 14 are effective for fiscal years periods beginning after June 15, 2021, and all reporting periods thereafter. UAB has determined there was no material impact from its adoption of the portions of GASB 93 which were effective for reporting periods beginning after June 15, 2020, and June 15, 2021, and there will be no material impact from its adoption of the portions of the Statement effective for reporting periods beginning after December 31, 2021.

The GASB issued Statement No. 94, *Public-Private and Public-Public Partnerships and Availability Payment Arrangements*, in March 2020. The objective of this Statement is to improve financial reporting by addressing issues related to public-private partnership arrangements. This Statement also provides guidance for accounting and financial reporting for availability payment arrangements. The statement is effective for reporting periods beginning after June 15, 2022. UAB has determined there will be no material impact from its adoption of GASB 94.

The GASB issued Statement No. 95, *Postponement of the Effective Dates of Certain Authoritative Guidance*, in May 2020. The objective of this Statement is to provide temporary relief to governments and other stakeholders in light of the COVID-19 pandemic. That objective is accomplished by postponing the effective dates of certain provisions in Statements 83 - 93. The effective dates disclosed above have been adjusted to reflect this deferral. UAB will apply the GASB 95 postponement of effective dates.

The GASB issued Statement No. 96, *Subscription-Based Information Technology Arrangements*, in May 2020. The objective of this Statement is to provide guidance on the accounting and financial reporting for subscription-based information technology arrangements for government end users. The statement is effective for reporting periods beginning after June 15, 2022. UAB is evaluating whether there will be any material impact from its adoption of GASB 96.

The GASB issued Statement No. 97, *Certain Component Unit Criteria, and Accounting and Financial Reporting for Internal Revenue Code Section 457 Deferred Compensation Plans* - an amendment of GASB Statements No. 14 and No. 84, and a supersession of GASB Statement No. 32, in June 2020. The primary objectives of this Statement are to (1) increase consistency and comparability related to the reporting of fiduciary component units in circumstances in which a potential component unit does not have a governing board and the primary government performs the duties that a governing board typically would perform; (2) mitigate costs associated with the reporting of certain defined contribution pension plans, defined contribution other postemployment benefit (OPEB) plans, and employee benefit plans other than pension plans or OPEB plans (other employee benefit plans) as fiduciary component units in fiduciary fund financial statements; and (3) enhance the relevance, consistency, and comparability of the accounting and financial reporting for Internal Revenue Code (IRC) Section 457 deferred compensation plans (Section 457 plans) that meet the definition of a pension plan and for benefits provided through those plans. The requirements in (1) paragraph 4 of this Statement as it applies to defined contribution pension plans, defined contribution OPEB plans, and other employee benefit plans and (2) paragraph 5 of this Statement are effective immediately. All other requirements of this Statement are effective for reporting periods beginning after June 15, 2021. UAB has determined there was no material impact from its adoption of GASB 97.

The GASB issued Statement No. 98, *The Annual Comprehensive Financial Report*, in October 2021. This Statement establishes the term annual comprehensive financial report and its acronym ACFR. That new term and acronym replace instances of comprehensive annual financial report and its acronym in generally accepted accounting principles for state and local governments. The requirements of this Statement are effective for fiscal years ending after December 15, 2021. UAB's early adoption of GASB 98 during fiscal year 2021 had no material impact on its financial statements.

The GASB issued Statement No. 99, Omnibus 2022, in April 2022. The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing (1) practice issues that have been identified during implementation and application of certain GASB Statements and (2) accounting and financial reporting for financial guarantees. The requirements related to extension of the use of LIBOR, accounting for SNAP distributions, disclosures of nonmonetary transactions, pledges of future revenues by pledging governments, clarification of certain provisions in Statement 34, as amended, and terminology updates related to Statement 53 and Statement 63 were effective upon issuance. The requirements related to leases, PPPs, and SBITAs are effective for fiscal years beginning after June 15, 2022, and all reporting periods thereafter. The requirements related to financial guarantees and the classification and reporting of derivative instruments within the scope of Statement 53 are effective for fiscal years beginning after June 15, 2023, and all reporting periods thereafter. UAB has determined there was no material impact from its adoption of the portions of GASB 99 which were effective immediately, and UAB is evaluating whether there will be any material impact from its adoption of the portions of this Statement effective for reporting periods beginning after June 15, 2022.

The GASB issued Statement No. 100, *Accounting Changes and Error Corrections* - an amendment of GASB Statement No. 62, in June 2022. The primary objective of this Statement is to enhance accounting and financial reporting requirements for accounting changes and error corrections to provide more understandable, reliable, relevant, consistent, and comparable information for making decisions or assessing accountability. The requirements of this Statement are effective for fiscal years beginning after June 15, 2023, and all reporting periods thereafter. As GASB Statement No. 100 is based on an unknown possible future event, materiality can not be determined. The University will continue to evaluate for any potential impact in the future.

The GASB issued Statement No. 101, *Compensated Absences*, in June 2022. The objective of this Statement is to better meet the information needs of financial statement users by updating the recognition and measurement guidance for compensated absences. That objective is achieved by aligning the recognition and measurement guidance under a unified model and by amending certain previously required disclosures. The requirements of this statement are effective for fiscal years beginning after December 15, 2023. UAB is evaluating whether there will be any material impact from its adoption of GASB 101.

The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information relates to UAB's participation in the Teachers' Retirement System of Alabama. (Dollars in thousands)

Schedule of UAB's Proportionate Share of the Net Pension Liability Teachers' Retirement Plan of Alabama

	2022	2021	2020	2019	2018	2017	2016	2015
Employer's proportion of the net pension liability	11.134965 %	11.425593 %	11.260686 %	11.750518 %	11.814264 %	11.863961 %	11.916376 %	12.188512 %
Employer's proportionate share of the collective net pension liability	\$1,048,949	\$1,413,306	\$1,245,083	\$1,168,305	\$ 1,161,162	\$1,284,396	\$1,247,128	\$1,107,275
Employer's covered payroll during the measurement period	\$ 947,482	\$ 946,085	\$ 940,203	\$ 916,059	\$ 901,338	\$ 876,899	\$ 864,300	\$ 880,666
Employer's proportionate share of the collective net pension liability as a percentage of its covered payroll	110.71 %	149.38 %	132.43 %	127.54 %	128.83 %	146.47 %	144.29 %	125.73 %
Plan fiduciary net position as a percentage of the total collective pension liability	76.44 %	67.72 %	69.85 %	72.29 %	71.50 %	67.93 %	67.51 %	71.01 %

Schedule of UAB's Contributions Teachers' Retirement Plan of Alabama

	2022	2021	2020	2019	2018	2017	2016	2015
Contractually required contribution	\$ 101,166	\$ 96,839	\$ 98,485	\$ 94,900	\$ 91,228	\$ 88,660	\$ 86,334	\$ 84,999
Contributions in relation to the contractually required contribution	\$ 101,166	\$ 96,839	\$ 98,485	\$ 94,900	\$ 91,228	\$ 88,660	\$ 86,334	\$ 84,999
Contribution deficiency (excess)	—	—	—	—	—	—	—	—
Employer's covered payroll	\$ 1,022,561	\$ 947,482	\$ 946,085	\$ 940,203	\$ 916,059	\$ 901,338	\$ 876,899	\$ 864,300
Contributions as a percentage of covered payroll	9.89%	10.22%	10.41%	10.09%	9.96%	9.84%	9.85%	9.83%

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to a pension plan are based.

Measurement period:

For fiscal year 2022, the measurement period is October 1, 2020 – September 30, 2021

For fiscal year 2021, the measurement period is October 1, 2019 – September 30, 2020

For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018

For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

For fiscal year 2017, the measurement period is October 1, 2015 – September 30, 2016

For fiscal year 2016, the measurement period is October 1, 2014 – September 30, 2015

For fiscal year 2015, the measurement period is October 1, 2013 – September 30, 2014

The following required supplementary information related to UAB's participation in the Alabama Retired Education Employees' Health Care Trust (PEEHIP). (Dollars in thousands)

Schedule of UAB's Proportionate Share of the Net OPEB Liability Alabama Retired Education Employees' Health Care Trust (PEEHIP)

	<u>2022</u>	<u>2021</u>	<u>2020</u>	<u>2019</u>	<u>2018</u>
Employers' proportion of the net OPEB liability	10.578406 %	10.484536 %	7.028808 %	8.029386 %	8.670675 %
Employer's proportionate share of the net OPEB liability	\$ 546,566	\$ 680,432	\$ 265,181	\$ 659,913	\$ 644,008
Employer's covered payroll during the measurement period	\$ 955,043	\$ 951,988	\$ 911,574	\$ 922,919	\$ 908,353
Employer's proportionate share of the collective net OPEB liability as a percentage of its covered payroll	57.23 %	71.47 %	29.09 %	71.50 %	70.90 %
Plan fiduciary net position as a percentage of the total OPEB liability	27.11 %	19.80 %	28.14 %	14.81 %	15.37 %

Schedule of UAB's Contributions to the Alabama Retired Education Employees' Health Care Trust (PEEHIP)

	2022	2021	2020	2019	2018
Contractually required contribution	\$ 15,600,447	\$ 18,240,187	\$20,775,402	\$ 19,976,210	\$ 19,713,541
Contributions in relation to the contractually required contribution	\$ 15,600,447	\$ 18,240,187	\$20,775,402	\$ 19,976,210	\$ 19,713,541
Contribution deficiency (excess)	—	—	—	—	—
Employer's covered payroll	\$1,018,753,848	\$955,043,349	\$951,987,983	\$911,573,992	\$922,919,000
Contributions as a percentage of covered payroll	1.53 %	1.91 %	2.18 %	2.19 %	2.14 %

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

Measurement period:

For fiscal year 2022, the measurement period is October 1, 2020 – September 30, 2021

For fiscal year 2021, the measurement period is October 1, 2019 – September 30, 2020

For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018

For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

The following required supplementary information is related to the UAB Health Care Plan.

Schedule of Change in UAB Health Care Plan's Total OPEB Liability

	2022	2021	2020	2019	2018
Total OPEB Liability					
Service cost*	176,656	168,931	169,614	168,312	6,230,996
Interest on TOL and cash flows	108,805	153,833	708,983	691,351	690,596
Changes in benefit terms	250	—	—	—	(6,710,449)
Difference between expected and actual experience	756,169	(436,896)	(6,173,296)	(787,087)	—
Changes of assumptions or other inputs	1,779,639	85,758	(4,662,781)	(767,436)	(961,631)
Benefit payments	(894,479)	(942,445)	(1,489,763)	(1,927,388)	(4,961,185)
Net changes in Total OPEB Liability	1,927,040	(970,819)	(11,447,243)	\$ (2,622,248)	\$ (5,711,673)
Total OPEB Liability - Beginning	\$ 5,280,513	\$ 6,251,332	\$ 17,698,575	\$ 20,320,823	\$ 26,032,496
Total OPEB Liability - Ending	\$ 7,207,553	\$ 5,280,513	\$ 6,251,332	\$ 17,698,575	\$ 20,320,823
Covered payroll	\$955,043,349	\$ 951,987,983	\$ 911,573,992	\$922,919,000	\$908,353,000
Total OPEB Liability as a percentage of covered payroll	0.75 %	0.55 %	0.69 %	1.92 %	2.24 %

*The service cost include interest for the year.

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

Measurement period:

For fiscal year 2022, the measurement period is October 1, 2020 – September 30, 2021

For fiscal year 2021, the measurement period is October 1, 2019 – September 30, 2020

For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018

For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

The University of Alabama at Birmingham Administration (Unaudited)

As of September 30, 2022



Ray L. Watts, M.D.
President

Pamela Benoit, Ph.D.
Senior Vice President for Academic Affairs
and Provost

Brian D. Burnett, Ph.D.
Senior Vice President for Finance and
Administration

Thomas I. Brannan
Vice President for Advancement and
Strategic Initiatives

Christopher S. Brown, Ph.D.
Vice President for Research

Curtis A. Carver, Jr., Ph.D.
Vice President for Information Technology
and Chief Information Officer

Paulette Patterson Dilworth, Ph.D.
Vice President for Diversity, Equity and
Inclusion

S. Dawn Bulgarella
Interim CEO, UAB Medicine Enterprise
President and CFO, UAB/Ascension St.
Vincent's Alliance

John R. Jones, III, Ph.D.
Vice President for Student Affairs

Anupam Agarwal, M.D.
Interim Senior Vice President for Medicine
and Interim Dean, UAB Marnix E. Heersink
School of Medicine

Shannon Blanton, Ph.D.
Dean, UAB Honors College

Andrew J. Butler, MPT, MBA, Ph.D.
Dean, School of Health Professions

Michelle Robinson, D.M.D.
Interim Dean, School of Education

Paul C. Erwin, M.D., DrPH
Dean, School of Public Health

Maria R. Shirey, MBA, RN, NEA-BC,
ANEF, FACHE, FAAN
Dean, School of Nursing

Jeffery W. Holmes, M.D., Ph.D.
Dean, School of Engineering

Eric P. Jack, Ph.D.
Dean, Collat School of Business

Dean, Graduate School
Chief International Officer

Kasia Gonnerman, MA
Dean, UAB Libraries

Kelly K. Nichols, O.D., MPH, Ph.D., FAAO
Dean, School of Optometry

Russell Taichman, D.M.D., DMSc.
Dean, School of Dentistry

Kecia M. Thomas, Ph.D.
Dean, College of Arts and Sciences

The Board of Trustees of The University of Alabama (Unaudited)

As of September 30, 2022

The Honorable Kay Ivey Governor of Alabama ■ ■ ■ ■ ■ ■
President ex officio

W. Stancil Stranes, President pro tempore ■ ■ ■ ■ ■ ■
Sixth Congressional District **Trustees Emeriti**

■ ■ ■ ■ ■ ■ Paul W. Bryant, Jr.

Mike Brock ■ ■ ■ ■ ■ ■
Second Congressional District Angus R. Cooper II

Karen P. Brooks ■ ■ ■ ■ ■ ■
Seventh Congressional District John H. England, Jr.

Ronald W. Gray ■ ■ ■ ■ ■ ■
Fifth Congressional District Joseph C. Espy III

Barbara Humphrey ■ ■ ■ ■ ■ ■
Seventh Congressional District Joseph L. Fine

Vanessa Leonard ■ ■ ■ ■ ■ ■
Sixth Congressional District Sandral Hullett, M.D.

W. Davis Malone III ■ ■ ■ ■ ■ ■
Second Congressional District Andria Scott Hurst

Evelyn VanSant Mauldin ■ ■ ■ ■ ■ ■
Fourth Congressional District John D. Johns

Harris V. Morrissette ■ ■ ■ ■ ■ ■
First Congressional District Peter L. Lowe

Scott M. Phelps ■ ■ ■ ■ ■ ■
Fourth Congressional District John J. McMahon, Jr.

Jeff Gronberg ■ ■ ■ ■ ■ ■
Fifth Congressional District Joe H. Ritch

Kenneth O'Neal Simon ■ ■ ■ ■ ■ ■
Seventh Congressional District Finis E. St. John IV

Marietta M. Urquhart ■ ■ ■ ■ ■ ■
First Congressional District William Britt Sexton

Kenneth L. Vandervoort, M.D. ■ ■ ■ ■ ■ ■
Third Congressional District Cleophus Thomas, Jr.

James W. Wilson III ■ ■ ■ ■ ■ ■
Third Congressional District John Russell Thomas

